Cover
Cover | 6 Months Ended |
Jun. 30, 2023 | |
Cover [Abstract] | |
Document Type | 6-K |
Entity Registrant Name | Barclays Bank PLC |
Amendment Flag | false |
Document Fiscal Year Focus | 2023 |
Document Fiscal Period Focus | Q2 |
Document Period End Date | Jun. 30, 2023 |
Entity Central Index Key | 0000312070 |
Current Fiscal Year End Date | --12-31 |
Condensed consolidated income s
Condensed consolidated income statement (unaudited) - GBP (£) £ in Millions | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Profit or loss [abstract] | ||
Interest and similar income | £ 10,692 | £ 4,098 |
Interest and similar expense | (7,572) | (1,865) |
Net interest income | 3,120 | 2,233 |
Fee and commission income | 4,527 | 4,008 |
Fee and commission expense | (1,721) | (1,169) |
Net fee and commission income | 2,806 | 2,839 |
Net trading income | 3,853 | 5,026 |
Net investment expense | (14) | (139) |
Other income | 39 | 31 |
Total income | 9,804 | 9,990 |
Staff costs | (2,827) | (2,600) |
Infrastructure, administration and general expenses | (3,125) | (2,659) |
Litigation and conduct | (34) | (1,833) |
Operating expenses | (5,986) | (7,092) |
Share of post-tax results of associates and joint ventures | 2 | 0 |
Profit/(loss) before impairment | 3,820 | 2,898 |
Credit impairment charge | (688) | (293) |
Profit before tax | 3,132 | 2,605 |
Tax charge | (525) | (476) |
Profit after tax | 2,607 | 2,129 |
Attributable to: | ||
Equity holders of the parent | 2,188 | 1,801 |
Other equity instrument holders | 419 | 328 |
Profit after tax | £ 2,607 | £ 2,129 |
Condensed consolidated statemen
Condensed consolidated statement of comprehensive income (unaudited) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | ||
Statement of comprehensive income [abstract] | |||
Profit after tax | £ 2,607 | £ 2,129 | |
Other comprehensive (loss)/income that may be recycled to profit or loss: | |||
Currency translation reserve | [1] | (1,325) | 2,008 |
Fair value through other comprehensive income reserve | [1] | 58 | (799) |
Cash flow hedging reserve | [1] | (383) | (2,874) |
Other comprehensive loss that may be recycled to profit or loss | [1] | (1,650) | (1,665) |
Other comprehensive (loss)/income not recycled to profit or loss | |||
Retirement benefit remeasurements | (476) | 1,090 | |
Own credit | (494) | 855 | |
Other comprehensive (loss)/income not recycled to profit or loss | (970) | 1,945 | |
Other comprehensive (loss)/income for the period | (2,620) | 280 | |
Total comprehensive (loss)/income for the period | £ (13) | £ 2,409 | |
[1]Reported net of tax. |
Condensed consolidated balance
Condensed consolidated balance sheet (unaudited) - GBP (£) £ in Millions | Jun. 30, 2023 | Dec. 31, 2022 | |
Assets | |||
Cash and balances at central banks | £ 211,644 | £ 202,142 | |
Cash collateral and settlement balances | 123,955 | 107,862 | |
Debt securities at amortised cost | [1] | 35,245 | 27,303 |
Loans and advances at amortised cost to banks | 10,433 | 8,961 | |
Loans and advances at amortised cost to customers | 137,559 | 146,243 | |
Reverse repurchase agreements and other similar secured lending | 1,293 | 725 | |
Trading portfolio assets | 165,095 | 133,771 | |
Financial assets at fair value through the income statement | 233,105 | 211,128 | |
Derivative financial instruments | 266,128 | 302,976 | |
Financial assets at fair value through other comprehensive income | 47,032 | 45,084 | |
Investments in associates and joint ventures | 27 | 26 | |
Goodwill and intangible assets | 1,531 | 1,665 | |
Property, plant and equipment | 1,305 | 1,379 | |
Current tax assets | 167 | 737 | |
Deferred tax assets | 4,795 | 4,583 | |
Retirement benefit assets | 4,140 | 4,743 | |
Other assets | 3,182 | 4,209 | |
Total assets | 1,246,636 | 1,203,537 | |
Liabilities | |||
Deposits at amortised cost from banks | 26,964 | 20,124 | |
Deposits at amortised cost from customers | 280,856 | 271,455 | |
Cash collateral and settlement balances | 114,289 | 96,811 | |
Repurchase agreements and other similar secured borrowing | 25,156 | 11,965 | |
Debt securities in issue | 58,377 | 60,012 | |
Subordinated liabilities | 36,325 | 38,253 | |
Trading portfolio liabilities | 70,269 | 72,460 | |
Financial liabilities designated at fair value | 311,595 | 272,055 | |
Derivative financial instruments | 254,794 | 289,206 | |
Current tax liabilities | 347 | 422 | |
Retirement benefit liabilities | 180 | 184 | |
Other liabilities | 8,404 | 10,779 | |
Provisions | 732 | 858 | |
Total liabilities | 1,188,288 | 1,144,584 | |
Equity | |||
Called up share capital and share premium | 2,348 | 2,348 | |
Other equity instruments | 11,304 | 10,691 | |
Other reserves | (3,388) | (1,464) | |
Retained earnings | 48,084 | 47,378 | |
Total equity | 58,348 | 58,953 | |
Total liabilities and equity | £ 1,246,636 | £ 1,203,537 | |
[1]For the fair value of debt securities at amortised cost see page 37. |
Condensed consolidated statem_2
Condensed consolidated statement of changes in equity (unaudited) - GBP (£) £ in Millions | Total | Called up share capital and share premium | Other equity instruments | [1] | Other reserves | [2] | Retained earnings | |
Beginning Balance, equity at Dec. 31, 2021 | £ 56,317 | £ 2,348 | £ 9,693 | £ 861 | £ 43,415 | |||
Profit after tax | 2,129 | 328 | 1,801 | |||||
Currency translation movements | 2,008 | [3] | 2,008 | |||||
Fair value through other comprehensive income reserve | (799) | [3] | (799) | |||||
Cash flow hedges | (2,874) | [3] | (2,874) | |||||
Retirement benefit remeasurements | 1,090 | 1,090 | ||||||
Own credit | 855 | 855 | ||||||
Total comprehensive (loss)/income for the period | 2,409 | 328 | (810) | 2,891 | ||||
Issue and exchange of equity instruments | 131 | 101 | 30 | |||||
Other equity instruments coupons paid | (328) | (328) | ||||||
Equity settled share schemes | 242 | 242 | ||||||
Vesting of Barclays PLC shares under equity settled share schemes | (402) | (402) | ||||||
Dividends paid - ordinary shares | (200) | (200) | ||||||
Dividends paid - preference shares | (15) | (15) | ||||||
Own credit realisation | 0 | |||||||
Capital contribution from Barclays PLC | 750 | 750 | ||||||
Other movements | 12 | 2 | 10 | |||||
Ending Balance, equity at Jun. 30, 2022 | 58,916 | 2,348 | 9,794 | 53 | 46,721 | |||
Profit after tax | 2,253 | 404 | 1,849 | |||||
Currency translation movements | 403 | 403 | ||||||
Fair value through other comprehensive income reserve | (425) | (425) | ||||||
Cash flow hedges | (2,065) | (2,065) | ||||||
Retirement benefit remeasurements | (1,372) | (1,372) | ||||||
Own credit | 608 | 608 | ||||||
Total comprehensive (loss)/income for the period | (598) | 404 | (1,479) | 477 | ||||
Issue and exchange of equity instruments | 905 | 897 | 8 | |||||
Other equity instruments coupons paid | (404) | (404) | ||||||
Equity settled share schemes | 177 | 177 | ||||||
Vesting of Barclays PLC shares under equity settled share schemes | (11) | (11) | ||||||
Dividends paid - ordinary shares | 0 | |||||||
Dividends paid - preference shares | (16) | (16) | ||||||
Own credit realisation | 0 | (36) | 36 | |||||
Capital contribution from Barclays PLC | 0 | |||||||
Other movements | (16) | (2) | (14) | |||||
Ending Balance, equity at Dec. 31, 2022 | 58,953 | 2,348 | 10,691 | (1,464) | 47,378 | |||
Profit after tax | 2,607 | 419 | 2,188 | |||||
Currency translation movements | (1,325) | [3] | (1,325) | |||||
Fair value through other comprehensive income reserve | 58 | [3] | 58 | |||||
Cash flow hedges | (383) | [3] | (383) | |||||
Retirement benefit remeasurements | (476) | (476) | ||||||
Own credit | (494) | (494) | ||||||
Total comprehensive (loss)/income for the period | (13) | 419 | (2,144) | 1,712 | ||||
Issue and exchange of equity instruments | 613 | 613 | ||||||
Other equity instruments coupons paid | (419) | (419) | ||||||
Equity settled share schemes | 241 | 241 | ||||||
Vesting of Barclays PLC shares under equity settled share schemes | (430) | (430) | ||||||
Dividends paid - ordinary shares | (700) | (700) | ||||||
Dividends paid - preference shares | (19) | (19) | ||||||
Own credit realisation | 0 | |||||||
Net equity impact on intra group transfers | 124 | 220 | (96) | |||||
Other movements | (2) | (2) | ||||||
Ending Balance, equity at Jun. 30, 2023 | £ 58,348 | £ 2,348 | £ 11,304 | £ (3,388) | £ 48,084 | |||
[1]Other equity instruments of £11,304m (December 2022: £10,691m) comprise AT1 securities issued to Barclays PLC. Barclays PLC uses funds from market issuances to purchase AT1 securities from Barclays Bank PLC. There were two issuances in the form of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities totalling £1,113m which includes issuance cost of £11m and one redemption for £500m for the period ended 30 June 2023. During the period ended 31 December 2022, there were three issuances in the form of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities totalling £3,134m, which includes issuance costs of £32m and two redemptions totalling £2,136m.[2]Details of other reserves are shown on pages 39.[3]Reported net of tax. |
Condensed consolidated cash flo
Condensed consolidated cash flow statement (unaudited) - GBP (£) £ in Millions | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Statement of cash flows [abstract] | ||
Profit before tax | £ 3,132 | £ 2,605 |
Adjustment for non-cash items | 5,832 | (7,938) |
Net decrease/(increase) in loans and advances at amortised cost | 8,081 | (22,252) |
Net increase in deposits at amortised cost | 16,241 | 48,637 |
Net (decrease)/increase in debt securities in issue | (1,635) | 20,268 |
Changes in other operating assets and liabilities | 308 | 14,462 |
Corporate income tax received/(paid) | 174 | |
Corporate income tax received/(paid) | (280) | |
Net cash from operating activities | 32,133 | 55,502 |
Net cash from investing activities | (11,947) | (7,071) |
Net cash from financing activities | (1,114) | 488 |
Effect of exchange rates on cash and cash equivalents | (6,546) | 7,045 |
Net increase in cash and cash equivalents | 12,526 | 55,964 |
Cash and cash equivalents at beginning of the period | 219,854 | 185,860 |
Cash and cash equivalents at end of the period | £ 232,380 | £ 241,824 |
Condensed consolidated statem_3
Condensed consolidated statement of changes in equity (unaudited) (Parenthetical) £ in Millions | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2023 GBP (£) redemption issuance | Dec. 31, 2022 GBP (£) redemption issuance | ||
Equity | £ 58,348 | £ 58,953 | |
Other equity instruments | |||
Equity | [1] | £ 11,304 | £ 10,691 |
Other equity instruments | Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities | |||
Number of convertible instruments issued | issuance | 2,000,000 | 3,000,000 | |
Issue of convertible instruments | £ 1,113 | £ 3,134 | |
Issuance costs of convertible instruments | £ 11 | £ 32 | |
Number of convertible instruments redeemed | redemption | 1,000,000 | 2,000,000 | |
Notional amount | £ 500 | £ 2,136 | |
[1]Other equity instruments of £11,304m (December 2022: £10,691m) comprise AT1 securities issued to Barclays PLC. Barclays PLC uses funds from market issuances to purchase AT1 securities from Barclays Bank PLC. There were two issuances in the form of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities totalling £1,113m which includes issuance cost of £11m and one redemption for £500m for the period ended 30 June 2023. During the period ended 31 December 2022, there were three issuances in the form of Fixed Rate Resetting Perpetual Subordinated Contingent Convertible Securities totalling £3,134m, which includes issuance costs of £32m and two redemptions totalling £2,136m. |
Credit Risk
Credit Risk | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of credit risk exposure [abstract] | |
Credit Risk | Taskforce on Disclosures about Expected Credit Losses (DECL) The latest DECL III Taskforce recommendation for the minimum product groupings has been adopted in the credit risk performance section for this period and the prior period comparatives have been aligned accordingly. The Barclays Bank Group intends to adopt further enhancements in the credit risk performance section for future periods. Loans and advances at amortised cost by product Total loans and advances at amortised cost in the credit risk performance section includes Loans and advances at amortised cost to banks, Loans and advances at amortised cost to customers and Debt securities at amortised cost. The table below presents a breakdown of loans and advances at amortised cost and the impairment allowance with stage allocation by asset classification. Impairment allowance under IFRS 9 considers both the drawn and the undrawn counterparty exposure. For retail portfolios, the total impairment allowance is allocated to the gross loans and advances to the extent that the allowance does not exceed the drawn exposure and any excess is reported on the liability side of the balance sheet as a provision. For wholesale portfolios the impairment allowance on the undrawn exposure is reported on the liability side of the balance sheet as a provision. Stage 2 As at 30.06.23 Stage 1 Not past due <=30 days past due >30 days past due Total Stage 3 Total 1 Gross exposure £m £m £m £m £m £m £m Retail mortgages 7,791 272 16 107 395 767 8,953 Retail credit cards 21,829 3,478 302 227 4,007 1,257 27,093 Retail other 4,583 368 33 249 650 336 5,569 Corporate loans 95,647 9,136 128 205 9,469 1,174 106,290 Debt securities and other 2 35,497 3,664 — — 3,664 2 39,163 Total 165,347 16,918 479 788 18,185 3,536 187,068 Impairment allowance Retail mortgages 9 18 3 2 23 327 359 Retail credit cards 307 860 143 128 1,131 1,006 2,444 Retail other 23 28 1 7 36 99 158 Corporate loans 201 261 11 8 280 336 817 Debt securities and other 2 19 34 — — 34 — 53 Total 559 1,201 158 145 1,504 1,768 3,831 Net exposure Retail mortgages 7,782 254 13 105 372 440 8,594 Retail credit cards 21,522 2,618 159 99 2,876 251 24,649 Retail other 4,560 340 32 242 614 237 5,411 Corporate loans 95,446 8,875 117 197 9,189 838 105,473 Debt securities and other 2 35,478 3,630 — — 3,630 2 39,110 Total 164,788 15,717 321 643 16,681 1,768 183,237 Coverage ratio % % % % % % % Retail mortgages 0.1 6.6 18.8 1.9 5.8 42.6 4.0 Retail credit cards 1.4 24.7 47.4 56.4 28.2 80.0 9.0 Retail other 0.5 7.6 3.0 2.8 5.5 29.5 2.8 Corporate loans 0.2 2.9 8.6 3.9 3.0 28.6 0.8 Debt securities and other 2 0.1 0.9 — — 0.9 — 0.1 Total 0.3 7.1 33.0 18.4 8.3 50.0 2.0 1 Other financial assets subject to impairment excluded in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £172.4bn and impairment allowance of £156m. This comprises £15m Expected Credit Losses (ECL) on £171.3bn Stage 1 assets, £12m on £877m Stage 2 fair value through other comprehensive income assets, cash collateral and settlement balances and £129m on £137m Stage 3 other assets. Loan commitments and financial guarantee contracts have total ECL of £467m. 2 Predominantly includes debt securities within Treasury and CIB, these have a total gross exposure of £35.3bn and impairment allowance of £53m. Also includes loans and advances of £3.4bn within Treasury and £0.4bn within Head Office, which have impairment allowance of £nil. Stage 2 As at 31.12.22 Stage 1 Not past due <=30 days past due >30 days past due Total Stage 3 Total 1 Gross exposure £m £m £m £m £m £m £m Retail mortgages 10,458 310 11 41 362 978 11,798 Retail credit cards 22,669 3,252 237 391 3,880 1,129 27,678 Retail other 6,915 384 45 95 524 523 7,962 Corporate loans 96,799 10,235 154 103 10,492 935 108,226 Debt securities and other 2 26,967 3,691 — — 3,691 5 30,663 Total 163,808 17,872 447 630 18,949 3,570 186,327 Impairment allowance Retail mortgages 12 22 2 1 25 356 393 Retail credit cards 331 887 82 158 1,127 818 2,276 Retail other 38 21 3 5 29 171 238 Corporate loans 304 254 12 9 275 293 872 Debt securities and other 2 8 33 — — 33 — 41 Total 693 1,217 99 173 1,489 1,638 3,820 Net exposure Retail mortgages 10,446 288 9 40 337 622 11,405 Retail credit cards 22,338 2,365 155 233 2,753 311 25,402 Retail other 6,877 363 42 90 495 352 7,724 Corporate loans 96,495 9,981 142 94 10,217 642 107,354 Debt securities and other 2 26,959 3,658 — — 3,658 5 30,622 Total 163,115 16,655 348 457 17,460 1,932 182,507 Coverage ratio % % % % % % % Retail mortgages 0.1 7.1 18.2 2.4 6.9 36.4 3.3 Retail credit cards 1.5 27.3 34.6 40.4 29.0 72.5 8.2 Retail other 0.5 5.5 6.7 5.3 5.5 32.7 3.0 Corporate loans 0.3 2.5 7.8 8.7 2.6 31.3 0.8 Debt securities and other 2 — 0.9 — — 0.9 — 0.1 Total 0.4 6.8 22.1 27.5 7.9 45.9 2.1 1 Other financial assets subject to impairment excluded in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £155.1bn and impairment allowance of £152m. This comprises £7m ECL on £153.8bn Stage 1 assets, £8m on £1,142m Stage 2 fair value through other comprehensive income assets, cash collateral and settlement balances and £137m on £141m Stage 3 other assets. Loan commitments and financial guarantee contracts have total ECL of £532m. 2 Predominantly includes debt securities within Treasury and CIB, these have a total gross exposure of £27.4bn and impairment allowance of £41m. Also includes loans and advances of £2.9bn within Treasury and £0.4bn within Head Office, which have impairment allowance of £nil. Movement in gross exposures and impairment allowance including provisions for loan commitments and financial guarantees The following tables present a reconciliation of the opening to the closing balance of the exposure and impairment allowance. An explanation of the methodology used to determine credit impairment provisions is included in the Barclays Bank PLC Annual Report 2022. Transfers between stages in the tables have been reflected as if they had taken place at the beginning of the period. 'Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes' includes additional drawdowns and partial repayments from existing facilities. Additionally, the below tables do not include other financial assets subject to impairment such as cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. The movements are measured over a six-month period. Loans and advances at amortised cost Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Retail mortgages As at 1 January 2023 10,458 12 362 25 978 356 11,798 393 Transfers from Stage 1 to Stage 2 (218) — 218 — — — — — Transfers from Stage 2 to Stage 1 65 3 (65) (3) — — — — Transfers to Stage 3 (90) — (36) (3) 126 3 — — Transfers from Stage 3 10 — 19 1 (29) (1) — — Business activity in the period 622 3 — — — — 622 3 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (2,154) (9) (58) 4 (218) (21) (2,430) (26) Final repayments (902) — (45) (1) (81) (1) (1,028) (2) Disposals — — — — — — — — Write-offs — — — — (9) (9) (9) (9) As at 30 June 2023 7,791 9 395 23 767 327 8,953 359 Retail credit cards As at 1 January 2023 22,669 331 3,880 1,127 1,129 818 27,678 2,276 Transfers from Stage 1 to Stage 2 (1,468) (42) 1,468 42 — — — — Transfers from Stage 2 to Stage 1 1,033 290 (1,033) (290) — — — — Transfers to Stage 3 (197) (12) (404) (205) 601 217 — — Transfers from Stage 3 5 3 4 2 (9) (5) — — Business activity in the period 904 16 45 16 1 1 950 33 Refinements to models used for calculation 1 — — — — — (20) — (20) Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (1,052) (267) 64 475 (128) 334 (1,116) 542 Final repayments (65) (12) (17) (36) — (6) (82) (54) Disposals 2 — — — — (12) (8) (12) (8) Write-offs — — — — (325) (325) (325) (325) As at 30 June 2023 21,829 307 4,007 1,131 1,257 1,006 27,093 2,444 1 Refinements to models used for calculation reported within Retail credit cards include a £20m movement in US cards. These reflect model enhancements made during the period. Barclays continually reviews the output of models to determine accuracy of the ECL calculation including review of model monitoring, external benchmarking and experience of model operation over an extended period of time. This helps to ensure that the models used continue to reflect the risks inherent across the businesses. 2 The £12m disposals reported within Retail credit cards relates to debt sales undertaken during the period. Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Retail other As at 1 January 2023 6,915 38 524 29 523 171 7,962 238 Transfers from Stage 1 to Stage 2 (446) (3) 446 3 — — — — Transfers from Stage 2 to Stage 1 138 4 (138) (4) — — — — Transfers to Stage 3 (57) (1) (41) (6) 98 7 — — Transfers from Stage 3 1 1 7 2 (8) (3) — — Business activity in the period 1,086 3 6 1 3 2 1,095 6 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (2,145) (17) (79) 12 (148) (32) (2,372) (37) Final repayments (909) (2) (75) (1) (47) (1) (1,031) (4) Disposals 1 — — — — (75) (35) (75) (35) Write-offs — — — — (10) (10) (10) (10) As at 30 June 2023 4,583 23 650 36 336 99 5,569 158 Corporate loans As at 1 January 2023 96,799 304 10,492 275 935 293 108,226 872 Transfers from Stage 1 to Stage 2 (4,747) (21) 4,747 21 — — — — Transfers from Stage 2 to Stage 1 4,312 49 (4,312) (49) — — — — Transfers to Stage 3 (139) (1) (225) (16) 364 17 — — Transfers from Stage 3 47 1 64 2 (111) (3) — — Business activity in the period 12,224 20 315 13 35 9 12,574 42 Refinements to models used for calculation 2 — (49) — 142 — — — 93 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 1,810 (46) (1,049) (90) 212 182 973 46 Final repayments (14,659) (56) (563) (18) (91) (7) (15,313) (81) Disposals 1 — — — — (110) (95) (110) (95) Write-offs — — — — (60) (60) (60) (60) As at 30 June 2023 95,647 201 9,469 280 1,174 336 106,290 817 1 The £75m of disposals reported within Retail other includes £64m part sale of Wealth portfolio in Italy and £11m relates to debt sales. The £110m of disposals reported within Corporate loans relates to debt sales undertaken during the period. 2 Refinements to models used for calculation reported within Corporate loans include a £93m movement in CIB . These reflect model enhancements made during the period. Barclays continually reviews the output of models to determine accuracy of the ECL calculation including review of model monitoring, external benchmarking and experience of model operation over an extended period of time. This helps to ensure that the models used continue to reflect the risks inherent across the businesses. Loans and advances at amortised cost Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Debt securities and other As at 1 January 2023 26,967 8 3,691 33 5 — 30,663 41 Transfers from Stage 1 to Stage 2 (260) — 260 — — — — — Transfers from Stage 2 to Stage 1 118 2 (118) (2) — — — — Transfers to Stage 3 — — — — — — — — Transfers from Stage 3 — — — — — — — — Business activity in the period 11,438 2 78 1 — — 11,516 3 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (768) 7 (79) 4 2 — (845) 11 Final repayments (1,998) — (168) (2) (5) — (2,171) (2) Disposals — — — — — — — — Write-off — — — — — — — — As at 30 June 2023 35,497 19 3,664 34 2 — 39,163 53 Reconciliation of ECL movement to impairment charge/(release) for the period Stage 1 Stage 2 Stage 3 Total £m £m £m £m Retail mortgages (3) (2) (20) (25) Retail credit cards (24) 4 521 501 Retail other (15) 7 (27) (35) Corporate loans (103) 5 198 100 Debt securities and other 11 1 12 ECL movement excluding assets derecognised due to disposals and write-offs 1 (134) 15 672 553 ECL movement on loan commitments and other financial guarantees (47) (36) 18 (65) ECL movement on other financial assets 8 4 (8) 4 Recoveries and reimbursements 2 64 (28) (36) — Total exchange and other adjustments 196 Total income statement charge for the period 688 1 In H123, gross write-offs amounted to £404m (H122: £560m). Post write-off recoveries amounted to £7m (H122: £20m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £397m (H122: £540m). 2 Recoveries and reimbursements include a net reduction of £7m (H122 gain: £11m) in amounts expected to be received under the arrangement where Barclays Bank Group has entered into financial guarantee contracts which provide credit protection over certain loan assets with third parties; cash recoveries of previously written off amounts are £7m (H122: £20m). Loan commitments and financial guarantees Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Retail mortgages As at 1 January 2023 61 — 1 — 5 — 67 — Net transfers between stages — — — — — — — — Business activity in the year 27 — — — — — 27 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (21) — — — (4) — (25) — Limit management and final repayments (25) — (1) — — — (26) — As at 30 June 2023 42 — — — 1 — 43 — Retail credit cards As at 1 January 2023 109,291 41 1,973 45 7 1 111,271 87 Net transfers between stages (646) 14 644 (14) 2 — — — Business activity in the year 9,242 6 76 5 — — 9,318 11 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (4,448) (19) (469) 23 (1) (1) (4,918) 3 Limit management and final repayments (6,304) (4) (274) (16) — — (6,578) (20) As at 30 June 2023 107,135 38 1,950 43 8 — 109,093 81 Retail other As at 1 January 2023 4,497 — 79 — 64 — 4,640 — Net transfers between stages (65) — 39 — 26 — — — Business activity in the year 467 — 1 — — — 468 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (1,120) 8 (30) — (47) — (1,197) 8 Limit management and final repayments (293) — (10) — — — (303) — As at 30 June 2023 3,486 8 79 — 43 — 3,608 8 Corporate loans As at 1 January 2023 205,207 193 23,873 230 812 22 229,892 445 Net transfers between stages 624 18 (768) (19) 144 1 — — Business activity in the year 22,926 7 543 8 1 — 23,470 15 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 1,862 (26) 534 (4) 208 20 2,604 (10) Limit management and final repayments (26,348) (51) (1,749) (19) (223) (2) (28,320) (72) As at 30 June 2023 204,271 141 22,433 196 942 41 227,646 378 Debt securities and other As at 1 January 2023 13 — — — — — 13 — Net transfers between stages — — — — — — — — Business activity in the year 14 — — — — — 14 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (1) — — — — — (1) — Limit management and final repayments — — — — — — — — As at 30 June 2023 26 — — — — — 26 — Management adjustments to models for impairment Management adjustments to impairment models are applied in order to factor in certain conditions or changes in policy that are not fully incorporated into the impairment models, or to reflect additional facts and circumstances at the period end. Management adjustments are reviewed and incorporated into future model development where applicable. Management adjustments are captured through “Economic uncertainty” and “Other” adjustments, and are presented by product below: Management adjustments to models for impairment allowance presented by product 1 Impairment allowance pre management adjustments 2 Economic uncertainty adjustments 3 Other adjustments Management adjustments Total impairment allowance 4 Proportion of Management adjustments to total impairment allowance (a) (b) (a+b) As at 30 June 2023 £m £m £m £m £m % Retail mortgages 361 — (2) (2) 359 (0.6) Retail credit cards 2,559 — (34) (34) 2,525 (1.3) Retail other 199 — (33) (33) 166 (19.9) Corporate loans 1,166 — 29 29 1,195 2.4 Debt securities and other 53 — — — 53 — Total 4,338 — (40) (40) 4,298 (0.9) As at 31 December 2022 Retail mortgages 393 — — — 393 — Retail credit cards 2,309 — 54 54 2,363 2.3 Retail other 217 2 19 21 238 8.8 Corporate loans 1,414 95 (192) (97) 1,317 (7.4) Debt securities and other 41 — — — 41 — Total 4,374 97 (119) (22) 4,352 (0.5) Economic uncertainty adjustments presented by stage Stage 1 Stage 2 Stage 3 Total As at 31 December 2022 £m £m £m £m Retail mortgages — — — — Retail credit cards — — — — Retail other — 2 — 2 Corporate loans 97 (2) — 95 Debt securities and other — — — — Total 97 — — 97 1 Positive values reflect an increase in impairment allowance and negative values reflect a reduction in the impairment allowance. 2 Includes £3.7bn (December 2022: £3.7bn) of modelled ECL, £0.3bn (December 2022: £0.3bn) of individually assessed impairments and £0.3bn (December 2022: £0.4bn) ECL from non-modelled exposures. 3 Economic uncertainty adjustments are nil (December 2022: £97m) following the re-build of certain CIB impairment models. 4 Total impairment allowance consists of ECL stock on drawn and undrawn exposure. Economic Uncertainty adjustments Economic uncertainty adjustments are captured in two ways. Firstly, customer uncertainty: the identification of customers and clients who may be more vulnerable to economic instability; and secondly, model uncertainty: to capture the impact from model limitations and sensitivities to specific macroeconomic parameters which are applied at a portfolio level. During the period, a re-build of certain Corporate and Investment Bank (CIB) models and a granular credit risk assessment for qualifying exposures have resulted in release of adjustments for high-risk sectors and model sensitivity. This is leading to £nil economic uncertainty adjustments as at 30 June 2023. Other adjustments Other adjustments are operational in nature and are expected to remain in place until they can be reflected in the underlying models. These adjustments result from data limitations and model performance related issues identified through model monitoring and other established governance processes. Other adjustments of £(40)m (December 2022: £(119)m) includes: • Retail credit cards: £(34)m (December 2022: £54m) primarily include adjustments informed by model monitoring partially offset by an adjustment in the US to the qualitative measures for high-risk account management (HRAM) accounts, and in Germany for recalibration of Loss Given Default (LGD) to reflect revised recovery expectations. The movement is primarily driven by an adjustment made during the period in the US to limit ECL sensitivity to certain macroeconomic variables. • Retail other: £(33)m (December 2022: £19m) the movement is primarily informed by operational model adjustments made during the period within Private Banking and Wealth Management. Furthermore, adjustments for model monitoring and the definition of default under the Capital Requirements Regulation have been re-sized within Germany Loans. • Corporate loans: £29m (December 2022: £(192)m) primarily includes an adjustment recognised to address unintuitive Probability of Default (PD) rates driven by the equity market volatilities. Management adjustments of £(192)m within Corporate loans as at 31 December 2022 primarily comprised of an adjustment to limit ECL sensitivity to the macroeconomic variable for Federal Tax Receipts and model monitoring adjustments. These adjustments are no longer needed following the re-build of certain CIB impairment models. Measurement uncertainty Scenarios used to calculate the Barclays Bank Group’s ECL charge were refreshed in Q223 with the Baseline scenario reflecting the latest consensus macroeconomic forecasts available at the time of the scenario refresh. In the Baseline scenario, although the outlook in major economies has improved somewhat (since Q422), the full effect of the inflation shock and rising rates is lagged and so contributes to a further squeeze of household finances over the coming quarters, posing downside risks to GDP. UK and US unemployment rates increase only gradually in the coming quarters, peaking at 4.5% in Q424 and 4.7% in Q224 respectively. Central banks continue raising interest rates, with both the UK bank rate and the US federal funds rate peaking at 5.25% during 2023. The Downside 2 scenario is broadly aligned to the previous scenario refresh. Inflation rates rise again as energy prices suddenly surge again amid renewed geopolitical risks. Inflation becomes entrenched and inflation expectations go up, contributing to higher pressure on wage growth. Central banks are forced to raise interest rates sharply with the UK bank rate reaching 8% and the US federal funds rate peaking at 7%. Weakened businesses lay off workers and consumers stop spending exacerbating the downward stress. Unemployment peaks at 8.5% in the UK and 9.8% in the US. Given already stretched valuations, the sharp increase in borrowing costs sees house prices decrease significantly. In the Upside scenarios, lower energy prices add downward pressure on prices globally, while recovering labour force participation limits wage growth. As a result of easing inflation, central banks lower interest rates to support the economic recovery. The methodology for estimating scenario probability weights involves simulating a range of future paths for UK and US GDP using historical data with the five scenarios mapped against the distribution of these future paths. The median is centred around the Baseline with scenarios further from the Baseline attracting a lower weighting before the five weights are normalised to total 100%. The decrease in the Downside weightings and the increase in the Upside weightings reflected the improving economic outlook which moved the Baseline UK/US GDP paths closer to the Upside scenarios. For further details see page 15. The tables on the following pages show the key macroeconomic variables used in the five scenarios (five year annual paths) and the probability weights applied to each scenario. Macroeconomic variables used in the calculation of ECL As at 30 June 2023 2023 2024 2025 2026 2027 Baseline % % % % % UK GDP 1 0.3 0.9 1.6 1.8 1.9 UK unemployment 2 4.1 4.4 4.2 4.2 4.2 UK HPI 3 (6.1) (1.3) 2.0 4.3 5.7 UK bank rate 4.8 4.6 3.9 3.8 3.5 US GDP 1 1.1 0.7 2.0 2.0 2.0 US unemployment 4 3.8 4.6 4.6 4.6 4.6 US HPI 5 (0.7) 3.6 2.4 2.7 2.7 US federal funds rate 5.0 3.7 3.0 2.8 3.0 Downside 2 UK GDP 1 (0.5) (5.0) (0.4) 2.5 1.9 UK unemployment 2 4.4 7.8 8.3 7.7 7.1 UK HPI 3 (10.2) (20.5) (17.7) 5.6 8.2 UK bank rate 5.5 8.0 7.3 6.1 4.8 US GDP 1 0.5 (4.8) (0.3) 2.8 2.1 US unemployment 4 4.5 8.7 9.6 8.5 7.0 US HPI 5 (1.8) (3.7) (4.2) 2.6 4.8 US federal funds rate 5.7 7.0 6.5 5.1 4.2 Downside 1 UK GDP 1 (0.1) (2.1) 0.6 2.2 1.9 UK unemployment 2 4.2 6.1 6.2 5.9 5.6 UK HPI 3 (8.1) (11.3) (8.2) 5.0 7.0 UK bank rate 5.2 6.1 5.6 4.8 4.1 US GDP 1 0.8 (2.0) 0.8 2.4 2.0 US unemployment 4 4.1 6.7 7.1 6.5 5.8 US HPI 5 (1.2) (0.1) (0.9) 2.7 3.8 US federal funds rate 5.2 4.9 4.5 4.3 3.8 Upside 2 UK GDP 1 1.2 4.1 3.2 2.6 2.3 UK unemployment 2 3.9 3.6 3.5 3.6 3.6 UK HPI 3 0.4 10.6 4.8 4.2 3.8 UK bank rate 4.4 3.3 2.5 2.5 2.5 US GDP 1 2.2 3.9 3.0 2.8 2.8 US unemployment 4 3.4 3.5 3.6 3.6 3.6 US HPI 5 2.5 5.5 4.6 4.5 4.5 US federal funds rate 4.7 3.2 2.2 2.0 2.0 Upside 1 UK GDP 1 0.8 2.5 2.4 2.2 2.1 UK unemployment 2 4.0 4.0 3.9 3.9 3.9 UK HPI 3 (2.9) 4.5 3.4 4.3 4.7 UK bank rate 4.6 4.0 3.1 3.0 3.0 US GDP 1 1.6 2.3 2.5 2.4 2.4 US unemployment 4 3.6 4.1 4.1 4.1 4.1 US HPI 5 0.9 4.6 3.5 3.6 3.6 US federal funds rate 4.8 3.4 2.6 2.5 2.5 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Macroeconomic variables used in the calculation of ECL As at 31 December 2022 2022 2023 2024 2025 2026 Baseline % % % % % UK GDP 1 3.3 (0.8) 0.9 1.8 1.9 UK unemployment 2 3.7 4.5 4.4 4.1 4.2 UK HPI 3 8.4 (4.7) (1.7) 2.2 2.2 UK bank rate 1.8 4.4 4.1 3.8 3.4 US GDP 1 1.8 0.5 1.2 1.5 1.5 US unemployment 4 3.7 4.3 4.7 4.7 4.7 US HPI 5 11.2 1.8 1.5 2.3 2.4 US federal funds rate 2.1 4.8 3.6 3.1 3.0 Downside 2 UK GDP 1 3.3 (3.4) (3.8) 2.0 2.3 UK unemployment 2 3.7 6.0 8.4 8.0 7.4 UK HPI 3 8.4 (18.3) (18.8) (7.7) 8.2 UK bank rate 1.8 7.3 7.9 6.6 5.5 US GDP 1 1.8 (2.7) (3.4) 2.0 2.6 US unemployment 4 3.7 6.0 8.5 8.1 7.1 US HPI 5 11.2 (3.1) (4.0) (1.9) 4.8 US federal funds rate 2.1 6.6 6.9 5.8 4.6 Downside 1 UK GDP 1 3.3 (2.1) (1.5) 1.9 2.1 UK unemployment 2 3.7 5.2 6.4 6.0 5.8 UK HPI 3 8.4 (11.7) (10.6) (2.8) 5.2 UK bank rate 1.8 5.9 6.1 5.3 4.6 US GDP 1 1.8 (1.1) (1.1) 1.7 2.1 US unemployment 4 3.7 5.1 6.6 6.4 5.9 US HPI 5 11.2 (0.7) (1.3) 0.2 3.6 US federal funds rate 2.1 5.8 5.4 4.4 3.9 Upside 2 UK GDP 1 3.3 2.8 3.7 2.9 2.4 UK unemployment 2 3.7 3.5 3.4 3.4 3.4 UK HPI 3 8.4 8.7 7.5 4.4 4.2 UK bank rate 1.8 3.1 2.6 2.5 2.5 US GDP 1 1.8 3.3 3.5 2.8 2.8 US unemployment 4 3.7 3.3 3.3 3.3 3.3 US HPI 5 11.2 5.8 5.1 4.5 4.5 US federal funds rate 2.1 3.6 2.9 2.8 2.8 Upside 1 UK GDP 1 3.3 1.0 2.3 2.4 2.1 UK unemployment 2 3.7 4.0 3.9 3.8 3.8 UK HPI 3 8.4 1.8 2.9 3.3 3.2 UK bank rate 1.8 3.5 3.3 3.0 2.8 US GDP 1 1.8 1.9 2.3 2.2 2.2 US unemployment 4 3.7 3.8 4.0 4.0 4.0 US HPI 5 11.2 3.8 3.3 3.4 3.4 US federal funds rate 2.1 3.9 3.4 3.0 3.0 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Scenario probability weighting Upside 2 Upside 1 Baseline Downside 1 Downside 2 % % % % % As at 30 June 2023 Scenario probability weighting 13.0 24.7 40.2 15.2 6.9 As at 31 December 2022 Scenario probability weighting 10.9 23.1 39.4 17.6 9.0 Specific bases show the most extreme position of each variable in the context of the downside/upside scenarios, for example, the highest unemployment for downside scenarios, average unemployment for baseline scenarios and lowest unemployment for upside scenarios. GDP and HPI downside and upside scenario data represents the lowest and highest cumulative position relative to the start point in the 20 quarter period. Macroeconomic variables (specific bases) 1 Upside 2 Upside 1 Baseline Downside 1 Downside 2 As at 30 June 2023 % % % % % UK GDP 2 15.1 11.2 1.3 (2.7) (6.9) UK unemployment 3 3.5 3.9 4.2 6.5 8.5 UK HPI 4 25.8 14.6 0.8 (25.2) (41.5) UK bank rate 3 2.5 3.0 4.1 6.3 8.0 US GDP 2 15.9 11.9 1.6 (2.3) (6.2) US unemployment 3 3.3 3.5 4.4 7.2 9.8 US HPI 4 23.6 17.2 2.1 (2.3) (10.1) US federal funds rate 3 2.0 2.5 3.5 5.3 7.0 As at 31 December 2022 UK GDP 2 13.9 9.4 1.4 (3.2) (6.8) UK unemployment 3 3.4 3.6 4.2 6.6 8.5 UK HPI 4 37.8 21.0 1.2 (17.9) (35.0) UK bank rate 3 0.5 0.5 3.5 6.3 8.0 US GDP 2 14.1 9.6 1.3 (2.5) (6.3) US unemployment 3 3.3 3.6 4.4 6.7 8.6 US HPI 4 35.0 27.5 3.8 3.7 0.2 US federal funds rate 3 0.1 0.1 3.3 6.0 7.0 1 UK GDP = Real GDP growth seasonally adjusted; UK unemployment = UK unemployment rate 16-year+; UK HI = Halifax All Houses, All Buyers Index; US GDP = Real GDP growth seasonally adjusted; US unemployment = US civilian unemployment rate 16-year+; US HPI = FHFA House Price Index. 20 quarter period starts from Q123 (2022: Q122). 2 Maximum growth relative to Q422 (2022: Q421), based on 20 quarter period in Upside scenarios; 5-year yearly average Compound Annual Growth Rate (CAGR) in Baseline; minimum growth relative to Q422 (2022: Q421), based on 20 quarter period in Downside scenarios. 3 Lowest quarter in 20 quarter period in Upside scenarios; 5-year average in Baseline; highest quarter 20 quarter period in Downside scenarios. 4 Maximum growth relative to Q422 (2022: Q421), based on 20 quarter period in Upside scenarios; 5-year quarter end CAGR in Baseline; minimum growth relative to Q422 (2022: Q421), based on 20 quarter period in Downside scenarios. Average basis represents the average quarterly value of variables in the 20 quarter period with GDP and HPI based on yearly average and quarterly CAGRs respectively. Macroeconomic variables (5-year averages) 1 Upside 2 Upside 1 Baseline Downside 1 Downside 2 As at 30 June 2023 % % % % % UK GDP 2 2.7 2.0 1.3 0.5 (0.3) UK unemployment 3 3.6 3.9 4.2 5.6 7.0 UK HPI 4 4.7 2.8 0.8 (3.4) (7.6) UK bank rate 3 3.0 3.6 4.1 5.2 6.4 US GDP 2 2.9 2.3 1.6 0.8 — US unemployment 3 3.5 4.0 4.4 6.0 7.6 US HPI 4 4.3 3.2 2.1 0.8 (0.5) US federal funds rate 3 2.8 3.2 3.5 4.5 5.7 As at 31 December 2022 UK GDP 2 3.0 2.2 1.4 0.7 — UK unemployment 3 3.5 3.8 4.2 5.4 6.7 UK HPI 4 6.6 3.9 1.2 (2.6) (6.4) UK bank rate 3 2.5 2.9 3.5 4.7 5.8 US GDP 2 2.9 2.1 1.3 0.7 — US unemployment 3 3.4 3.9 4.4 5.5 6.7 US HPI 4 6.2 5.0 3.8 2.5 1.2 US federal funds rate 3 2.8 3.1 3.3 4.3 5.2 1 UK GDP = Real GDP growth seasonally adjusted; UK unemployment = UK unemployment rate 16-year+; UK HPI = Halifax All Houses, All Buyers Index; US GDP = Real GDP growth seasonally adjusted; US unemployment = US civilian unemployment rate 16-year+; US HPI = FHFA House Price Index. 2 5-year yearly average CAGR, starting 2022 (2022: 2021). 3 5-year average. Period based on 20 quarters from Q123 (2022: Q122). 4 5-year quarter end CAGR, starting Q422 (2022: Q421). |
Basis of preparation
Basis of preparation | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of initial application of standards or interpretations [abstract] | |
Basis of preparation | Basis of preparation These condensed consolidated interim financial statements (“the financial statements”) for the six months ended 30 June 2023 have been prepared in accordance with (a) the Disclosure Guidance and Transparency Rules (DTR) of the UK’s Financial Conduct Authority (FCA), (b) the Transparency (Directive 2004/109/EC) Regulations 2007 of Ireland (as amended), and (c) (i) UK adopted IAS 34, Interim Financial Reporting (ii) IAS 34, Interim Financial Reporting, as published by the International Accounting Standards Board (IASB), and (iii) IAS 34, Interim Financial Reporting as adopted pursuant to Regulation (EC) No 1606/2002 as it applies in the European Union (EU). UK adopted IAS 34 and EU adopted IAS 34 are currently the same and were the same as at 31 December 2022. The condensed consolidated interim financial statements should be read in conjunction with the annual financial statements for the year ended 31 December 2022. The annual financial statements for the year ended 31 December 2022 were prepared in accordance with the requirements of the Companies Act 2006 and in accordance with (i) UK-adopted international accounting standards (ii) International Financial Reporting Standards (IFRS) and interpretations (IFRICs) as issued by the IASB, and (iii) IFRS adopted pursuant to Regulation (EC) No 1606/2002 as it applies in the EU. UK adopted IFRS and EU adopted IFRS are currently the same and were the same as at 31 December 2022. The accounting policies and methods of computation used in these condensed consolidated interim financial statements are the same as those used in the Barclays Bank PLC Annual Report 2022. 1. Going concern The financial statements are prepared on a going concern basis, as the Directors are satisfied that the Barclays Bank Group and parent company have the resources to continue in business for a period of at least 12 months from approval of the interim financial statements. In making this assessment, the Directors have considered a wide range of information relating to present and future conditions which includes a review of a working capital report (WCR). The WCR is used by the Directors to assess the future performance of the Barclays Bank Group and that it has the resources in place that are required to meet its ongoing regulatory requirements. The WCR includes an assessment of the impact of internally generated stress testing scenarios on the liquidity and capital requirements forecasts. The stress tests used were based upon an assessment of reasonably possible downside economic scenarios that the Barclays Bank Group could experience. The WCR indicated that the Barclays Bank Group had sufficient capital in place to support its future business requirements and remained above its regulatory minimum requirements in the internal stress scenarios. 2. Other disclosures The Credit risk disclosures on pages 6 to 18 form part of these interim financial statements. |
Segmental reporting
Segmental reporting | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of operating segments [abstract] | |
Segmental reporting | Segmental reporting Analysis of results by business Corporate and Investment Bank Consumer, Cards and Payments Head Office Barclays Bank Group Half year ended 30.06.23 £m £m £m £m Total income 7,362 2,599 (157) 9,804 Operating expenses (4,324) (1,544) (84) (5,952) Litigation and conduct 2 (32) (4) (34) Total operating expenses (4,322) (1,576) (88) (5,986) Other net income 1 2 — — 2 Profit/(loss) before impairment 3,042 1,023 (245) 3,820 Credit impairment charge (20) (659) (9) (688) Profit/(loss) before tax 3,022 364 (254) 3,132 As at 30.06.23 £bn £bn £bn £bn Total assets 1,147.2 88.0 11.4 1,246.6 Total liabilities 1,105.7 82.4 0.2 1,188.3 Corporate and Investment Bank Consumer, Cards and Payments Head Office Barclays Bank Group Half year ended 30.06.22 £m £m £m £m Total income 8,086 1,992 (88) 9,990 Operating expenses (3,912) (1,285) (62) (5,259) Litigation and conduct (1,632) (200) (1) (1,833) Total operating expenses (5,544) (1,485) (63) (7,092) Other net income 1 — — — — Profit/(loss) before impairment 2,542 507 (151) 2,898 Credit impairment (charge)/release (31) (278) 16 (293) Profit/(loss) before tax 2,511 229 (135) 2,605 As at 31.12.22 £bn £bn £bn £bn Total assets 1,111.2 79.9 12.4 1,203.5 Total liabilities 1,058.2 85.0 1.4 1,144.6 Split of income by geographic region 2 Half year ended 30.06.23 Half year ended 30.06.22 £m £m United Kingdom 3,555 4,674 Europe 1,255 1,310 Americas 4,234 3,276 Africa and Middle East 42 31 Asia 718 699 Total 9,804 9,990 1 Other net income represents the share of post-tax results of associates and joint ventures. 2 The geographical analysis is based on the location of the office where the transactions are recorded. |
Net fee and commission income
Net fee and commission income | 6 Months Ended |
Jun. 30, 2023 | |
Fee and commission income (expense) [abstract] | |
Net fee and commission income | Net fee and commission income Fee and commission income is disaggregated below and includes a total for fees in scope of IFRS 15, Revenue from Contracts with Customers: Corporate and Investment Bank Consumer, Cards and Payments Head Office Total Half year ended 30.06.23 £m £m £m £m Fee type Transactional 242 1,583 — 1,825 Advisory 363 94 — 457 Brokerage and execution 999 43 — 1,042 Underwriting and syndication 1,036 — — 1,036 Other 49 36 8 93 Total revenue from contracts with customers 2,689 1,756 8 4,453 Other non-contract fee income 71 3 — 74 Fee and commission income 2,760 1,759 8 4,527 Fee and commission expense (747) (973) (1) (1,721) Net fee and commission income 2,013 786 7 2,806 Corporate and Investment Bank Consumer, Cards and Payments Head Office Total Half year ended 30.06.22 £m £m £m £m Fee type Transactional 216 1,229 — 1,445 Advisory 440 72 — 512 Brokerage and execution 734 28 — 762 Underwriting and syndication 1,101 — — 1,101 Other 30 78 11 119 Total revenue from contracts with customers 2,521 1,407 11 3,939 Other non-contract fee income 67 2 — 69 Fee and commission income 2,588 1,409 11 4,008 Fee and commission expense (461) (707) (1) (1,169) Net fee and commission income 2,127 702 10 2,839 Transactional fees are service charges on deposit accounts, cash management services and transactional processing fees. These include interchange and merchant fee income generated from credit and bank card usage. Advisory fees are generated from wealth management services and investment banking advisory services related to mergers, acquisitions and financial restructurings. Brokerage and execution fees are earned for executing client transactions with various exchanges and over-the-counter markets and assisting clients in clearing transactions and facilitating foreign exchange transactions for spot/forward contracts. Underwriting and syndication fees are earned for the distribution of client equity or debt securities and the arrangement and administration of a loan syndication. These include commitment fees to provide loan financing. |
Dividends on ordinary shares an
Dividends on ordinary shares and preference shares | 6 Months Ended |
Jun. 30, 2023 | |
Dividends [Abstract] | |
Dividends on ordinary shares and preference shares | Dividends on ordinary shares and preference shares Half year ended 30.06.23 Half year ended 30.06.22 Dividends paid during the period £m £m Ordinary shares 700 200 Preference shares 19 15 Total 719 215 An interim dividend in respect of six months ended 30 June 2023 of £648m was declared on 26 July 2023. |
Fair value of financial instrum
Fair value of financial instruments | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of fair value measurement of assets [abstract] | |
Fair value of financial instruments | Fair value of financial instruments This section should be read in conjunction with Note 16, Fair value of financial instruments of the Barclays Bank PLC Annual Report 2022, which provides more detail about accounting policies adopted, valuation methodologies used in calculating fair value and the valuation control framework which governs oversight of valuations. There have been no changes in the accounting policies adopted or the valuation methodologies used. Valuation The following table shows the Barclays Bank Group’s assets and liabilities that are held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification: Valuation technique using Quoted market prices Observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) Total As at 30.06.23 £m £m £m £m Trading portfolio assets 86,232 72,064 6,799 165,095 Financial assets at fair value through the income statement 6,067 220,867 6,171 233,105 Derivative financial instruments 3,484 258,112 4,532 266,128 Financial assets at fair value through other comprehensive income 18,683 28,299 50 47,032 Investment property — — 2 2 Total assets 114,466 579,342 17,554 711,362 Trading portfolio liabilities (36,740) (33,477) (52) (70,269) Financial liabilities designated at fair value (115) (310,388) (1,092) (311,595) Derivative financial instruments (4,064) (245,461) (5,269) (254,794) Total liabilities (40,919) (589,326) (6,413) (636,658) As at 31.12.22 Trading portfolio assets 62,469 64,822 6,480 133,771 Financial assets at fair value through the income statement 5,647 199,370 6,111 211,128 Derivative financial instruments 10,054 287,749 5,173 302,976 Financial assets at fair value through other comprehensive income 15,029 30,051 4 45,084 Investment property — — 5 5 Total assets 93,199 581,992 17,773 692,964 Trading portfolio liabilities (43,679) (28,725) (56) (72,460) Financial liabilities designated at fair value (133) (270,880) (1,042) (272,055) Derivative financial instruments (10,823) (272,020) (6,363) (289,206) Total liabilities (54,635) (571,625) (7,461) (633,721) The following table shows the Barclays Bank Group’s Level 3 assets and liabilities that are held at fair value disaggregated by product type: As at 30.06.23 As at 31.12.22 Assets Liabilities Assets Liabilities £m £m £m £m Interest rate derivatives 2,520 (2,043) 2,361 (2,858) Foreign exchange derivatives 182 (176) 1,513 (1,474) Credit derivatives 342 (694) 290 (603) Equity derivatives 1,488 (2,356) 1,009 (1,428) Corporate debt 1,710 (35) 1,677 (49) Reverse repurchase and repurchase agreements 44 (643) 37 (434) Non-asset backed loans 7,946 — 8,105 — Private equity investments 138 — 140 — Other 1 3,184 (466) 2,641 (615) Total 17,554 (6,413) 17,773 (7,461) 1 Other includes commercial real estate loans, fund and fund-linked products, asset backed loans, asset backed securities, equity cash products, issued debt, commercial paper, Government and Government sponsored debt and investment property. Assets and liabilities reclassified between Level 1 and Level 2 During the period there were no material transfers between Level 1 and Level 2 (year ended December 2022: no material transfers between Level 1 and Level 2). Level 3 movement analysis The following table summarises the movements in the balances of Level 3 assets and liabilities during the period. The table shows gains and losses and includes amounts for all financial assets and liabilities that are held at fair value transferred to and from Level 3 during the period. Transfers have been reflected as if they had taken place at the beginning of the period. Asset and liability moves between Level 2 and Level 3 are primarily due to i) an increase or decrease in observable market activity related to an input or ii) a change in the significance of the unobservable input, with assets and liabilities classified as Level 3 if an unobservable input is deemed significant. Level 3 movement analysis Purchases Sales Issues Settle- ments Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 30.06.23 As at 01.01.23 Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 595 338 (118) — (53) 5 — — 36 (29) 774 Non-asset backed loans 4,837 919 (1,152) — (311) 4 — — 556 (334) 4,519 Other 1,048 1,028 (606) — (38) (43) — — 430 (313) 1,506 Trading portfolio assets 6,480 2,285 (1,876) — (402) (34) — — 1,022 (676) 6,799 Corporate debt 1,079 — (120) — — (20) (3) — — — 936 Non-asset backed loans 3,268 1,053 (305) — (483) (33) (42) — 28 (106) 3,380 Private equity investments 140 — — — (5) (5) 8 — — — 138 Reverse repurchase and repurchase agreements 38 — — — — (11) — — 46 (29) 44 Other 1,586 794 (530) — (150) (23) (10) — 22 (16) 1,673 Financial assets at fair value through the income statement 6,111 1,847 (955) — (638) (92) (47) — 96 (151) 6,171 Non-asset backed loans — 47 — — — — — — — — 47 Other 4 — — — (1) — — — — — 3 Financial assets at fair value through other comprehensive income 4 47 — — (1) — — — — — 50 Investment property 5 — — — — — (3) — — — 2 Trading portfolio liabilities (56) (16) 4 — — 15 — — (8) 9 (52) Financial liabilities designated at fair value (1,042) — — (226) — 4 (1) — (290) 463 (1,092) Interest rate derivatives (497) — — — 19 (35) — — 544 446 477 Foreign exchange derivatives 39 — — — — (31) — — 13 (15) 6 Credit derivatives (313) (191) 5 — 66 13 — — 52 16 (352) Equity derivatives (419) (90) — — (132) (135) — — (104) 12 (868) Net derivative financial instruments 1 (1,190) (281) 5 — (47) (188) — — 505 459 (737) Total 10,312 3,882 (2,822) (226) (1,088) (295) (51) — 1,325 104 11,141 1 Derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets were £4,532m and derivative financial liabilities were £5,269m. Level 3 movement analysis Purchases Sales Issues Settle- ments Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 30.06.22 As at 01.01.22 Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 389 90 (144) — (17) 54 — — 43 (11) 404 Non-asset backed loans 758 2,448 (459) — — 11 — — 50 (113) 2,695 Other 1,134 419 (178) — (302) 60 — — 191 (167) 1,157 Trading portfolio assets 2,281 2,957 (781) — (319) 125 — — 284 (291) 4,256 Corporate debt 816 45 — — (148) 55 — — — — 768 Non-asset backed loans 2,985 1,848 (757) — (315) (76) — — 52 — 3,737 Private equity investments 148 19 (60) — — 7 11 — 3 (4) 124 Reverse repurchase and repurchase agreements 13 66 — — (12) 16 — — 95 — 178 Other 2,117 4,706 (5,579) — 5 (59) 181 — 4 (19) 1,356 Financial assets at fair value through the income statement 6,079 6,684 (6,396) — (470) (57) 192 — 154 (23) 6,163 Non-asset backed loans — — — — — — — — — — — Other 38 — — — — — — (2) — — 36 Financial assets at fair value through other comprehensive income 38 — — — — — — (2) — — 36 Investment property 7 — (1) — — — (1) — — — 5 Trading portfolio liabilities (27) (35) 3 — — (29) — — — 6 (82) Financial liabilities designated at fair value (404) (5) — (13) 47 (22) 2 — (81) 37 (439) Interest rate derivatives (260) 25 — — (4) (305) (9) — 271 6 (276) Foreign exchange derivatives 2 — — — (9) 273 — — (65) 25 226 Credit derivatives (386) (36) 5 — 60 (99) — — 20 55 (381) Equity derivatives (1,405) (83) — — 170 980 — — (9) 272 (75) Net derivative financial instruments 1 (2,049) (94) 5 — 217 849 (9) — 217 358 (506) Total 5,925 9,507 (7,170) (13) (525) 866 184 (2) 574 87 9,433 1 Derivative financial instruments are presented on a net basis. On a gross basis, derivative financial assets were £3,873m and derivative financial liabilities were £4,379m. Unrealised gains and losses on Level 3 financial assets and liabilities The following table discloses the unrealised gains and losses recognised in the period arising on Level 3 financial assets and liabilities held at the period end. Half year ended 30.06.23 Half year ended 30.06.22 Income statement Other compre-hensive income Total Income statement Other compre-hensive income Total Trading income Other income Trading income Other income £m £m £m £m £m £m £m £m Trading portfolio assets (35) — — (35) 121 — — 121 Financial assets at fair value through the income statement (87) (50) — (137) 16 9 — 25 Financial assets at fair value through other comprehensive income — — — — — — (2) (2) Investment properties — (3) — (3) — (1) — (1) Trading portfolio liabilities 15 — — 15 (35) — — (35) Financial liabilities designated at fair value 2 (1) — 1 (14) — — (14) Net derivative financial instruments (186) — — (186) 862 (1) — 861 Total (291) (54) — (345) 950 7 (2) 955 Valuation techniques and sensitivity analysis Sensitivity analysis is performed on products with significant unobservable inputs (Level 3) to generate a range of reasonably possible alternative valuations. The sensitivity methodologies applied take account of the nature of valuation techniques used, as well as the availability and reliability of observable proxy and historical data and the impact of using alternative models. Sensitivities are dynamically calculated on a monthly basis. The calculation is based on range or spread data of a reliable reference source or a scenario based on relevant market analysis alongside the impact of using alternative models. Sensitivities are calculated without reflecting the impact of any diversification in the portfolio. Current period valuation and sensitivity methodologies are consistent with those described within Note 16, Fair value of financial instruments in the Barclays Bank PLC Annual Report 2022. Sensitivity analysis of valuations using unobservable inputs As at 30.06.23 As at 31.12.22 Favourable changes Unfavourable changes Favourable changes Unfavourable changes Income statement Equity Income Statement Equity Income statement Equity Income Statement Equity £m £m £m £m £m £m £m £m Interest rate derivatives 123 — (186) — 119 — (155) — Foreign exchange derivatives 11 — (17) — 16 — (22) — Credit derivatives 27 — (79) — 79 — (71) — Equity derivatives 186 — (264) — 161 — (168) — Corporate debt 23 — (22) — 45 — (27) — Non-asset backed loans 295 1 (535) (1) 244 — (450) — Private equity investments 7 — (7) — 10 — (10) — Other 1 112 — (109) — 53 — (64) — Total 784 1 (1,219) (1) 727 — (967) — 1 Other includes commercial real estate loans, asset backed securities, equity cash products, fund and fund-linked products, asset backed loans, issued debt, commercial paper, Government and Government sponsored debt and investment property. The effect of stressing unobservable inputs to a range of reasonably possible alternatives, alongside considering the impact of using alternative models, would be to increase fair values by up to £785m (December 2022: £727m) or to decrease fair values by up to £1,220m (December 2022: £967m) with substantially all the potential effect impacting profit and loss rather than reserves. Significant unobservable inputs The valuation techniques and significant unobservable inputs for assets and liabilities recognised at fair value and classified as Level 3 are consistent with those set out in Note 16, Fair value of financial instruments in the Barclays Bank PLC Annual Report 2022. Fair value adjustments Key balance sheet valuation adjustments are quantified below: As at 30.06.23 As at 31.12.22 £m £m Exit price adjustments derived from market bid-offer spreads (543) (566) Uncollateralised derivative funding (24) (11) Derivative credit valuation adjustments (241) (319) Derivative debit valuation adjustments 196 208 • Exit price adjustments derived from market bid-offer spreads decreased by £23m to £543m • Uncollateralised derivative funding increased by £13m to £24m • Derivative credit valuation adjustments decreased by £78m to £241m as a result of tightening input counterparty credit spreads • Derivative debit valuation adjustments decreased by £12m to £196m Portfolio exemption The Barclays Bank Group uses the portfolio exemption in IFRS 13, Fair Value Measurement to measure the fair value of groups of financial assets and liabilities. Instruments are measured using the price that would be received to sell a net long position (i.e. an asset) for a particular risk exposure or to transfer a net short position (i.e. a liability) for a particular risk exposure in an orderly transaction between market participants at the balance sheet date under current market conditions. Accordingly, the Barclays Bank Group measures the fair value of the group of financial assets and liabilities consistently with how market participants would price the net risk exposure at the measurement date. Unrecognised gains as a result of the use of valuation models using unobservable inputs The amount that has yet to be recognised in income that relates to the difference between the transaction price (the fair value at initial recognition) and the amount that would have arisen had valuation models using unobservable inputs been used on initial recognition, less amounts subsequently recognised, is £183m (December 2022: £106m) for financial instruments measured at fair value and £24m (December 2022: £25m) for financial instruments carried at amortised cost. There are additions and FX gains of £107m (December 2022: £49m) and amortisation and releases of £30m (December 2022: £65m) for financial instruments measured at fair value and amortisation and releases of £1m (December 2022: £3m) offset by additions of nil (December 2022: £nil) for financial instruments carried at amortised cost. Third party credit enhancements Structured and brokered certificates of deposit issued by the Barclays Bank Group are insured up to $250,000 per depositor by the Federal Deposit Insurance Corporation (FDIC) in the United States. The FDIC is funded by premiums that the Barclays Bank Group and other banks pay for deposit insurance coverage. The carrying value of these issued certificates of deposit that are designated under the IFRS 9 fair value option includes this third party credit enhancement. The on-balance sheet value of these brokered certificates of deposit amounted to £4,648m (December 2022: £5,197m). Comparison of carrying amounts and fair values for assets and liabilities not held at fair value Valuation methodologies employed in calculating the fair value of financial assets and liabilities measured at amortised cost are consistent with those described within Note 16, Fair value of financial instruments in the Barclays Bank PLC Annual Report 2022. The following table summarises the fair value of financial assets and liabilities measured at amortised cost on the Barclays Bank Group’s balance sheet: As at 30.06.23 As at 31.12.22 Carrying amount Fair value Carrying amount Fair value Financial assets £m £m £m £m Debt securities at amortised cost 35,245 33,869 27,303 27,006 Loans and advances at amortised cost 147,992 148,490 155,204 154,721 Reverse repurchase agreements and other similar secured lending 1,293 1,293 725 725 Financial liabilities Deposits at amortised cost (307,820) (307,811) (291,579) (291,552) Repurchase agreements and other similar secured borrowing (25,156) (25,153) (11,965) (11,966) Debt securities in issue (58,377) (58,266) (60,012) (59,895) Subordinated liabilities (36,325) (35,403) (38,253) (38,686) |
Subordinated liabilities
Subordinated liabilities | 6 Months Ended |
Jun. 30, 2023 | |
Subordinated liabilities [abstract] | |
Subordinated liabilities | Subordinated liabilities Half year ended 30.06.23 Year ended 31.12.22 £m £m Opening balance 38,253 32,185 Issuances 3,502 15,381 Redemptions (3,661) (8,367) Other (1,769) (946) Closing balance 36,325 38,253 Designated at fair value (Note 5) 503 521 Total subordinated liabilities 36,828 38,774 Issuances of £3,502m comprise £3,365m in intra-group loans from Barclays PLC and £137m USD Floating Rate Notes issued externally by a Barclays Bank PLC subsidiary. Redemptions of £3,661m comprise £3,644m in intra-group loans from Barclays PLC and £17m USD Floating Rate Notes issued externally by a Barclays Bank PLC subsidiary. Other movements predominantly comprise foreign exchange movements and fair value hedge adjustments. |
Provisions
Provisions | 6 Months Ended |
Jun. 30, 2023 | |
Provisions [abstract] | |
Provisions | Provisions As at 30.06.23 As at 31.12.22 £m £m Customer redress 35 46 Legal, competition and regulatory matters 59 113 Redundancy and restructuring 17 45 Undrawn contractually committed facilities and guarantees 467 532 Sundry provisions 154 122 Total 732 858 |
Retirement benefits
Retirement benefits | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of defined benefit plans [abstract] | |
Retirement benefits | Retirement benefits As at 30 June 2023, the Barclays Bank Group’s IAS 19 net pension surplus across all schemes was £4.0bn (December 2022: £4.6bn). The UK Retirement Fund (UKRF), which is the Barclays Bank Group’s main scheme, had an IAS 19 net pension surplus of £4.1bn (December 2022: £4.7bn). The movement for the UKRF was mainly driven by actual price inflation being higher than assumed, future long-term price inflation expected to be higher than assumed at the start of the year and assets underperforming relative to the discount rate, partially offset by an increase in discount rate. UKRF funding valuations The latest triennial actuarial valuation of the UKRF with an effective date of 30 September 2022 was completed in February 2023. The valuation showed a funding surplus of £2bn (2021 update: £0.6bn surplus). As the UKRF had a funding surplus at the valuation date the 2023 deficit reduction contribution (£286m), agreed as part of the 2019 triennial actuarial valuation, is no longer required, and no recovery plan is needed. |
Other reserves
Other reserves | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of reserves within equity [abstract] | |
Other reserves | Other reserves As at 30.06.23 As at 31.12.22 £m £m Currency translation reserve 3,667 4,992 Fair value through other comprehensive income reserve (1,284) (1,342) Cash flow hedging reserve (5,940) (5,557) Own credit reserve (27) 467 Other reserves 196 (24) Total (3,388) (1,464) Currency translation reserve The currency translation reserve represents the cumulative gains and losses on the retranslation of the Barclays Bank Group’s net investment in foreign operations, net of the effects of hedging. As at 30 June 2023, there was a cumulative gain of £3,667m (December 2022: £4,992m gain) in the currency translation reserve, a loss during the period of £1,325m. This principally reflects the strengthening of GBP against USD and EUR during the period. Fair value through other comprehensive income reserve The fair value through other comprehensive income reserve represents the cumulative unrealised gains and losses on fair value through other comprehensive income investments since initial recognition. As at 30 June 2023, there was a cumulative loss of £1,284m (December 2022: £1,342m loss) in the fair value through other comprehensive income reserve, a gain during the period of £58m. This is principally driven by a £96m gain from the increase in fair value of bonds due to decreasing bond yields, partially offset by a net gain of £19m transferred to the income statement and a tax charge of £19m. Cash flow hedging reserve The cash flow hedging reserve represents the cumulative gains and losses on effective cash flow hedging instruments that will be recycled to the income statement when the hedged transactions affect profit or loss. As at 30 June 2023, there was a cumulative loss of £5,940m (December 2022: £5,557m loss) in the cash flow hedging reserve, a loss during the period of £383m. This principally reflects a £1,262m loss from fair value movements of interest rate swaps held for hedging purposes as major interest rate forward curves increased partially offset by £724m losses transferred to the income statement and a tax credit of £155m. Own credit reserve The own credit reserve reflects the cumulative own credit gains and losses on financial liabilities at fair value. Amounts in the own credit reserve are not recycled to profit or loss in future periods. As at 30 June 2023, there was a cumulative loss of £27m (December 2022: £467m gain) in the own credit reserve, a loss during the period of £494m. This principally reflects a £682m loss from the tightening of credit spreads partially offset by a tax credit of £188m. Other reserves As at 30 June 2023, there was a cumulative gain of £196m (December 2022: £24m loss) in other reserves. The gain during the period is driven by the recognition of a £124m merger reserve, which arose on the acquisition of the issued share capital of Barclays Asset Management Limited and Barclays Investment Solutions Limited and certain other assets and liabilities, business guarantees, business contracts and business employee contracts from Barclays Bank UK PLC. See Note 14 Barclays Bank PLC parent company information for further information. |
Contingent liabilities and comm
Contingent liabilities and commitments | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of contingent liabilities [abstract] | |
Contingent liabilities and commitments | Contingent liabilities and commitments As at 30.06.23 As at 31.12.22 Contingent liabilities and financial guarantees £m £m Guarantees and letters of credit pledged as collateral security 19,108 17,700 Performance guarantees, acceptances and endorsements 8,041 8,100 Total 27,149 25,800 Commitments Documentary credits and other short-term trade related transactions 1,356 1,748 Standby facilities, credit lines and other commitments 324,223 333,229 Total 325,579 334,977 Further details on contingent liabilities, where it is not practicable to disclose an estimate of the potential financial effect on the Barclays Bank Group relating to legal and competition and regulatory matters can be found in note 11 below. |
Legal, competition and regulato
Legal, competition and regulatory matters | 6 Months Ended |
Jun. 30, 2023 | |
Legal, Competition And Regulatory Matters | |
Legal, competition and regulatory matters | Legal, competition and regulatory matters The Barclays Bank Group faces legal, competition and regulatory challenges, many of which are beyond our control. The extent of the impact of these matters cannot always be predicted but may materially impact our operations, financial results, condition and prospects. Matters arising from a set of similar circumstances can give rise to either a contingent liability or a provision, or both, depending on the relevant facts and circumstances. The recognition of provisions in relation to such matters involves critical accounting estimates and judgments in accordance with the relevant accounting policies applicable to Note 7, Provisions. We have not disclosed an estimate of the potential financial impact or effect on the Barclays Bank Group of contingent liabilities where it is not currently practicable to do so. Various matters detailed in this note seek damages of an unspecified amount. While certain matters specify the damages claimed, such claimed amounts do not necessarily reflect the Barclays Bank Group’s potential financial exposure in respect of those matters. Investigations into certain advisory services agreements FCA proceedings In 2008, Barclays Bank PLC and Qatar Holdings LLC entered into two advisory service agreements (the Agreements). The Financial Conduct Authority (FCA) conducted an investigation into whether the Agreements may have related to Barclays PLC’s capital raisings in June and November 2008 (the Capital Raisings) and therefore should have been disclosed in the announcements or public documents relating to the Capital Raisings. In 2013, the FCA issued warning notices (the Warning Notices) finding that Barclays PLC and Barclays Bank PLC acted recklessly and in breach of certain disclosure-related listing rules, and that Barclays PLC was also in breach of Listing Principle 3. The financial penalty provided in the Warning Notices was £50m. Barclays PLC and Barclays Bank PLC contested the findings. In September 2022, the FCA’s Regulatory Decisions Committee (RDC) issued Decision Notices finding that Barclays PLC and Barclays Bank PLC breached certain disclosure-related listing rules. The RDC also found that in relation to the disclosures made in the Capital Raising of November 2008, Barclays PLC and Barclays Bank PLC acted recklessly, and that Barclays PLC breached Listing Principle 3. The RDC upheld the combined penalty of £50m on Barclays PLC and Barclays Bank PLC, the same penalty as in the Warning Notices. Barclays PLC and Barclays Bank PLC have referred the RDC’s findings to the Upper Tribunal for reconsideration. Investigations into LIBOR and other benchmarks and related civil actions Regulators and law enforcement agencies, including certain competition authorities, from a number of governments have conducted investigations relating to Barclays Bank PLC’s involvement in allegedly manipulating certain financial benchmarks, such as LIBOR. Various individuals and corporates in a range of jurisdictions have threatened or brought civil actions against the Barclays Bank Group and other banks in relation to the alleged manipulation of LIBOR and/or other benchmarks. USD LIBOR civil actions The majority of the USD LIBOR cases, which have been filed in various US jurisdictions, have been consolidated for pre-trial purposes in the US District Court in the Southern District of New York (SDNY). The complaints are substantially similar and allege, among other things, that Barclays PLC, Barclays Bank PLC, Barclays Capital Inc. (BCI) and other financial institutions individually and collectively violated provisions of the US Sherman Antitrust Act (Antitrust Act), the US Commodity Exchange Act (CEA), the US Racketeer Influenced and Corrupt Organizations Act (RICO), the US Securities Exchange Act of 1934 and various state laws by manipulating USD LIBOR rates. Putative class actions and individual actions seek unspecified damages with the exception of one lawsuit, in which the plaintiffs are seeking no less than $100m in actual damages and additional punitive damages against all defendants, including Barclays Bank PLC. Some of the lawsuits also seek trebling of damages under the Antitrust Act and RICO. Barclays Bank PLC has previously settled certain claims. The financial impact of these settlements is not material to the Barclays Bank Group’s operating results, cash flows or financial position. Sterling LIBOR civil actions In 2016, two putative class actions filed in the SDNY against Barclays Bank PLC, BCI and other Sterling LIBOR panel banks alleging, among other things, that the defendants manipulated the Sterling LIBOR rate in violation of the Antitrust Act, CEA and RICO, were consolidated. The defendants’ motion to dismiss the claims was granted in 2018. The plaintiffs have appealed the dismissal. Japanese Yen LIBOR civil actions In 2012, a putative class action was filed in the SDNY against Barclays Bank PLC and other Japanese Yen LIBOR panel banks by a lead plaintiff involved in exchange-traded derivatives and members of the Japanese Bankers Association’s Euroyen Tokyo Interbank Offered Rate (Euroyen TIBOR) panel. The complaint alleges, among other things, manipulation of the Euroyen TIBOR and Yen LIBOR rates and breaches of the CEA and the Antitrust Act. In 2014, the court dismissed the plaintiff’s antitrust claims, and, in 2020, the court dismissed the plaintiff’s remaining CEA claims. In 2015, a second putative class action, making similar allegations to the above class action, was filed in the SDNY against Barclays PLC, Barclays Bank PLC and BCI. Barclays and the plaintiffs reached a settlement of $17.75m for both actions, which received final court approval in March 2023. This matter is now concluded. ICE LIBOR civil action In August 2020, an action related to the LIBOR benchmark administered by the Intercontinental Exchange Inc. and certain of its affiliates (ICE) was filed by a group of individual plaintiffs in the US District Court for the Northern District of California on behalf of individual borrowers and consumers of loans and credit cards with variable interest rates linked to USD ICE LIBOR. The plaintiffs’ motion seeking, among other things, preliminary and permanent injunctions to enjoin the defendants from continuing to set LIBOR or enforce any financial instrument that relies in whole or in part on USD LIBOR was denied. The defendants’ motion to dismiss the case was granted in September 2022. The plaintiffs have filed an amended complaint, which the defendants have moved to dismiss. Non-US benchmarks civil actions There remains one claim, issued in 2017 against Barclays Bank PLC and other banks in the UK in connection with alleged manipulation of LIBOR. Proceedings have also been brought in a number of other jurisdictions in Europe, Argentina and Israel relating to alleged manipulation of LIBOR and EURIBOR. Additional proceedings in other jurisdictions may be brought in the future. Credit Default Swap civil action A putative antitrust class action is pending in New Mexico federal court against Barclays Bank PLC, BCI and various other financial institutions. The plaintiffs, the New Mexico State Investment Council and certain New Mexico pension funds, allege that the defendants conspired to manipulate the benchmark price used to value Credit Default Swap (CDS) contracts at settlement (i.e. the CDS final auction price). The plaintiffs allege violations of US antitrust laws and the CEA, and unjust enrichment under state law. The defendants’ motion to dismiss was denied in June 2023. Foreign Exchange investigations and related civil actions The Barclays Bank Group has been the subject of investigations in various jurisdictions in relation to certain sales and trading practices in the Foreign Exchange market. Settlements were reached in various jurisdictions in connection with these investigations, including the EU and US. The financial impact of any remaining ongoing investigations is not expected to be material to the Barclays Bank Group’s operating results, cash flows or financial position. Various individuals and corporates in a range of jurisdictions have threatened or brought civil actions against the Barclays Bank Group and other banks in relation to alleged manipulation of Foreign Exchange markets. US FX opt out civil action In 2018, Barclays Bank PLC and BCI settled a consolidated action filed in the SDNY, alleging manipulation of Foreign Exchange markets (Consolidated FX Action), for a total amount of $384m. Also in 2018, a group of plaintiffs who opted out of the Consolidated FX Action filed a complaint in the SDNY against Barclays PLC, Barclays Bank PLC, BCI and other defendants. Some of the plaintiffs’ claims were dismissed in 2020. Barclays PLC, Barclays Bank PLC, and BCI have reached a settlement of all claims against them in the matter. A settlement payment was made in April 2023 and the matter is now concluded. The financial impact of this settlement is not material to the Barclays Bank Group’s operating results, cash flows or financial position. US retail basis civil action In 2015, a putative class action was filed against several international banks, including Barclays PLC and BCI, on behalf of a proposed class of individuals who exchanged currencies on a retail basis at bank branches (Retail Basis Claims). The SDNY has ruled that the Retail Basis Claims are not covered by the settlement agreement in the Consolidated FX Action. The Court subsequently dismissed all Retail Basis Claims against the Barclays Bank Group and all other defendants. The plaintiffs filed an amended complaint. The defendants’ motion for summary judgment was granted in March 2023, dismissing the plaintiffs’ remaining claims. The plaintiffs are appealing the decision. Non-US FX civil actions Legal proceedings have been brought or are threatened against Barclays PLC, Barclays Bank PLC, BCI and Barclays Execution Services Limited (BX) in connection with alleged manipulation of Foreign Exchange in the UK, a number of other jurisdictions in Europe, Israel, Brazil and Australia. Additional proceedings may be brought in the future. The above-mentioned proceedings include two purported class actions filed against Barclays PLC, Barclays Bank PLC, BX, BCI and other financial institutions in the UK Competition Appeal Tribunal (CAT) in 2019. The CAT refused to certify these claims in the first quarter of 2022. In July 2023, the Court of Appeal overturned the CAT’s decision and found that the claims should be certified on an opt out basis. The Court of Appeal upheld the CAT’s determination as to which of the two purported class representatives should be chosen to bring the claim. Subject to further appeal, only the claim brought by the chosen class representative will now proceed in the CAT. Also in 2019, a separate claim was filed in the UK in the High Court of Justice (High Court), and subsequently transferred to the CAT, by various banks and asset management firms against Barclays Bank PLC and other financial institutions alleging breaches of European and UK competition laws related to FX trading. This claim has been settled as part of the settlement payment referred to under the US FX opt out civil action above and the matter is now concluded. Metals related civil actions A US civil complaint alleging manipulation of the price of silver in violation of the CEA, the Antitrust Act and state antitrust and consumer protection laws was brought by a proposed class of plaintiffs against a number of banks, including Barclays Bank PLC, BCI and BX, and transferred to the SDNY. The complaint was dismissed against these Barclays entities and certain other defendants in 2018, and against the remaining defendants in May 2023. The plaintiffs have appealed the dismissal of the complaint against all defendants. Civil actions have also been filed in Canadian courts against Barclays PLC, Barclays Bank PLC, Barclays Capital Canada Inc. and BCI on behalf of proposed classes of plaintiffs alleging manipulation of gold and silver prices. US residential mortgage related civil actions There are two US Residential Mortgage-Backed Securities (RMBS) related civil actions arising from unresolved repurchase requests submitted by Trustees for certain RMBS, alleging breaches of various loan-level representations and warranties (R&Ws) made by Barclays Bank PLC and/or a subsidiary acquired in 2007. In one action, the parties have agreed to settle the litigation. The financial impact of the settlement is not material to the Barclays Bank Group’s operating results, cash flows or financial position. The other repurchase action is pending. Government and agency securities civil actions Treasury auction securities civil actions Consolidated putative class action complaints filed in US federal court against Barclays Bank PLC, BCI and other financial institutions under the Antitrust Act and state common law allege that the defendants (i) conspired to manipulate the US Treasury securities market and/or (ii) conspired to prevent the creation of certain platforms by boycotting or threatening to boycott such trading platforms. The court dismissed the consolidated action in March 2021. The plaintiffs filed an amended complaint. The defendants’ motion to dismiss the amended complaint was granted in March 2022. The plaintiffs are appealing this decision. In addition, certain plaintiffs have filed a related, direct action against BCI and certain other financial institutions, alleging that defendants conspired to fix and manipulate the US Treasury securities market in violation of the Antitrust Act, the CEA and state common law. This action remains stayed. Supranational, Sovereign and Agency bonds civil actions Civil antitrust actions have been filed in the SDNY and Federal Court of Canada in Toronto against Barclays Bank PLC, BCI, BX, Barclays Capital Securities Limited and, with respect to the civil action filed in Canada only, Barclays Capital Canada, Inc. and other financial institutions alleging that the defendants conspired to fix prices and restrain competition in the market for US dollar-denominated Supranational, Sovereign and Agency bonds. The SDNY actions were dismissed and these matters are now concluded. In the Federal Court of Canada action, the parties have reached a settlement in principle, which will require court approval. The financial impact of the settlement is not expected to be material to the Barclays Bank Group’s operating results, cash flows or financial position. Variable Rate Demand Obligations civil actions Civil actions have been filed against Barclays Bank PLC and BCI and other financial institutions alleging the defendants conspired or colluded to artificially inflate interest rates set for Variable Rate Demand Obligations (VRDOs). VRDOs are municipal bonds with interest rates that reset on a periodic basis, most commonly weekly. Two actions in state court have been filed by private plaintiffs on behalf of the states of Illinois and California. Three putative class action complaints have been consolidated in the SDNY. In the consolidated SDNY class action, certain of the plaintiffs’ claims were dismissed in November 2020 and June 2022 and the plaintiffs’ motion for class certification is pending. In the California action, the California appeals court reversed the dismissal of the plaintiffs’ claims in April 2023. In the Illinois action, the defendants have reached a settlement in principle with the Attorney General for the State of Illinois to resolve the litigation, which is subject to approval by the court. The financial impact of the settlement is not material to the Barclays Bank Group’s operating results, cash flows or financial position. Odd-lot corporate bonds antitrust class action In 2020, BCI, together with other financial institutions, were named as defendants in a putative class action. The complaint alleges a conspiracy to boycott developing electronic trading platforms for odd-lots and price fixing. The plaintiffs demand unspecified money damages. The defendants’ motion to dismiss was granted in 2021 and the plaintiffs have appealed the dismissal. Interest rate swap and credit default swap US civil actions Barclays PLC, Barclays Bank PLC and BCI, together with other financial institutions that act as market makers for interest rate swaps (IRS), are named as defendants in several antitrust class actions which were consolidated in the SDNY in 2016. The complaints allege the defendants conspired to prevent the development of exchanges for IRS and demand unspecified money damages. In 2018, trueEX LLC filed an antitrust class action in the SDNY against a number of financial institutions including Barclays PLC, Barclays Bank PLC and BCI based on similar allegations with respect to trueEX LLC’s development of an IRS platform. In 2017, Tera Group Inc. filed a separate civil antitrust action in the SDNY claiming that certain conduct alleged in the IRS cases also caused the plaintiff to suffer harm with respect to the Credit Default Swaps market. In 2018 and 2019, respectively, the court dismissed certain claims in both cases for unjust enrichment and tortious interference but denied motions to dismiss the federal and state antitrust claims, which remain pending. BDC Finance L.L.C. In 2008, BDC Finance L.L.C. (BDC) filed a complaint in the Supreme Court of the State of New York (NY Supreme Court), demanding damages of $298m, alleging that Barclays Bank PLC had breached a contract in connection with a portfolio of total return swaps governed by an ISDA Master Agreement (the Master Agreement). Following a trial, the court ruled in 2018 that Barclays Bank PLC was not a defaulting party, which was affirmed on appeal. In April 2021, the trial court entered judgement in favour of Barclays Bank PLC for $3.3m and as yet to be determined legal fees and costs. BDC appealed. In January 2022, the appellate court reversed the trial court’s summary judgment decision in favour of Barclays Bank PLC and remanded the case to the lower court for further proceedings. The parties have filed cross-motions on the scope of trial. The trial has been adjourned pending a decision on the motions and any subsequent appeal. In 2011, BDC’s investment advisor, BDCM Fund Adviser, LLC and its parent company, Black Diamond Capital Holdings, LLC also sued Barclays Bank PLC and BCI in Connecticut State Court for unspecified damages allegedly resulting from Barclays Bank PLC’s conduct relating to the Master Agreement, asserting claims for violation of the Connecticut Unfair Trade Practices Act and tortious interference with business and prospective business relations. This case is currently stayed. Civil actions in respect of the US Anti-Terrorism Act There are a number of civil actions, on behalf of more than 4,000 plaintiffs, filed in US federal courts in the US District Court in the Eastern District of New York (EDNY) and SDNY against Barclays Bank PLC and a number of other banks. The complaints generally allege that Barclays Bank PLC and those banks engaged in a conspiracy to facilitate US dollar-denominated transactions for the Iranian Government and various Iranian banks, which in turn funded acts of terrorism that injured or killed the plaintiffs or the plaintiffs’ family members. The plaintiffs seek to recover damages for pain, suffering and mental anguish under the provisions of the US Anti-Terrorism Act, which allow for the trebling of any proven damages. The court granted the defendants’ motions to dismiss three out of the six actions in the EDNY. The plaintiffs appealed in one action and the dismissal was affirmed, and judgment was entered, in January 2023. The court later gave the plaintiffs until December 2023 to make a motion to vacate the judgment. The plaintiffs have also petitioned for US Supreme Court review. In the other two dismissed actions in the EDNY, the court gave plaintiffs until September 2023 to serve amended complaints. This was also the case for the fourth action in the EDNY. Those actions, as well as the two other actions in the EDNY, are currently stayed. Out of the two actions in the SDNY, the court granted the defendants’ motion to dismiss the first action. That action is stayed and the second SDNY action is stayed pending any appeal on the dismissal of the first. Shareholder derivative action In November 2020, a purported Barclays shareholder filed a putative derivative action in New York state court against BCI and a number of current and former members of the Board of Directors of Barclays PLC and senior executives or employees of the Barclays Bank Group. The shareholder filed the claim on behalf of nominal defendant Barclays PLC, alleging that the individual defendants harmed the company through breaches of their duties, including under the Companies Act 2006. The plaintiff seeks damages on behalf of Barclays PLC for the losses that Barclays PLC allegedly suffered as a result of these alleged breaches. An amended complaint was filed in April 2021, which BCI and certain other defendants moved to dismiss. The motion to dismiss was granted in April 2022. The plaintiff appealed the decision, and the dismissal was unanimously affirmed in June 2023 by the First Judicial Department in New York. The plaintiff has sought leave to appeal the First Judicial Department’s decision to the New York Court of Appeals. Derivative transactions civil action In 2021, Vestia a Dutch housing association brought a claim against Barclays Bank PLC in the UK in the High Court in relation to a series of derivative transactions entered into with Barclays Bank PLC between 2008 and 2011, seeking damages of £329m. Barclays Bank PLC is defending the claim and has made a counterclaim. Skilled person review in relation to historic timeshare loans and associated matters Clydesdale Financial Services Limited (CFS), which trades as Barclays Partner Finance and houses Barclays’ point-of-sale finance business, was required by the FCA to undertake a skilled person review in 2020 following concerns about historic affordability assessments for certain loans to customers in connection with timeshare purchases. The skilled person review was concluded in 2021. CFS complied fully with the skilled person review requirements, including carrying out certain remediation measures. CFS was not required to conduct a full back book review. Instead, CFS reviewed limited historic lending to ascertain whether its practices caused customer harm and is remediating any examples of harm. This work is expected to be substantially completed during 2023, utilising provisions booked to account for any remediations. Over-issuance of securities in the US In March 2022, executive management became aware that Barclays Bank PLC had issued securities materially in excess of the set amount under its US shelf registration statements. As a result, Barclays Bank PLC commenced a rescission offer on 1 August 2022, by which Barclays Bank PLC offered to repurchase relevant affected securities from certain holders, which expired on 12 September 2022. Further, in September 2022, the SEC announced the resolution of its investigation of Barclays PLC and Barclays Bank PLC relating to such over-issuance of securities. The Barclays Bank Group has engaged with, and responded to inquiries and requests for information from, various other regulators who may seek to impose fines, penalties and/or other sanctions as a result of this matter. Furthermore, Barclays Bank PLC and/or its affiliates may incur costs and liabilities in relation to private civil claims which have been filed and may face other potential private civil claims, class actions or other enforcement actions in relation to the over-issuance of securities. By way of example, in September 2022, a purported class action claim was filed in the US District Court in Manhattan seeking to hold Barclays PLC, Barclays Bank PLC and former and current executives responsible for declines in the prices of Barclays PLC’s American depositary receipts, which the plaintiffs claim occurred as a result of alleged misstatements and omissions in its public disclosures. The defendants have moved to dismiss the case. In addition, holders of a series of ETNs have brought claims against Barclays PLC, Barclays Bank PLC, and former and current executives and board members in the US alleging, among other things, that Barclays’ failure to disclose that these ETNs were unregistered securities misled investors and that, as a result, Barclays is liable for the holders’ alleged losses following the suspension of further sales and issuances of such series of ETNs. Two such actions are purported class actions that the plaintiffs have moved to consolidate into a single action in federal court in New York. A contingent liability exists in relation to civil claims or any further enforcement actions taken against Barclays Bank PLC and/or its affiliates, but Barclays Bank PLC is unable to assess the likelihood of liabilities that may arise out of such claims or actions. Any liabilities, claims or actions in connection with the over-issuance of securities under Barclays Bank PLC’s US shelf registration statements could have an adverse effect on Barclays Bank PLC’s and the Barclays Bank Group’s business, financial condition, results of operations and reputation as a frequent issuer in the securities markets. HM Revenue & Customs (HMRC) assessments concerning UK Value Added Tax In 2018, HMRC issued notices that have the effect of removing certain overseas subsidiaries that have operations in the UK from Barclays’ UK VAT group, in which group supplies between members are generally free from VAT. The notices have retrospective effect and correspond to assessments of £181m (inclusive of interest), of which Barclays would expect to attribute an amount of approximately £128m to Barclays Bank UK PLC and £53m to Barclays Bank PLC. HMRC’s decision has been appealed to the First Tier Tribunal (Tax Chamber). FCA investigation into transaction monitoring The FCA has been investigating Barclays’ compliance with UK money laundering regulations and the FCA’s rules and Principles for Businesses in an investigation which is focussed on aspects of Barclays’ transaction monitoring in relation to certain business lines now in Barclays Bank UK PLC. Barclays has been co-operating with the investigation and responding to information requests. General The Barclays Bank Group is engaged in various other legal, competition and regulatory matters in the UK, the US and a number of other overseas jurisdictions. It is subject to legal proceedings brought by and against the Barclays Bank Group which arise in the ordinary course of business from time to time, including (but not limited to) disputes in relation to contracts, securities, debt collection, consumer credit, fraud, trusts, client assets, competition, data management and protection, intellectual property, money laundering, financial crime, employment, environmental and other statutory and common law issues. The Barclays Bank Group is also subject to enquiries and examinations, requests for information, audits, investigations and legal and other proceedings by regulators, governmental and other public bodies in connection with (but not limited to) consumer protection measures, compliance with legislation and regulation, wholesale trading activity and other areas of banking and business activities in which the Barclays Bank Group is or has been engaged. The Barclays Bank Group is cooperating with the relevant authorities and keeping all relevant agencies briefed as appropriate in relation to these matters and others described in this note on an ongoing basis. At the present time, Barclays Bank PLC does not expect the ultimate resolution of any of these other matters to have a material adverse effect on its financial position. However, in light of the uncertainties involved in such matters and the matters specifically described in this note, there can be no assurance that the outcome of a particular matter or matters (including formerly active matters or those matters arising after the date of this note) will not be material to Barclays Bank PLC’s results, operations or cash flows for a particular period, depending on, among other things, the amount of the loss resulting from the matter(s) and the amount of profit otherwise reported for the reporting period. |
Related party transactions
Related party transactions | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of transactions between related parties [abstract] | |
Related party transactions | Related party transactions Related party transactions in the half year ended 30 June 2023 were similar in nature to those disclosed in the Barclays Bank PLC Annual Report 2022. No related party transactions that have taken place in the half year ended 30 June 2023 have materially affected the financial position or performance of the Barclays Bank Group during this period. During the six month ended 30 June 2023, Barclays Bank PLC acquired the entire issued share capital of Barclays Asset Management Limited and Barclays Investment Solutions Limited along with certain other assets and liabilities, business guarantees and business contracts (together with the transfer of associated employees of Barclays Bank UK PLC) from Barclays Bank UK PLC. See Note 14 Barclays Bank PLC parent company information for further details. |
Interest rate benchmark reform
Interest rate benchmark reform | 6 Months Ended |
Jun. 30, 2023 | |
Interest Rate Benchmark Reform [Abstract] | |
Interest rate benchmark reform | Interest rate benchmark reform Following the financial crisis, the reform and replacement of benchmark interest rates such as LIBOR became a priority for global regulators. The FCA and other global regulators instructed market participants to prepare for the cessation of most LIBOR rates after the end of 2021, and to adopt “Risk Free Rates” (RFRs). Barclays established a Barclays Group-wide LIBOR Transition Programme, which aims to drive strategic execution and identify, manage and resolve keys risks and issues as they arise. Whilst EUR and CHF LIBOR ceased to be published after 31 December 2021, a synthetic version of GBP and JPY LIBOR was made available for certain tenors for a limited period of time, to mitigate the risk of widespread disruption to legacy contracts which had not transitioned by end-2021. • Synthetic JPY LIBOR tenors ceased permanently at the end of 2022 in line with an announcement made by the FCA on 29 September 2022. • 1- and 6-month synthetic GBP LIBOR tenors ceased permanently after 31 March 2023 in line with the announcement made by the FCA on 29 September 2022. • 3-month synthetic GBP LIBOR remains available until 31 March 2024 as per an announcement made by the FCA on 23rd November 2022. In addition, GBP LIBOR ICE Swap Rate and JPY LIBOR Tokyo Swap Rate ceased to be published at the end of 2021. All of the Barclays Bank Group’s exposure to JPY LIBOR and JPY LIBOR Tokyo Swap Rates and to 1- and 6-month GBP LIBOR have now been remediated with only residual exposure remaining to 3-month synthetic GBP LIBOR and GBP LIBOR ICE Swap Rates. For USD LIBOR, certain actively used tenors continued to be published after 2021. However, in line with the US banking regulators’ joint statement, the Barclays Bank Group ceased issuing or entering into new contracts that use USD LIBOR as a reference rate from 31 December 2021, other than in relation to those allowable use cases set out under the FCA’s prohibition notice (ref 21A). The overnight and 12-month USD LIBOR tenors ceased to be published after 30 June 2023, with synthetic versions of the 1-, 3- and 6-month USD LIBOR tenors made available for a limited period of time until 30 September 2024. The synthetic versions are for use in legacy contracts only, to help ensure an orderly wind-down of USD LIBOR, as outlined in a statement made by the FCA on 3 April 2023. In addition, the USD LIBOR ICE Swap Rate ceased to be published at the end of June 2023. During H123, the Barclays Group-wide LIBOR Transition Programme focused on the remediation of its exposure to the benchmarks which ceased at the end of June 2023. The majority of the Barclays Bank Group’s’ exposure to those rates is now considered remediated contractually via central clearing counterparties (CCP) led conversions for cleared derivatives and actively negotiated conversion or insertion of fallbacks to RFRs for other products. In addition to this, whilst active transition and fallback insertion were attempted in most cases, there were also exposures under certain US law governed contracts which were transitioned pursuant to the US Federal Legislation (the Adjustable Interest Rate (LIBOR) Act) at the end of June 2023. The Barclays Bank Group continues to (i) identify, manage and mitigate key risks and issues as they arise, (ii) work with clients and counterparties to remediate any trades which remain on synthetic LIBOR or on the GBP or USD LIBOR ICE Swap Rates and (iii) remain on track to meet the associated industry deadlines. |
Barclays Bank PLC parent compan
Barclays Bank PLC parent company information | 6 Months Ended |
Jun. 30, 2023 | |
Condensed Financial Information Disclosure [Abstract] | |
Barclays Bank PLC parent company information | Barclays Bank PLC parent company information Investments in subsidiaries In May 2023, Barclays Bank PLC acquired the entire issued share capital of Barclays Asset Management Limited and Barclays Investment Solutions Limited along with certain other assets and liabilities, business guarantees and business contracts (together with the transfer of associated employees of Barclays Bank UK PLC) from Barclays Bank UK PLC. Consideration of £3 was paid by Barclays Bank PLC, which represented the fair value of the transferring businesses. Barclays Bank Group recognised the difference between the carrying value of the net assets acquired and the cash consideration paid directly in equity as a £124m merger reserve within Other reserves. During the period, Barclays Bank PL C injected €150m (£130m) of additional capital into its subsidiary Barclays Bank Ireland PLC by way of a subscription for ordinary shares. This capital injection was subsequently fully impa ired. The carrying value of the investment in Barclays Bank Ireland PLC at 30 June 2023 was £2.5bn. |
Credit Risk (Tables)
Credit Risk (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of credit risk exposure [abstract] | |
Disclosure of provision matrix | The table below presents a breakdown of loans and advances at amortised cost and the impairment allowance with stage allocation by asset classification. Impairment allowance under IFRS 9 considers both the drawn and the undrawn counterparty exposure. For retail portfolios, the total impairment allowance is allocated to the gross loans and advances to the extent that the allowance does not exceed the drawn exposure and any excess is reported on the liability side of the balance sheet as a provision. For wholesale portfolios the impairment allowance on the undrawn exposure is reported on the liability side of the balance sheet as a provision. Stage 2 As at 30.06.23 Stage 1 Not past due <=30 days past due >30 days past due Total Stage 3 Total 1 Gross exposure £m £m £m £m £m £m £m Retail mortgages 7,791 272 16 107 395 767 8,953 Retail credit cards 21,829 3,478 302 227 4,007 1,257 27,093 Retail other 4,583 368 33 249 650 336 5,569 Corporate loans 95,647 9,136 128 205 9,469 1,174 106,290 Debt securities and other 2 35,497 3,664 — — 3,664 2 39,163 Total 165,347 16,918 479 788 18,185 3,536 187,068 Impairment allowance Retail mortgages 9 18 3 2 23 327 359 Retail credit cards 307 860 143 128 1,131 1,006 2,444 Retail other 23 28 1 7 36 99 158 Corporate loans 201 261 11 8 280 336 817 Debt securities and other 2 19 34 — — 34 — 53 Total 559 1,201 158 145 1,504 1,768 3,831 Net exposure Retail mortgages 7,782 254 13 105 372 440 8,594 Retail credit cards 21,522 2,618 159 99 2,876 251 24,649 Retail other 4,560 340 32 242 614 237 5,411 Corporate loans 95,446 8,875 117 197 9,189 838 105,473 Debt securities and other 2 35,478 3,630 — — 3,630 2 39,110 Total 164,788 15,717 321 643 16,681 1,768 183,237 Coverage ratio % % % % % % % Retail mortgages 0.1 6.6 18.8 1.9 5.8 42.6 4.0 Retail credit cards 1.4 24.7 47.4 56.4 28.2 80.0 9.0 Retail other 0.5 7.6 3.0 2.8 5.5 29.5 2.8 Corporate loans 0.2 2.9 8.6 3.9 3.0 28.6 0.8 Debt securities and other 2 0.1 0.9 — — 0.9 — 0.1 Total 0.3 7.1 33.0 18.4 8.3 50.0 2.0 1 Other financial assets subject to impairment excluded in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £172.4bn and impairment allowance of £156m. This comprises £15m Expected Credit Losses (ECL) on £171.3bn Stage 1 assets, £12m on £877m Stage 2 fair value through other comprehensive income assets, cash collateral and settlement balances and £129m on £137m Stage 3 other assets. Loan commitments and financial guarantee contracts have total ECL of £467m. 2 Predominantly includes debt securities within Treasury and CIB, these have a total gross exposure of £35.3bn and impairment allowance of £53m. Also includes loans and advances of £3.4bn within Treasury and £0.4bn within Head Office, which have impairment allowance of £nil. Stage 2 As at 31.12.22 Stage 1 Not past due <=30 days past due >30 days past due Total Stage 3 Total 1 Gross exposure £m £m £m £m £m £m £m Retail mortgages 10,458 310 11 41 362 978 11,798 Retail credit cards 22,669 3,252 237 391 3,880 1,129 27,678 Retail other 6,915 384 45 95 524 523 7,962 Corporate loans 96,799 10,235 154 103 10,492 935 108,226 Debt securities and other 2 26,967 3,691 — — 3,691 5 30,663 Total 163,808 17,872 447 630 18,949 3,570 186,327 Impairment allowance Retail mortgages 12 22 2 1 25 356 393 Retail credit cards 331 887 82 158 1,127 818 2,276 Retail other 38 21 3 5 29 171 238 Corporate loans 304 254 12 9 275 293 872 Debt securities and other 2 8 33 — — 33 — 41 Total 693 1,217 99 173 1,489 1,638 3,820 Net exposure Retail mortgages 10,446 288 9 40 337 622 11,405 Retail credit cards 22,338 2,365 155 233 2,753 311 25,402 Retail other 6,877 363 42 90 495 352 7,724 Corporate loans 96,495 9,981 142 94 10,217 642 107,354 Debt securities and other 2 26,959 3,658 — — 3,658 5 30,622 Total 163,115 16,655 348 457 17,460 1,932 182,507 Coverage ratio % % % % % % % Retail mortgages 0.1 7.1 18.2 2.4 6.9 36.4 3.3 Retail credit cards 1.5 27.3 34.6 40.4 29.0 72.5 8.2 Retail other 0.5 5.5 6.7 5.3 5.5 32.7 3.0 Corporate loans 0.3 2.5 7.8 8.7 2.6 31.3 0.8 Debt securities and other 2 — 0.9 — — 0.9 — 0.1 Total 0.4 6.8 22.1 27.5 7.9 45.9 2.1 1 Other financial assets subject to impairment excluded in the table above include cash collateral and settlement balances, financial assets at fair value through other comprehensive income, accrued income and sundry debtors. These have a total gross exposure of £155.1bn and impairment allowance of £152m. This comprises £7m ECL on £153.8bn Stage 1 assets, £8m on £1,142m Stage 2 fair value through other comprehensive income assets, cash collateral and settlement balances and £137m on £141m Stage 3 other assets. Loan commitments and financial guarantee contracts have total ECL of £532m. 2 Predominantly includes debt securities within Treasury and CIB, these have a total gross exposure of £27.4bn and impairment allowance of £41m. Also includes loans and advances of £2.9bn within Treasury and £0.4bn within Head Office, which have impairment allowance of £nil. |
Disclosure of credit risk | The following tables present a reconciliation of the opening to the closing balance of the exposure and impairment allowance. An explanation of the methodology used to determine credit impairment provisions is included in the Barclays Bank PLC Annual Report 2022. Transfers between stages in the tables have been reflected as if they had taken place at the beginning of the period. 'Net drawdowns, repayments, net re-measurement and movements due to exposure and risk parameter changes' includes additional drawdowns and partial repayments from existing facilities. Additionally, the below tables do not include other financial assets subject to impairment such as cash collateral and settlement balances, financial assets at fair value through other comprehensive income and other assets. The movements are measured over a six-month period. Loans and advances at amortised cost Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Retail mortgages As at 1 January 2023 10,458 12 362 25 978 356 11,798 393 Transfers from Stage 1 to Stage 2 (218) — 218 — — — — — Transfers from Stage 2 to Stage 1 65 3 (65) (3) — — — — Transfers to Stage 3 (90) — (36) (3) 126 3 — — Transfers from Stage 3 10 — 19 1 (29) (1) — — Business activity in the period 622 3 — — — — 622 3 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (2,154) (9) (58) 4 (218) (21) (2,430) (26) Final repayments (902) — (45) (1) (81) (1) (1,028) (2) Disposals — — — — — — — — Write-offs — — — — (9) (9) (9) (9) As at 30 June 2023 7,791 9 395 23 767 327 8,953 359 Retail credit cards As at 1 January 2023 22,669 331 3,880 1,127 1,129 818 27,678 2,276 Transfers from Stage 1 to Stage 2 (1,468) (42) 1,468 42 — — — — Transfers from Stage 2 to Stage 1 1,033 290 (1,033) (290) — — — — Transfers to Stage 3 (197) (12) (404) (205) 601 217 — — Transfers from Stage 3 5 3 4 2 (9) (5) — — Business activity in the period 904 16 45 16 1 1 950 33 Refinements to models used for calculation 1 — — — — — (20) — (20) Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (1,052) (267) 64 475 (128) 334 (1,116) 542 Final repayments (65) (12) (17) (36) — (6) (82) (54) Disposals 2 — — — — (12) (8) (12) (8) Write-offs — — — — (325) (325) (325) (325) As at 30 June 2023 21,829 307 4,007 1,131 1,257 1,006 27,093 2,444 1 Refinements to models used for calculation reported within Retail credit cards include a £20m movement in US cards. These reflect model enhancements made during the period. Barclays continually reviews the output of models to determine accuracy of the ECL calculation including review of model monitoring, external benchmarking and experience of model operation over an extended period of time. This helps to ensure that the models used continue to reflect the risks inherent across the businesses. 2 The £12m disposals reported within Retail credit cards relates to debt sales undertaken during the period. Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Retail other As at 1 January 2023 6,915 38 524 29 523 171 7,962 238 Transfers from Stage 1 to Stage 2 (446) (3) 446 3 — — — — Transfers from Stage 2 to Stage 1 138 4 (138) (4) — — — — Transfers to Stage 3 (57) (1) (41) (6) 98 7 — — Transfers from Stage 3 1 1 7 2 (8) (3) — — Business activity in the period 1,086 3 6 1 3 2 1,095 6 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (2,145) (17) (79) 12 (148) (32) (2,372) (37) Final repayments (909) (2) (75) (1) (47) (1) (1,031) (4) Disposals 1 — — — — (75) (35) (75) (35) Write-offs — — — — (10) (10) (10) (10) As at 30 June 2023 4,583 23 650 36 336 99 5,569 158 Corporate loans As at 1 January 2023 96,799 304 10,492 275 935 293 108,226 872 Transfers from Stage 1 to Stage 2 (4,747) (21) 4,747 21 — — — — Transfers from Stage 2 to Stage 1 4,312 49 (4,312) (49) — — — — Transfers to Stage 3 (139) (1) (225) (16) 364 17 — — Transfers from Stage 3 47 1 64 2 (111) (3) — — Business activity in the period 12,224 20 315 13 35 9 12,574 42 Refinements to models used for calculation 2 — (49) — 142 — — — 93 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 1,810 (46) (1,049) (90) 212 182 973 46 Final repayments (14,659) (56) (563) (18) (91) (7) (15,313) (81) Disposals 1 — — — — (110) (95) (110) (95) Write-offs — — — — (60) (60) (60) (60) As at 30 June 2023 95,647 201 9,469 280 1,174 336 106,290 817 1 The £75m of disposals reported within Retail other includes £64m part sale of Wealth portfolio in Italy and £11m relates to debt sales. The £110m of disposals reported within Corporate loans relates to debt sales undertaken during the period. 2 Refinements to models used for calculation reported within Corporate loans include a £93m movement in CIB . These reflect model enhancements made during the period. Barclays continually reviews the output of models to determine accuracy of the ECL calculation including review of model monitoring, external benchmarking and experience of model operation over an extended period of time. This helps to ensure that the models used continue to reflect the risks inherent across the businesses. Loans and advances at amortised cost Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Debt securities and other As at 1 January 2023 26,967 8 3,691 33 5 — 30,663 41 Transfers from Stage 1 to Stage 2 (260) — 260 — — — — — Transfers from Stage 2 to Stage 1 118 2 (118) (2) — — — — Transfers to Stage 3 — — — — — — — — Transfers from Stage 3 — — — — — — — — Business activity in the period 11,438 2 78 1 — — 11,516 3 Refinements to models used for calculation — — — — — — — — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (768) 7 (79) 4 2 — (845) 11 Final repayments (1,998) — (168) (2) (5) — (2,171) (2) Disposals — — — — — — — — Write-off — — — — — — — — As at 30 June 2023 35,497 19 3,664 34 2 — 39,163 53 Reconciliation of ECL movement to impairment charge/(release) for the period Stage 1 Stage 2 Stage 3 Total £m £m £m £m Retail mortgages (3) (2) (20) (25) Retail credit cards (24) 4 521 501 Retail other (15) 7 (27) (35) Corporate loans (103) 5 198 100 Debt securities and other 11 1 12 ECL movement excluding assets derecognised due to disposals and write-offs 1 (134) 15 672 553 ECL movement on loan commitments and other financial guarantees (47) (36) 18 (65) ECL movement on other financial assets 8 4 (8) 4 Recoveries and reimbursements 2 64 (28) (36) — Total exchange and other adjustments 196 Total income statement charge for the period 688 1 In H123, gross write-offs amounted to £404m (H122: £560m). Post write-off recoveries amounted to £7m (H122: £20m). Net write-offs represent gross write-offs less post write-off recoveries and amounted to £397m (H122: £540m). 2 Recoveries and reimbursements include a net reduction of £7m (H122 gain: £11m) in amounts expected to be received under the arrangement where Barclays Bank Group has entered into financial guarantee contracts which provide credit protection over certain loan assets with third parties; cash recoveries of previously written off amounts are £7m (H122: £20m). Loan commitments and financial guarantees Stage 1 Stage 2 Stage 3 Total Gross exposure ECL Gross exposure ECL Gross exposure ECL Gross exposure ECL £m £m £m £m £m £m £m £m Retail mortgages As at 1 January 2023 61 — 1 — 5 — 67 — Net transfers between stages — — — — — — — — Business activity in the year 27 — — — — — 27 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (21) — — — (4) — (25) — Limit management and final repayments (25) — (1) — — — (26) — As at 30 June 2023 42 — — — 1 — 43 — Retail credit cards As at 1 January 2023 109,291 41 1,973 45 7 1 111,271 87 Net transfers between stages (646) 14 644 (14) 2 — — — Business activity in the year 9,242 6 76 5 — — 9,318 11 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (4,448) (19) (469) 23 (1) (1) (4,918) 3 Limit management and final repayments (6,304) (4) (274) (16) — — (6,578) (20) As at 30 June 2023 107,135 38 1,950 43 8 — 109,093 81 Retail other As at 1 January 2023 4,497 — 79 — 64 — 4,640 — Net transfers between stages (65) — 39 — 26 — — — Business activity in the year 467 — 1 — — — 468 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (1,120) 8 (30) — (47) — (1,197) 8 Limit management and final repayments (293) — (10) — — — (303) — As at 30 June 2023 3,486 8 79 — 43 — 3,608 8 Corporate loans As at 1 January 2023 205,207 193 23,873 230 812 22 229,892 445 Net transfers between stages 624 18 (768) (19) 144 1 — — Business activity in the year 22,926 7 543 8 1 — 23,470 15 Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes 1,862 (26) 534 (4) 208 20 2,604 (10) Limit management and final repayments (26,348) (51) (1,749) (19) (223) (2) (28,320) (72) As at 30 June 2023 204,271 141 22,433 196 942 41 227,646 378 Debt securities and other As at 1 January 2023 13 — — — — — 13 — Net transfers between stages — — — — — — — — Business activity in the year 14 — — — — — 14 — Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes (1) — — — — — (1) — Limit management and final repayments — — — — — — — — As at 30 June 2023 26 — — — — — 26 — |
Drivers of loan impairment charge | Management adjustments to models for impairment allowance presented by product 1 Impairment allowance pre management adjustments 2 Economic uncertainty adjustments 3 Other adjustments Management adjustments Total impairment allowance 4 Proportion of Management adjustments to total impairment allowance (a) (b) (a+b) As at 30 June 2023 £m £m £m £m £m % Retail mortgages 361 — (2) (2) 359 (0.6) Retail credit cards 2,559 — (34) (34) 2,525 (1.3) Retail other 199 — (33) (33) 166 (19.9) Corporate loans 1,166 — 29 29 1,195 2.4 Debt securities and other 53 — — — 53 — Total 4,338 — (40) (40) 4,298 (0.9) As at 31 December 2022 Retail mortgages 393 — — — 393 — Retail credit cards 2,309 — 54 54 2,363 2.3 Retail other 217 2 19 21 238 8.8 Corporate loans 1,414 95 (192) (97) 1,317 (7.4) Debt securities and other 41 — — — 41 — Total 4,374 97 (119) (22) 4,352 (0.5) Economic uncertainty adjustments presented by stage Stage 1 Stage 2 Stage 3 Total As at 31 December 2022 £m £m £m £m Retail mortgages — — — — Retail credit cards — — — — Retail other — 2 — 2 Corporate loans 97 (2) — 95 Debt securities and other — — — — Total 97 — — 97 1 Positive values reflect an increase in impairment allowance and negative values reflect a reduction in the impairment allowance. 2 Includes £3.7bn (December 2022: £3.7bn) of modelled ECL, £0.3bn (December 2022: £0.3bn) of individually assessed impairments and £0.3bn (December 2022: £0.4bn) ECL from non-modelled exposures. 3 Economic uncertainty adjustments are nil (December 2022: £97m) following the re-build of certain CIB impairment models. 4 Total impairment allowance consists of ECL stock on drawn and undrawn exposure. |
Macroeconomic variables used in the calculation of ECL and the respective scenario probability weighting | Macroeconomic variables used in the calculation of ECL As at 30 June 2023 2023 2024 2025 2026 2027 Baseline % % % % % UK GDP 1 0.3 0.9 1.6 1.8 1.9 UK unemployment 2 4.1 4.4 4.2 4.2 4.2 UK HPI 3 (6.1) (1.3) 2.0 4.3 5.7 UK bank rate 4.8 4.6 3.9 3.8 3.5 US GDP 1 1.1 0.7 2.0 2.0 2.0 US unemployment 4 3.8 4.6 4.6 4.6 4.6 US HPI 5 (0.7) 3.6 2.4 2.7 2.7 US federal funds rate 5.0 3.7 3.0 2.8 3.0 Downside 2 UK GDP 1 (0.5) (5.0) (0.4) 2.5 1.9 UK unemployment 2 4.4 7.8 8.3 7.7 7.1 UK HPI 3 (10.2) (20.5) (17.7) 5.6 8.2 UK bank rate 5.5 8.0 7.3 6.1 4.8 US GDP 1 0.5 (4.8) (0.3) 2.8 2.1 US unemployment 4 4.5 8.7 9.6 8.5 7.0 US HPI 5 (1.8) (3.7) (4.2) 2.6 4.8 US federal funds rate 5.7 7.0 6.5 5.1 4.2 Downside 1 UK GDP 1 (0.1) (2.1) 0.6 2.2 1.9 UK unemployment 2 4.2 6.1 6.2 5.9 5.6 UK HPI 3 (8.1) (11.3) (8.2) 5.0 7.0 UK bank rate 5.2 6.1 5.6 4.8 4.1 US GDP 1 0.8 (2.0) 0.8 2.4 2.0 US unemployment 4 4.1 6.7 7.1 6.5 5.8 US HPI 5 (1.2) (0.1) (0.9) 2.7 3.8 US federal funds rate 5.2 4.9 4.5 4.3 3.8 Upside 2 UK GDP 1 1.2 4.1 3.2 2.6 2.3 UK unemployment 2 3.9 3.6 3.5 3.6 3.6 UK HPI 3 0.4 10.6 4.8 4.2 3.8 UK bank rate 4.4 3.3 2.5 2.5 2.5 US GDP 1 2.2 3.9 3.0 2.8 2.8 US unemployment 4 3.4 3.5 3.6 3.6 3.6 US HPI 5 2.5 5.5 4.6 4.5 4.5 US federal funds rate 4.7 3.2 2.2 2.0 2.0 Upside 1 UK GDP 1 0.8 2.5 2.4 2.2 2.1 UK unemployment 2 4.0 4.0 3.9 3.9 3.9 UK HPI 3 (2.9) 4.5 3.4 4.3 4.7 UK bank rate 4.6 4.0 3.1 3.0 3.0 US GDP 1 1.6 2.3 2.5 2.4 2.4 US unemployment 4 3.6 4.1 4.1 4.1 4.1 US HPI 5 0.9 4.6 3.5 3.6 3.6 US federal funds rate 4.8 3.4 2.6 2.5 2.5 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Macroeconomic variables used in the calculation of ECL As at 31 December 2022 2022 2023 2024 2025 2026 Baseline % % % % % UK GDP 1 3.3 (0.8) 0.9 1.8 1.9 UK unemployment 2 3.7 4.5 4.4 4.1 4.2 UK HPI 3 8.4 (4.7) (1.7) 2.2 2.2 UK bank rate 1.8 4.4 4.1 3.8 3.4 US GDP 1 1.8 0.5 1.2 1.5 1.5 US unemployment 4 3.7 4.3 4.7 4.7 4.7 US HPI 5 11.2 1.8 1.5 2.3 2.4 US federal funds rate 2.1 4.8 3.6 3.1 3.0 Downside 2 UK GDP 1 3.3 (3.4) (3.8) 2.0 2.3 UK unemployment 2 3.7 6.0 8.4 8.0 7.4 UK HPI 3 8.4 (18.3) (18.8) (7.7) 8.2 UK bank rate 1.8 7.3 7.9 6.6 5.5 US GDP 1 1.8 (2.7) (3.4) 2.0 2.6 US unemployment 4 3.7 6.0 8.5 8.1 7.1 US HPI 5 11.2 (3.1) (4.0) (1.9) 4.8 US federal funds rate 2.1 6.6 6.9 5.8 4.6 Downside 1 UK GDP 1 3.3 (2.1) (1.5) 1.9 2.1 UK unemployment 2 3.7 5.2 6.4 6.0 5.8 UK HPI 3 8.4 (11.7) (10.6) (2.8) 5.2 UK bank rate 1.8 5.9 6.1 5.3 4.6 US GDP 1 1.8 (1.1) (1.1) 1.7 2.1 US unemployment 4 3.7 5.1 6.6 6.4 5.9 US HPI 5 11.2 (0.7) (1.3) 0.2 3.6 US federal funds rate 2.1 5.8 5.4 4.4 3.9 Upside 2 UK GDP 1 3.3 2.8 3.7 2.9 2.4 UK unemployment 2 3.7 3.5 3.4 3.4 3.4 UK HPI 3 8.4 8.7 7.5 4.4 4.2 UK bank rate 1.8 3.1 2.6 2.5 2.5 US GDP 1 1.8 3.3 3.5 2.8 2.8 US unemployment 4 3.7 3.3 3.3 3.3 3.3 US HPI 5 11.2 5.8 5.1 4.5 4.5 US federal funds rate 2.1 3.6 2.9 2.8 2.8 Upside 1 UK GDP 1 3.3 1.0 2.3 2.4 2.1 UK unemployment 2 3.7 4.0 3.9 3.8 3.8 UK HPI 3 8.4 1.8 2.9 3.3 3.2 UK bank rate 1.8 3.5 3.3 3.0 2.8 US GDP 1 1.8 1.9 2.3 2.2 2.2 US unemployment 4 3.7 3.8 4.0 4.0 4.0 US HPI 5 11.2 3.8 3.3 3.4 3.4 US federal funds rate 2.1 3.9 3.4 3.0 3.0 1 Average Real GDP seasonally adjusted change in year. 2 Average UK unemployment rate 16-year+. 3 Change in year end UK HPI = Halifax All Houses, All Buyers index, relative to prior year end. 4 Average US civilian unemployment rate 16-year+. 5 Change in year end US HPI = FHFA House Price Index, relative to prior year end. Scenario probability weighting Upside 2 Upside 1 Baseline Downside 1 Downside 2 % % % % % As at 30 June 2023 Scenario probability weighting 13.0 24.7 40.2 15.2 6.9 As at 31 December 2022 Scenario probability weighting 10.9 23.1 39.4 17.6 9.0 Specific bases show the most extreme position of each variable in the context of the downside/upside scenarios, for example, the highest unemployment for downside scenarios, average unemployment for baseline scenarios and lowest unemployment for upside scenarios. GDP and HPI downside and upside scenario data represents the lowest and highest cumulative position relative to the start point in the 20 quarter period. Macroeconomic variables (specific bases) 1 Upside 2 Upside 1 Baseline Downside 1 Downside 2 As at 30 June 2023 % % % % % UK GDP 2 15.1 11.2 1.3 (2.7) (6.9) UK unemployment 3 3.5 3.9 4.2 6.5 8.5 UK HPI 4 25.8 14.6 0.8 (25.2) (41.5) UK bank rate 3 2.5 3.0 4.1 6.3 8.0 US GDP 2 15.9 11.9 1.6 (2.3) (6.2) US unemployment 3 3.3 3.5 4.4 7.2 9.8 US HPI 4 23.6 17.2 2.1 (2.3) (10.1) US federal funds rate 3 2.0 2.5 3.5 5.3 7.0 As at 31 December 2022 UK GDP 2 13.9 9.4 1.4 (3.2) (6.8) UK unemployment 3 3.4 3.6 4.2 6.6 8.5 UK HPI 4 37.8 21.0 1.2 (17.9) (35.0) UK bank rate 3 0.5 0.5 3.5 6.3 8.0 US GDP 2 14.1 9.6 1.3 (2.5) (6.3) US unemployment 3 3.3 3.6 4.4 6.7 8.6 US HPI 4 35.0 27.5 3.8 3.7 0.2 US federal funds rate 3 0.1 0.1 3.3 6.0 7.0 1 UK GDP = Real GDP growth seasonally adjusted; UK unemployment = UK unemployment rate 16-year+; UK HI = Halifax All Houses, All Buyers Index; US GDP = Real GDP growth seasonally adjusted; US unemployment = US civilian unemployment rate 16-year+; US HPI = FHFA House Price Index. 20 quarter period starts from Q123 (2022: Q122). 2 Maximum growth relative to Q422 (2022: Q421), based on 20 quarter period in Upside scenarios; 5-year yearly average Compound Annual Growth Rate (CAGR) in Baseline; minimum growth relative to Q422 (2022: Q421), based on 20 quarter period in Downside scenarios. 3 Lowest quarter in 20 quarter period in Upside scenarios; 5-year average in Baseline; highest quarter 20 quarter period in Downside scenarios. 4 Maximum growth relative to Q422 (2022: Q421), based on 20 quarter period in Upside scenarios; 5-year quarter end CAGR in Baseline; minimum growth relative to Q422 (2022: Q421), based on 20 quarter period in Downside scenarios. Average basis represents the average quarterly value of variables in the 20 quarter period with GDP and HPI based on yearly average and quarterly CAGRs respectively. Macroeconomic variables (5-year averages) 1 Upside 2 Upside 1 Baseline Downside 1 Downside 2 As at 30 June 2023 % % % % % UK GDP 2 2.7 2.0 1.3 0.5 (0.3) UK unemployment 3 3.6 3.9 4.2 5.6 7.0 UK HPI 4 4.7 2.8 0.8 (3.4) (7.6) UK bank rate 3 3.0 3.6 4.1 5.2 6.4 US GDP 2 2.9 2.3 1.6 0.8 — US unemployment 3 3.5 4.0 4.4 6.0 7.6 US HPI 4 4.3 3.2 2.1 0.8 (0.5) US federal funds rate 3 2.8 3.2 3.5 4.5 5.7 As at 31 December 2022 UK GDP 2 3.0 2.2 1.4 0.7 — UK unemployment 3 3.5 3.8 4.2 5.4 6.7 UK HPI 4 6.6 3.9 1.2 (2.6) (6.4) UK bank rate 3 2.5 2.9 3.5 4.7 5.8 US GDP 2 2.9 2.1 1.3 0.7 — US unemployment 3 3.4 3.9 4.4 5.5 6.7 US HPI 4 6.2 5.0 3.8 2.5 1.2 US federal funds rate 3 2.8 3.1 3.3 4.3 5.2 1 UK GDP = Real GDP growth seasonally adjusted; UK unemployment = UK unemployment rate 16-year+; UK HPI = Halifax All Houses, All Buyers Index; US GDP = Real GDP growth seasonally adjusted; US unemployment = US civilian unemployment rate 16-year+; US HPI = FHFA House Price Index. 2 5-year yearly average CAGR, starting 2022 (2022: 2021). 3 5-year average. Period based on 20 quarters from Q123 (2022: Q122). 4 5-year quarter end CAGR, starting Q422 (2022: Q421). |
Segmental reporting (Tables)
Segmental reporting (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of operating segments [abstract] | |
Analysis of results by business | Analysis of results by business Corporate and Investment Bank Consumer, Cards and Payments Head Office Barclays Bank Group Half year ended 30.06.23 £m £m £m £m Total income 7,362 2,599 (157) 9,804 Operating expenses (4,324) (1,544) (84) (5,952) Litigation and conduct 2 (32) (4) (34) Total operating expenses (4,322) (1,576) (88) (5,986) Other net income 1 2 — — 2 Profit/(loss) before impairment 3,042 1,023 (245) 3,820 Credit impairment charge (20) (659) (9) (688) Profit/(loss) before tax 3,022 364 (254) 3,132 As at 30.06.23 £bn £bn £bn £bn Total assets 1,147.2 88.0 11.4 1,246.6 Total liabilities 1,105.7 82.4 0.2 1,188.3 Corporate and Investment Bank Consumer, Cards and Payments Head Office Barclays Bank Group Half year ended 30.06.22 £m £m £m £m Total income 8,086 1,992 (88) 9,990 Operating expenses (3,912) (1,285) (62) (5,259) Litigation and conduct (1,632) (200) (1) (1,833) Total operating expenses (5,544) (1,485) (63) (7,092) Other net income 1 — — — — Profit/(loss) before impairment 2,542 507 (151) 2,898 Credit impairment (charge)/release (31) (278) 16 (293) Profit/(loss) before tax 2,511 229 (135) 2,605 As at 31.12.22 £bn £bn £bn £bn Total assets 1,111.2 79.9 12.4 1,203.5 Total liabilities 1,058.2 85.0 1.4 1,144.6 |
Split of income by geographic region | Split of income by geographic region 2 Half year ended 30.06.23 Half year ended 30.06.22 £m £m United Kingdom 3,555 4,674 Europe 1,255 1,310 Americas 4,234 3,276 Africa and Middle East 42 31 Asia 718 699 Total 9,804 9,990 1 Other net income represents the share of post-tax results of associates and joint ventures. 2 The geographical analysis is based on the location of the office where the transactions are recorded. |
Net fee and commission income (
Net fee and commission income (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Fee and commission income (expense) [abstract] | |
Total fees in scope of IFRS 15 revenues from contracts with customers | Fee and commission income is disaggregated below and includes a total for fees in scope of IFRS 15, Revenue from Contracts with Customers: Corporate and Investment Bank Consumer, Cards and Payments Head Office Total Half year ended 30.06.23 £m £m £m £m Fee type Transactional 242 1,583 — 1,825 Advisory 363 94 — 457 Brokerage and execution 999 43 — 1,042 Underwriting and syndication 1,036 — — 1,036 Other 49 36 8 93 Total revenue from contracts with customers 2,689 1,756 8 4,453 Other non-contract fee income 71 3 — 74 Fee and commission income 2,760 1,759 8 4,527 Fee and commission expense (747) (973) (1) (1,721) Net fee and commission income 2,013 786 7 2,806 Corporate and Investment Bank Consumer, Cards and Payments Head Office Total Half year ended 30.06.22 £m £m £m £m Fee type Transactional 216 1,229 — 1,445 Advisory 440 72 — 512 Brokerage and execution 734 28 — 762 Underwriting and syndication 1,101 — — 1,101 Other 30 78 11 119 Total revenue from contracts with customers 2,521 1,407 11 3,939 Other non-contract fee income 67 2 — 69 Fee and commission income 2,588 1,409 11 4,008 Fee and commission expense (461) (707) (1) (1,169) Net fee and commission income 2,127 702 10 2,839 |
Dividends on ordinary shares (T
Dividends on ordinary shares (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Dividends [Abstract] | |
Dividends on ordinary shares and preference shares | Half year ended 30.06.23 Half year ended 30.06.22 Dividends paid during the period £m £m Ordinary shares 700 200 Preference shares 19 15 Total 719 215 |
Fair value of financial instr_2
Fair value of financial instruments (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of fair value measurement of assets [abstract] | |
Assets and liabilities held at fair value disaggregated by valuation technique (fair value hierarchy) | The following table shows the Barclays Bank Group’s assets and liabilities that are held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification: Valuation technique using Quoted market prices Observable inputs Significant unobservable inputs (Level 1) (Level 2) (Level 3) Total As at 30.06.23 £m £m £m £m Trading portfolio assets 86,232 72,064 6,799 165,095 Financial assets at fair value through the income statement 6,067 220,867 6,171 233,105 Derivative financial instruments 3,484 258,112 4,532 266,128 Financial assets at fair value through other comprehensive income 18,683 28,299 50 47,032 Investment property — — 2 2 Total assets 114,466 579,342 17,554 711,362 Trading portfolio liabilities (36,740) (33,477) (52) (70,269) Financial liabilities designated at fair value (115) (310,388) (1,092) (311,595) Derivative financial instruments (4,064) (245,461) (5,269) (254,794) Total liabilities (40,919) (589,326) (6,413) (636,658) As at 31.12.22 Trading portfolio assets 62,469 64,822 6,480 133,771 Financial assets at fair value through the income statement 5,647 199,370 6,111 211,128 Derivative financial instruments 10,054 287,749 5,173 302,976 Financial assets at fair value through other comprehensive income 15,029 30,051 4 45,084 Investment property — — 5 5 Total assets 93,199 581,992 17,773 692,964 Trading portfolio liabilities (43,679) (28,725) (56) (72,460) Financial liabilities designated at fair value (133) (270,880) (1,042) (272,055) Derivative financial instruments (10,823) (272,020) (6,363) (289,206) Total liabilities (54,635) (571,625) (7,461) (633,721) The following table shows the Barclays Bank Group’s Level 3 assets and liabilities that are held at fair value disaggregated by product type: As at 30.06.23 As at 31.12.22 Assets Liabilities Assets Liabilities £m £m £m £m Interest rate derivatives 2,520 (2,043) 2,361 (2,858) Foreign exchange derivatives 182 (176) 1,513 (1,474) Credit derivatives 342 (694) 290 (603) Equity derivatives 1,488 (2,356) 1,009 (1,428) Corporate debt 1,710 (35) 1,677 (49) Reverse repurchase and repurchase agreements 44 (643) 37 (434) Non-asset backed loans 7,946 — 8,105 — Private equity investments 138 — 140 — Other 1 3,184 (466) 2,641 (615) Total 17,554 (6,413) 17,773 (7,461) 1 Other includes commercial real estate loans, fund and fund-linked products, asset backed loans, asset backed securities, equity cash products, issued debt, commercial paper, Government and Government sponsored debt and investment property. |
Analysis of movements in Level 3 assets and liabilities | Level 3 movement analysis The following table summarises the movements in the balances of Level 3 assets and liabilities during the period. The table shows gains and losses and includes amounts for all financial assets and liabilities that are held at fair value transferred to and from Level 3 during the period. Transfers have been reflected as if they had taken place at the beginning of the period. Asset and liability moves between Level 2 and Level 3 are primarily due to i) an increase or decrease in observable market activity related to an input or ii) a change in the significance of the unobservable input, with assets and liabilities classified as Level 3 if an unobservable input is deemed significant. Level 3 movement analysis Purchases Sales Issues Settle- ments Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 30.06.23 As at 01.01.23 Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 595 338 (118) — (53) 5 — — 36 (29) 774 Non-asset backed loans 4,837 919 (1,152) — (311) 4 — — 556 (334) 4,519 Other 1,048 1,028 (606) — (38) (43) — — 430 (313) 1,506 Trading portfolio assets 6,480 2,285 (1,876) — (402) (34) — — 1,022 (676) 6,799 Corporate debt 1,079 — (120) — — (20) (3) — — — 936 Non-asset backed loans 3,268 1,053 (305) — (483) (33) (42) — 28 (106) 3,380 Private equity investments 140 — — — (5) (5) 8 — — — 138 Reverse repurchase and repurchase agreements 38 — — — — (11) — — 46 (29) 44 Other 1,586 794 (530) — (150) (23) (10) — 22 (16) 1,673 Financial assets at fair value through the income statement 6,111 1,847 (955) — (638) (92) (47) — 96 (151) 6,171 Non-asset backed loans — 47 — — — — — — — — 47 Other 4 — — — (1) — — — — — 3 Financial assets at fair value through other comprehensive income 4 47 — — (1) — — — — — 50 Investment property 5 — — — — — (3) — — — 2 Trading portfolio liabilities (56) (16) 4 — — 15 — — (8) 9 (52) Financial liabilities designated at fair value (1,042) — — (226) — 4 (1) — (290) 463 (1,092) Interest rate derivatives (497) — — — 19 (35) — — 544 446 477 Foreign exchange derivatives 39 — — — — (31) — — 13 (15) 6 Credit derivatives (313) (191) 5 — 66 13 — — 52 16 (352) Equity derivatives (419) (90) — — (132) (135) — — (104) 12 (868) Net derivative financial instruments 1 (1,190) (281) 5 — (47) (188) — — 505 459 (737) Total 10,312 3,882 (2,822) (226) (1,088) (295) (51) — 1,325 104 11,141 1 Derivative financial instruments are represented on a net basis. On a gross basis, derivative financial assets were £4,532m and derivative financial liabilities were £5,269m. Level 3 movement analysis Purchases Sales Issues Settle- ments Total gains and (losses) in the period recognised in the income statement Total gains or (losses) recognised in OCI Transfers As at 30.06.22 As at 01.01.22 Trading income Other income In Out £m £m £m £m £m £m £m £m £m £m £m Corporate debt 389 90 (144) — (17) 54 — — 43 (11) 404 Non-asset backed loans 758 2,448 (459) — — 11 — — 50 (113) 2,695 Other 1,134 419 (178) — (302) 60 — — 191 (167) 1,157 Trading portfolio assets 2,281 2,957 (781) — (319) 125 — — 284 (291) 4,256 Corporate debt 816 45 — — (148) 55 — — — — 768 Non-asset backed loans 2,985 1,848 (757) — (315) (76) — — 52 — 3,737 Private equity investments 148 19 (60) — — 7 11 — 3 (4) 124 Reverse repurchase and repurchase agreements 13 66 — — (12) 16 — — 95 — 178 Other 2,117 4,706 (5,579) — 5 (59) 181 — 4 (19) 1,356 Financial assets at fair value through the income statement 6,079 6,684 (6,396) — (470) (57) 192 — 154 (23) 6,163 Non-asset backed loans — — — — — — — — — — — Other 38 — — — — — — (2) — — 36 Financial assets at fair value through other comprehensive income 38 — — — — — — (2) — — 36 Investment property 7 — (1) — — — (1) — — — 5 Trading portfolio liabilities (27) (35) 3 — — (29) — — — 6 (82) Financial liabilities designated at fair value (404) (5) — (13) 47 (22) 2 — (81) 37 (439) Interest rate derivatives (260) 25 — — (4) (305) (9) — 271 6 (276) Foreign exchange derivatives 2 — — — (9) 273 — — (65) 25 226 Credit derivatives (386) (36) 5 — 60 (99) — — 20 55 (381) Equity derivatives (1,405) (83) — — 170 980 — — (9) 272 (75) Net derivative financial instruments 1 (2,049) (94) 5 — 217 849 (9) — 217 358 (506) Total 5,925 9,507 (7,170) (13) (525) 866 184 (2) 574 87 9,433 1 Derivative financial instruments are presented on a net basis. On a gross basis, derivative financial assets were £3,873m and derivative financial liabilities were £4,379m. |
Unrealised gains and losses recognised during the period on Level 3 assets and liabilities held at period end | Unrealised gains and losses on Level 3 financial assets and liabilities The following table discloses the unrealised gains and losses recognised in the period arising on Level 3 financial assets and liabilities held at the period end. Half year ended 30.06.23 Half year ended 30.06.22 Income statement Other compre-hensive income Total Income statement Other compre-hensive income Total Trading income Other income Trading income Other income £m £m £m £m £m £m £m £m Trading portfolio assets (35) — — (35) 121 — — 121 Financial assets at fair value through the income statement (87) (50) — (137) 16 9 — 25 Financial assets at fair value through other comprehensive income — — — — — — (2) (2) Investment properties — (3) — (3) — (1) — (1) Trading portfolio liabilities 15 — — 15 (35) — — (35) Financial liabilities designated at fair value 2 (1) — 1 (14) — — (14) Net derivative financial instruments (186) — — (186) 862 (1) — 861 Total (291) (54) — (345) 950 7 (2) 955 |
Sensitivity analysis of valuations using unobservable inputs | Sensitivity analysis of valuations using unobservable inputs As at 30.06.23 As at 31.12.22 Favourable changes Unfavourable changes Favourable changes Unfavourable changes Income statement Equity Income Statement Equity Income statement Equity Income Statement Equity £m £m £m £m £m £m £m £m Interest rate derivatives 123 — (186) — 119 — (155) — Foreign exchange derivatives 11 — (17) — 16 — (22) — Credit derivatives 27 — (79) — 79 — (71) — Equity derivatives 186 — (264) — 161 — (168) — Corporate debt 23 — (22) — 45 — (27) — Non-asset backed loans 295 1 (535) (1) 244 — (450) — Private equity investments 7 — (7) — 10 — (10) — Other 1 112 — (109) — 53 — (64) — Total 784 1 (1,219) (1) 727 — (967) — 1 Other includes commercial real estate loans, asset backed securities, equity cash products, fund and fund-linked products, asset backed loans, issued debt, commercial paper, Government and Government sponsored debt and investment property. |
Fair value adjustments | Key balance sheet valuation adjustments are quantified below: As at 30.06.23 As at 31.12.22 £m £m Exit price adjustments derived from market bid-offer spreads (543) (566) Uncollateralised derivative funding (24) (11) Derivative credit valuation adjustments (241) (319) Derivative debit valuation adjustments 196 208 |
Comparison of carrying amounts and fair values for assets and liabilities not held at fair value | The following table summarises the fair value of financial assets and liabilities measured at amortised cost on the Barclays Bank Group’s balance sheet: As at 30.06.23 As at 31.12.22 Carrying amount Fair value Carrying amount Fair value Financial assets £m £m £m £m Debt securities at amortised cost 35,245 33,869 27,303 27,006 Loans and advances at amortised cost 147,992 148,490 155,204 154,721 Reverse repurchase agreements and other similar secured lending 1,293 1,293 725 725 Financial liabilities Deposits at amortised cost (307,820) (307,811) (291,579) (291,552) Repurchase agreements and other similar secured borrowing (25,156) (25,153) (11,965) (11,966) Debt securities in issue (58,377) (58,266) (60,012) (59,895) Subordinated liabilities (36,325) (35,403) (38,253) (38,686) |
Subordinated Liabilities (Table
Subordinated Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Subordinated liabilities [abstract] | |
Subordinated liabilities | Half year ended 30.06.23 Year ended 31.12.22 £m £m Opening balance 38,253 32,185 Issuances 3,502 15,381 Redemptions (3,661) (8,367) Other (1,769) (946) Closing balance 36,325 38,253 Designated at fair value (Note 5) 503 521 Total subordinated liabilities 36,828 38,774 |
Provisions (Tables)
Provisions (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Provisions [abstract] | |
Provisions | As at 30.06.23 As at 31.12.22 £m £m Customer redress 35 46 Legal, competition and regulatory matters 59 113 Redundancy and restructuring 17 45 Undrawn contractually committed facilities and guarantees 467 532 Sundry provisions 154 122 Total 732 858 |
Other reserves (Tables)
Other reserves (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of reserves within equity [abstract] | |
Other reserves | As at 30.06.23 As at 31.12.22 £m £m Currency translation reserve 3,667 4,992 Fair value through other comprehensive income reserve (1,284) (1,342) Cash flow hedging reserve (5,940) (5,557) Own credit reserve (27) 467 Other reserves 196 (24) Total (3,388) (1,464) |
Contingent liabilities and co_2
Contingent liabilities and commitments (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Disclosure of contingent liabilities [abstract] | |
Disclosure of contingent liabilities and commitments | As at 30.06.23 As at 31.12.22 Contingent liabilities and financial guarantees £m £m Guarantees and letters of credit pledged as collateral security 19,108 17,700 Performance guarantees, acceptances and endorsements 8,041 8,100 Total 27,149 25,800 Commitments Documentary credits and other short-term trade related transactions 1,356 1,748 Standby facilities, credit lines and other commitments 324,223 333,229 Total 325,579 334,977 |
Credit Risk - Loans and advance
Credit Risk - Loans and advances at amortised cost by product (Details) £ in Millions | Jun. 30, 2023 GBP (£) | Dec. 31, 2022 GBP (£) |
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Provisions | £ 732 | £ 858 |
Provision for credit commitments | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Provisions | 467 | 532 |
Loans and advances | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 183,237 | £ 182,507 |
Coverage ratio | 0.020 | 0.021 |
Loans and advances | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 164,788 | £ 163,115 |
Coverage ratio | 0.003 | 0.004 |
Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 16,681 | £ 17,460 |
Coverage ratio | 0.083 | 0.079 |
Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 15,717 | £ 16,655 |
Coverage ratio | 0.071 | 0.068 |
Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 321 | £ 348 |
Coverage ratio | 0.330 | 0.221 |
Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 643 | £ 457 |
Coverage ratio | 0.184 | 0.275 |
Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 1,768 | £ 1,932 |
Coverage ratio | 0.500 | 0.459 |
Retail mortgages | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 8,594 | £ 11,405 |
Coverage ratio | 0.040 | 0.033 |
Retail mortgages | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 7,782 | £ 10,446 |
Coverage ratio | 0.001 | 0.001 |
Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 372 | £ 337 |
Coverage ratio | 0.058 | 0.069 |
Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 254 | £ 288 |
Coverage ratio | 0.066 | 0.071 |
Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 13 | £ 9 |
Coverage ratio | 0.188 | 0.182 |
Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 105 | £ 40 |
Coverage ratio | 0.019 | 0.024 |
Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 440 | £ 622 |
Coverage ratio | 0.426 | 0.364 |
Retail credit cards | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 24,649 | £ 25,402 |
Coverage ratio | 0.090 | 0.082 |
Retail credit cards | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 21,522 | £ 22,338 |
Coverage ratio | 0.014 | 0.015 |
Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 2,876 | £ 2,753 |
Coverage ratio | 0.282 | 0.290 |
Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 2,618 | £ 2,365 |
Coverage ratio | 0.247 | 0.273 |
Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 159 | £ 155 |
Coverage ratio | 0.474 | 0.346 |
Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 99 | £ 233 |
Coverage ratio | 0.564 | 0.404 |
Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 251 | £ 311 |
Coverage ratio | 0.800 | 0.725 |
Retail other | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 5,411 | £ 7,724 |
Coverage ratio | 0.028 | 0.030 |
Retail other | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 4,560 | £ 6,877 |
Coverage ratio | 0.005 | 0.005 |
Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 614 | £ 495 |
Coverage ratio | 0.055 | 0.055 |
Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 340 | £ 363 |
Coverage ratio | 0.076 | 0.055 |
Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 32 | £ 42 |
Coverage ratio | 0.030 | 0.067 |
Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 242 | £ 90 |
Coverage ratio | 0.028 | 0.053 |
Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 237 | £ 352 |
Coverage ratio | 0.295 | 0.327 |
Corporate loans | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 105,473 | £ 107,354 |
Coverage ratio | 0.008 | 0.008 |
Corporate loans | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 95,446 | £ 96,495 |
Coverage ratio | 0.002 | 0.003 |
Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 9,189 | £ 10,217 |
Coverage ratio | 0.030 | 0.026 |
Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 8,875 | £ 9,981 |
Coverage ratio | 0.029 | 0.025 |
Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 117 | £ 142 |
Coverage ratio | 0.086 | 0.078 |
Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 197 | £ 94 |
Coverage ratio | 0.039 | 0.087 |
Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 838 | £ 642 |
Coverage ratio | 0.286 | 0.313 |
Debt securities and other | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 39,110 | £ 30,622 |
Coverage ratio | 0.001 | 0.001 |
Debt securities and other | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 35,478 | £ 26,959 |
Coverage ratio | 0.001 | 0 |
Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 3,630 | £ 3,658 |
Coverage ratio | 0.009 | 0.009 |
Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 3,630 | £ 3,658 |
Coverage ratio | 0.009 | 0.009 |
Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 0 | £ 0 |
Coverage ratio | 0 | 0 |
Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 0 | £ 0 |
Coverage ratio | 0 | 0 |
Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 2 | £ 5 |
Coverage ratio | 0 | 0 |
Gross exposure | Loans and advances | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ 187,068 | £ 186,327 |
Gross exposure | Loans and advances | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 165,347 | 163,808 |
Gross exposure | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 18,185 | 18,949 |
Gross exposure | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 16,918 | 17,872 |
Gross exposure | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 479 | 447 |
Gross exposure | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 788 | 630 |
Gross exposure | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 3,536 | 3,570 |
Gross exposure | Retail mortgages | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 8,953 | 11,798 |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 7,791 | 10,458 |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 395 | 362 |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 272 | 310 |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 16 | 11 |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 107 | 41 |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 767 | 978 |
Gross exposure | Retail credit cards | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 27,093 | 27,678 |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 21,829 | 22,669 |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 4,007 | 3,880 |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 3,478 | 3,252 |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 302 | 237 |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 227 | 391 |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 1,257 | 1,129 |
Gross exposure | Retail other | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 5,569 | 7,962 |
Gross exposure | Retail other | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 4,583 | 6,915 |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 650 | 524 |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 368 | 384 |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 33 | 45 |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 249 | 95 |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 336 | 523 |
Gross exposure | Corporate loans | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 106,290 | 108,226 |
Gross exposure | Corporate loans | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 95,647 | 96,799 |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 9,469 | 10,492 |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 9,136 | 10,235 |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 128 | 154 |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 205 | 103 |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 1,174 | 935 |
Gross exposure | Debt securities and other | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 39,163 | 30,663 |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 35,497 | 26,967 |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 3,664 | 3,691 |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 3,664 | 3,691 |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 0 | 0 |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 0 | 0 |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 2 | 5 |
Gross exposure | Debt securities | Financial assets at amortised cost | Treasury and CIB | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 35,300 | 27,400 |
Gross exposure | Loans and advances | Financial assets at amortised cost | Treasury | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 3,400 | 2,900 |
Gross exposure | Loans and advances | Financial assets at amortised cost | Head Office | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 400 | 400 |
Gross exposure | Other financial assets subject to impairment | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 172,400 | 155,100 |
Gross exposure | Other financial assets subject to impairment | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 171,300 | 153,800 |
Gross exposure | Financial assets at fair value through other comprehensive income | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 877 | 1,142 |
Gross exposure | Other assets | Lifetime expected credit losses | Stage 3 | Provision for credit commitments | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 137 | 141 |
Impairment allowance | Loans and advances | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (3,831) | (3,820) |
Impairment allowance | Loans and advances | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (559) | (693) |
Impairment allowance | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (1,504) | (1,489) |
Impairment allowance | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (1,201) | (1,217) |
Impairment allowance | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (158) | (99) |
Impairment allowance | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (145) | (173) |
Impairment allowance | Loans and advances | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (1,768) | (1,638) |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (359) | (393) |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (9) | (12) |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (23) | (25) |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (18) | (22) |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (3) | (2) |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (2) | (1) |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (327) | (356) |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (2,444) | (2,276) |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (307) | (331) |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (1,131) | (1,127) |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (860) | (887) |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (143) | (82) |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (128) | (158) |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (1,006) | (818) |
Impairment allowance | Retail other | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (158) | (238) |
Impairment allowance | Retail other | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (23) | (38) |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (36) | (29) |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (28) | (21) |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (1) | (3) |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (7) | (5) |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (99) | (171) |
Impairment allowance | Corporate loans | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (817) | (872) |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (201) | (304) |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (280) | (275) |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (261) | (254) |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (11) | (12) |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (8) | (9) |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (336) | (293) |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (53) | (41) |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (19) | (8) |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (34) | (33) |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (34) | (33) |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Not later than 30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 0 | 0 |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | >30 days past due | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 0 | 0 |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 0 | 0 |
Impairment allowance | Debt securities | Financial assets at amortised cost | Treasury and CIB | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (53) | (41) |
Impairment allowance | Loans and advances | Financial assets at amortised cost | Treasury | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 0 | 0 |
Impairment allowance | Loans and advances | Financial assets at amortised cost | Head Office | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | 0 | 0 |
Impairment allowance | Other financial assets subject to impairment | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (156) | (152) |
Impairment allowance | Other financial assets subject to impairment | Stage 1 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (15) | (7) |
Impairment allowance | Financial assets at fair value through other comprehensive income | Lifetime expected credit losses | Stage 2 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | (12) | (8) |
Impairment allowance | Other assets | Lifetime expected credit losses | Stage 3 | ||
Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] | ||
Financial assets | £ (129) | £ (137) |
Credit Risk - Movement in gross
Credit Risk - Movement in gross exposures and impairment allowance (Details) - GBP (£) £ in Millions | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Recoveries and reimbursements | £ 0 | |
Total exchange and other adjustments | 196 | |
Total income statement charge for the period | 688 | £ 293 |
Financial guarantee contracts | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Recoveries and reimbursements | (7) | (11) |
Post write-off recoveries | 7 | 20 |
Stage 1 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Recoveries and reimbursements | 64 | |
Lifetime expected credit losses | Stage 2 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Recoveries and reimbursements | (28) | |
Lifetime expected credit losses | Stage 3 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Recoveries and reimbursements | (36) | |
Loans and advances | ||
Loans and advances at amortised cost | ||
Opening balance | 4,352 | |
Ending balance | 4,298 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 553 | |
Loans and advances | Stage 1 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | (134) | |
Loans and advances | Lifetime expected credit losses | Stage 2 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 15 | |
Loans and advances | Lifetime expected credit losses | Stage 3 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 672 | |
Retail mortgages | ||
Loans and advances at amortised cost | ||
Opening balance | 393 | |
Ending balance | 359 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | (25) | |
Retail mortgages | Stage 1 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | (3) | |
Retail mortgages | Lifetime expected credit losses | Stage 2 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | (2) | |
Retail mortgages | Lifetime expected credit losses | Stage 3 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | (20) | |
Retail credit cards | ||
Loans and advances at amortised cost | ||
Opening balance | 2,363 | |
Ending balance | 2,525 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 501 | |
Retail credit cards | Stage 1 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | (24) | |
Retail credit cards | Lifetime expected credit losses | Stage 2 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 4 | |
Retail credit cards | Lifetime expected credit losses | Stage 3 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 521 | |
Retail other | ||
Loans and advances at amortised cost | ||
Opening balance | 238 | |
Ending balance | 166 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | (35) | |
Retail other | Stage 1 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | (15) | |
Retail other | Lifetime expected credit losses | Stage 2 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 7 | |
Retail other | Lifetime expected credit losses | Stage 3 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | (27) | |
Corporate loans | ||
Loans and advances at amortised cost | ||
Opening balance | 1,317 | |
Ending balance | 1,195 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 100 | |
Corporate loans | Stage 1 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | (103) | |
Corporate loans | Lifetime expected credit losses | Stage 2 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 5 | |
Corporate loans | Lifetime expected credit losses | Stage 3 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 198 | |
Debt securities and other | ||
Loans and advances at amortised cost | ||
Opening balance | 41 | |
Ending balance | 53 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 12 | |
Debt securities and other | Stage 1 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 11 | |
Debt securities and other | Lifetime expected credit losses | Stage 2 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | 1 | |
Debt securities and other | Lifetime expected credit losses | Stage 3 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement excluding assets derecognised due to disposals and write-offs | ||
ECL movement on loan commitments and other financial guarantees | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement | (65) | |
ECL movement on loan commitments and other financial guarantees | Stage 1 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement | (47) | |
ECL movement on loan commitments and other financial guarantees | Lifetime expected credit losses | Stage 2 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement | (36) | |
ECL movement on loan commitments and other financial guarantees | Lifetime expected credit losses | Stage 3 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement | 18 | |
ECL movement on other financial assets | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement | 4 | |
ECL movement on other financial assets | Stage 1 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement | 8 | |
ECL movement on other financial assets | Lifetime expected credit losses | Stage 2 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement | 4 | |
ECL movement on other financial assets | Lifetime expected credit losses | Stage 3 | ||
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
ECL movement | (8) | |
Gross exposure | Loans and advances | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Write-offs | (404) | (560) |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 404 | 560 |
Post write-off recoveries | 7 | 20 |
Net write-offs | 397 | £ 540 |
Gross exposure | Retail mortgages | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (25) | |
Gross exposure | Retail mortgages | Stage 1 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (21) | |
Gross exposure | Retail mortgages | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Gross exposure | Retail mortgages | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4) | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Opening balance | 11,798 | |
Business activity in the period | 622 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (2,430) | |
Final repayments | (1,028) | |
Disposals | 0 | |
Write-offs | (9) | |
Ending balance | 8,953 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 9 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Stage 1 | ||
Loans and advances at amortised cost | ||
Opening balance | 10,458 | |
Business activity in the period | 622 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (2,154) | |
Final repayments | (902) | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 7,791 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Stage 1 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | (218) | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Stage 1 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 65 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Stage 1 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (90) | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Stage 1 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 10 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Opening balance | 362 | |
Business activity in the period | 0 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (58) | |
Final repayments | (45) | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 395 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 218 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | (65) | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (36) | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 19 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Opening balance | 978 | |
Business activity in the period | 0 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (218) | |
Final repayments | (81) | |
Disposals | 0 | |
Write-offs | (9) | |
Ending balance | 767 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 9 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 126 | |
Gross exposure | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (29) | |
Gross exposure | Retail credit cards | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4,918) | |
Gross exposure | Retail credit cards | Stage 1 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4,448) | |
Gross exposure | Retail credit cards | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (469) | |
Gross exposure | Retail credit cards | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1) | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Opening balance | 27,678 | |
Business activity in the period | 950 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,116) | |
Final repayments | (82) | |
Disposals | (12) | |
Write-offs | (325) | |
Ending balance | 27,093 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 325 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Stage 1 | ||
Loans and advances at amortised cost | ||
Opening balance | 22,669 | |
Business activity in the period | 904 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,052) | |
Final repayments | (65) | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 21,829 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Stage 1 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | (1,468) | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Stage 1 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 1,033 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Stage 1 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (197) | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Stage 1 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 5 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Opening balance | 3,880 | |
Business activity in the period | 45 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 64 | |
Final repayments | (17) | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 4,007 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 1,468 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | (1,033) | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (404) | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 4 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Opening balance | 1,129 | |
Business activity in the period | 1 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (128) | |
Final repayments | 0 | |
Disposals | (12) | |
Write-offs | (325) | |
Ending balance | 1,257 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 325 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 601 | |
Gross exposure | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (9) | |
Gross exposure | Retail other | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,197) | |
Gross exposure | Retail other | Stage 1 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,120) | |
Gross exposure | Retail other | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (30) | |
Gross exposure | Retail other | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (47) | |
Gross exposure | Retail other | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Opening balance | 7,962 | |
Business activity in the period | 1,095 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (2,372) | |
Final repayments | (1,031) | |
Disposals | (75) | |
Write-offs | (10) | |
Ending balance | 5,569 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 10 | |
Gross exposure | Retail other | Financial assets at amortised cost | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail other | Financial assets at amortised cost | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail other | Financial assets at amortised cost | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail other | Financial assets at amortised cost | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail other | Financial assets at amortised cost | Stage 1 | ||
Loans and advances at amortised cost | ||
Opening balance | 6,915 | |
Business activity in the period | 1,086 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (2,145) | |
Final repayments | (909) | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 4,583 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Gross exposure | Retail other | Financial assets at amortised cost | Stage 1 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | (446) | |
Gross exposure | Retail other | Financial assets at amortised cost | Stage 1 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 138 | |
Gross exposure | Retail other | Financial assets at amortised cost | Stage 1 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (57) | |
Gross exposure | Retail other | Financial assets at amortised cost | Stage 1 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 1 | |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Opening balance | 524 | |
Business activity in the period | 6 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (79) | |
Final repayments | (75) | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 650 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 446 | |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | (138) | |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (41) | |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 7 | |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Opening balance | 523 | |
Business activity in the period | 3 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (148) | |
Final repayments | (47) | |
Disposals | (75) | |
Write-offs | (10) | |
Ending balance | 336 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 10 | |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 98 | |
Gross exposure | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (8) | |
Gross exposure | Disposal | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Disposals | (64) | |
Gross exposure | Debt sales | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Disposals | (11) | |
Gross exposure | Corporate loans | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2,604 | |
Gross exposure | Corporate loans | Stage 1 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 1,862 | |
Gross exposure | Corporate loans | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 534 | |
Gross exposure | Corporate loans | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 208 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Opening balance | 108,226 | |
Business activity in the period | 12,574 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 973 | |
Final repayments | (15,313) | |
Disposals | (110) | |
Write-offs | (60) | |
Ending balance | 106,290 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 60 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Stage 1 | ||
Loans and advances at amortised cost | ||
Opening balance | 96,799 | |
Business activity in the period | 12,224 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 1,810 | |
Final repayments | (14,659) | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 95,647 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Stage 1 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | (4,747) | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Stage 1 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 4,312 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Stage 1 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (139) | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Stage 1 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 47 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Opening balance | 10,492 | |
Business activity in the period | 315 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,049) | |
Final repayments | (563) | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 9,469 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 4,747 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | (4,312) | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (225) | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 64 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Opening balance | 935 | |
Business activity in the period | 35 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 212 | |
Final repayments | (91) | |
Disposals | (110) | |
Write-offs | (60) | |
Ending balance | 1,174 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 60 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 364 | |
Gross exposure | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (111) | |
Gross exposure | Debt securities and other | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1) | |
Gross exposure | Debt securities and other | Stage 1 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1) | |
Gross exposure | Debt securities and other | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Gross exposure | Debt securities and other | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Opening balance | 30,663 | |
Business activity in the period | 11,516 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (845) | |
Final repayments | (2,171) | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 39,163 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Stage 1 | ||
Loans and advances at amortised cost | ||
Opening balance | 26,967 | |
Business activity in the period | 11,438 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (768) | |
Final repayments | (1,998) | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 35,497 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Stage 1 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | (260) | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Stage 1 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 118 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Stage 1 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Stage 1 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Opening balance | 3,691 | |
Business activity in the period | 78 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (79) | |
Final repayments | (168) | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 3,664 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 260 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | (118) | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Opening balance | 5 | |
Business activity in the period | 0 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2 | |
Final repayments | (5) | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 2 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Gross exposure | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail mortgages | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Impairment allowance | Retail mortgages | Stage 1 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Impairment allowance | Retail mortgages | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Impairment allowance | Retail mortgages | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Opening balance | 393 | |
Business activity in the period | 3 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (26) | |
Final repayments | 2 | |
Disposals | 0 | |
Write-offs | 9 | |
Ending balance | 359 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | (9) | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Stage 1 | ||
Loans and advances at amortised cost | ||
Opening balance | 12 | |
Business activity in the period | 3 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (9) | |
Final repayments | 0 | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 9 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Stage 1 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Stage 1 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 3 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Stage 1 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Stage 1 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Opening balance | 25 | |
Business activity in the period | 0 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 4 | |
Final repayments | 1 | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 23 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | (3) | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (3) | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 1 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Opening balance | 356 | |
Business activity in the period | 0 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (21) | |
Final repayments | 1 | |
Disposals | 0 | |
Write-offs | 9 | |
Ending balance | 327 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | (9) | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 3 | |
Impairment allowance | Retail mortgages | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (1) | |
Impairment allowance | Retail credit cards | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 3 | |
Impairment allowance | Retail credit cards | Stage 1 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (19) | |
Impairment allowance | Retail credit cards | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 23 | |
Impairment allowance | Retail credit cards | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1) | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Opening balance | 2,276 | |
Business activity in the period | 33 | |
Refinements to models used for calculation | (20) | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 542 | |
Final repayments | 54 | |
Disposals | 8 | |
Write-offs | 325 | |
Ending balance | 2,444 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | (325) | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Stage 1 | ||
Loans and advances at amortised cost | ||
Opening balance | 331 | |
Business activity in the period | 16 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (267) | |
Final repayments | 12 | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 307 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Stage 1 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | (42) | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Stage 1 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 290 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Stage 1 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (12) | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Stage 1 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 3 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Opening balance | 1,127 | |
Business activity in the period | 16 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 475 | |
Final repayments | 36 | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 1,131 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 42 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | (290) | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (205) | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 2 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Opening balance | 818 | |
Business activity in the period | 1 | |
Refinements to models used for calculation | (20) | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 334 | |
Final repayments | 6 | |
Disposals | 8 | |
Write-offs | 325 | |
Ending balance | 1,006 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | (325) | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 217 | |
Impairment allowance | Retail credit cards | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (5) | |
Impairment allowance | Retail other | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 8 | |
Impairment allowance | Retail other | Stage 1 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 8 | |
Impairment allowance | Retail other | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Impairment allowance | Retail other | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Impairment allowance | Retail other | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Opening balance | 238 | |
Business activity in the period | 6 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (37) | |
Final repayments | 4 | |
Disposals | 35 | |
Write-offs | 10 | |
Ending balance | 158 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | (10) | |
Impairment allowance | Retail other | Financial assets at amortised cost | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Stage 1 | ||
Loans and advances at amortised cost | ||
Opening balance | 38 | |
Business activity in the period | 3 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (17) | |
Final repayments | 2 | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 23 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Stage 1 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | (3) | |
Impairment allowance | Retail other | Financial assets at amortised cost | Stage 1 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 4 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Stage 1 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (1) | |
Impairment allowance | Retail other | Financial assets at amortised cost | Stage 1 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 1 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Opening balance | 29 | |
Business activity in the period | 1 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 12 | |
Final repayments | 1 | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 36 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 3 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | (4) | |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (6) | |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 2 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Opening balance | 171 | |
Business activity in the period | 2 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (32) | |
Final repayments | 1 | |
Disposals | 35 | |
Write-offs | 10 | |
Ending balance | 99 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | (10) | |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 7 | |
Impairment allowance | Retail other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (3) | |
Impairment allowance | Corporate loans | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (10) | |
Impairment allowance | Corporate loans | Stage 1 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (26) | |
Impairment allowance | Corporate loans | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4) | |
Impairment allowance | Corporate loans | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 20 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Opening balance | 872 | |
Business activity in the period | 42 | |
Refinements to models used for calculation | 93 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 46 | |
Final repayments | 81 | |
Disposals | 95 | |
Write-offs | 60 | |
Ending balance | 817 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | (60) | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Corporate and Investment Bank | ||
Loans and advances at amortised cost | ||
Refinements to models used for calculation | 93 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Stage 1 | ||
Loans and advances at amortised cost | ||
Opening balance | 304 | |
Business activity in the period | 20 | |
Refinements to models used for calculation | (49) | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (46) | |
Final repayments | 56 | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 201 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Stage 1 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | (21) | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Stage 1 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 49 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Stage 1 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (1) | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Stage 1 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 1 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Opening balance | 275 | |
Business activity in the period | 13 | |
Refinements to models used for calculation | 142 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (90) | |
Final repayments | 18 | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 280 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 21 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | (49) | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (16) | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 2 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Opening balance | 293 | |
Business activity in the period | 9 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 182 | |
Final repayments | 7 | |
Disposals | 95 | |
Write-offs | 60 | |
Ending balance | 336 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | (60) | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 17 | |
Impairment allowance | Corporate loans | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | (3) | |
Impairment allowance | Debt securities and other | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Impairment allowance | Debt securities and other | Stage 1 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Impairment allowance | Debt securities and other | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Impairment allowance | Debt securities and other | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | ||
Loans and advances at amortised cost | ||
Opening balance | 41 | |
Business activity in the period | 3 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 11 | |
Final repayments | 2 | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 53 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Stage 1 | ||
Loans and advances at amortised cost | ||
Opening balance | 8 | |
Business activity in the period | 2 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 7 | |
Final repayments | 0 | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 19 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Stage 1 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Stage 1 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 2 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Stage 1 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Stage 1 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | ||
Loans and advances at amortised cost | ||
Opening balance | 33 | |
Business activity in the period | 1 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 4 | |
Final repayments | 2 | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 34 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | (2) | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 2 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | ||
Loans and advances at amortised cost | ||
Opening balance | 0 | |
Business activity in the period | 0 | |
Refinements to models used for calculation | 0 | |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 | |
Final repayments | 0 | |
Disposals | 0 | |
Write-offs | 0 | |
Ending balance | 0 | |
Reconciliation of ECL movement to impairment charge/(release) for the period | ||
Gross write-offs | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 1 to Stage 2 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 2 to Stage 1 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers to Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | 0 | |
Impairment allowance | Debt securities and other | Financial assets at amortised cost | Lifetime expected credit losses | Stage 3 | Transfers from Stage 3 | ||
Loans and advances at amortised cost | ||
Transfers | £ 0 |
Credit Risk - Provisions for lo
Credit Risk - Provisions for loan commitment and financial guarantees (Details) £ in Millions | 6 Months Ended |
Jun. 30, 2023 GBP (£) | |
Gross exposure | Retail mortgages | |
Loan commitments and financial guarantees | |
Opening balance | £ 67 |
Net transfers between stages | 0 |
Business activity in the year | 27 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (25) |
Limit management and final repayments | (26) |
Ending balance | 43 |
Gross exposure | Retail credit cards | |
Loan commitments and financial guarantees | |
Opening balance | 111,271 |
Net transfers between stages | 0 |
Business activity in the year | 9,318 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4,918) |
Limit management and final repayments | (6,578) |
Ending balance | 109,093 |
Gross exposure | Retail other | |
Loan commitments and financial guarantees | |
Opening balance | 4,640 |
Net transfers between stages | 0 |
Business activity in the year | 468 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,197) |
Limit management and final repayments | (303) |
Ending balance | 3,608 |
Gross exposure | Corporate loans | |
Loan commitments and financial guarantees | |
Opening balance | 229,892 |
Net transfers between stages | 0 |
Business activity in the year | 23,470 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 2,604 |
Limit management and final repayments | (28,320) |
Ending balance | 227,646 |
Gross exposure | Debt securities and other | |
Loan commitments and financial guarantees | |
Opening balance | 13 |
Net transfers between stages | 0 |
Business activity in the year | 14 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1) |
Limit management and final repayments | 0 |
Ending balance | 26 |
Impairment allowance | Retail mortgages | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Impairment allowance | Retail credit cards | |
Loan commitments and financial guarantees | |
Opening balance | 87 |
Net transfers between stages | 0 |
Business activity in the year | 11 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 3 |
Limit management and final repayments | (20) |
Ending balance | 81 |
Impairment allowance | Retail other | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 8 |
Limit management and final repayments | 0 |
Ending balance | 8 |
Impairment allowance | Corporate loans | |
Loan commitments and financial guarantees | |
Opening balance | 445 |
Net transfers between stages | 0 |
Business activity in the year | 15 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (10) |
Limit management and final repayments | (72) |
Ending balance | 378 |
Impairment allowance | Debt securities and other | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Stage 1 | Gross exposure | Retail mortgages | |
Loan commitments and financial guarantees | |
Opening balance | 61 |
Net transfers between stages | 0 |
Business activity in the year | 27 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (21) |
Limit management and final repayments | (25) |
Ending balance | 42 |
Stage 1 | Gross exposure | Retail credit cards | |
Loan commitments and financial guarantees | |
Opening balance | 109,291 |
Net transfers between stages | (646) |
Business activity in the year | 9,242 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4,448) |
Limit management and final repayments | (6,304) |
Ending balance | 107,135 |
Stage 1 | Gross exposure | Retail other | |
Loan commitments and financial guarantees | |
Opening balance | 4,497 |
Net transfers between stages | (65) |
Business activity in the year | 467 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1,120) |
Limit management and final repayments | (293) |
Ending balance | 3,486 |
Stage 1 | Gross exposure | Corporate loans | |
Loan commitments and financial guarantees | |
Opening balance | 205,207 |
Net transfers between stages | 624 |
Business activity in the year | 22,926 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 1,862 |
Limit management and final repayments | (26,348) |
Ending balance | 204,271 |
Stage 1 | Gross exposure | Debt securities and other | |
Loan commitments and financial guarantees | |
Opening balance | 13 |
Net transfers between stages | 0 |
Business activity in the year | 14 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1) |
Limit management and final repayments | 0 |
Ending balance | 26 |
Stage 1 | Impairment allowance | Retail mortgages | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Stage 1 | Impairment allowance | Retail credit cards | |
Loan commitments and financial guarantees | |
Opening balance | 41 |
Net transfers between stages | 14 |
Business activity in the year | 6 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (19) |
Limit management and final repayments | (4) |
Ending balance | 38 |
Stage 1 | Impairment allowance | Retail other | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 8 |
Limit management and final repayments | 0 |
Ending balance | 8 |
Stage 1 | Impairment allowance | Corporate loans | |
Loan commitments and financial guarantees | |
Opening balance | 193 |
Net transfers between stages | 18 |
Business activity in the year | 7 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (26) |
Limit management and final repayments | (51) |
Ending balance | 141 |
Stage 1 | Impairment allowance | Debt securities and other | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 2 | Gross exposure | Retail mortgages | |
Loan commitments and financial guarantees | |
Opening balance | 1 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | (1) |
Ending balance | 0 |
Lifetime expected credit losses | Stage 2 | Gross exposure | Retail credit cards | |
Loan commitments and financial guarantees | |
Opening balance | 1,973 |
Net transfers between stages | 644 |
Business activity in the year | 76 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (469) |
Limit management and final repayments | (274) |
Ending balance | 1,950 |
Lifetime expected credit losses | Stage 2 | Gross exposure | Retail other | |
Loan commitments and financial guarantees | |
Opening balance | 79 |
Net transfers between stages | 39 |
Business activity in the year | 1 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (30) |
Limit management and final repayments | (10) |
Ending balance | 79 |
Lifetime expected credit losses | Stage 2 | Gross exposure | Corporate loans | |
Loan commitments and financial guarantees | |
Opening balance | 23,873 |
Net transfers between stages | (768) |
Business activity in the year | 543 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 534 |
Limit management and final repayments | (1,749) |
Ending balance | 22,433 |
Lifetime expected credit losses | Stage 2 | Gross exposure | Debt securities and other | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 2 | Impairment allowance | Retail mortgages | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 2 | Impairment allowance | Retail credit cards | |
Loan commitments and financial guarantees | |
Opening balance | 45 |
Net transfers between stages | (14) |
Business activity in the year | 5 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 23 |
Limit management and final repayments | (16) |
Ending balance | 43 |
Lifetime expected credit losses | Stage 2 | Impairment allowance | Retail other | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 2 | Impairment allowance | Corporate loans | |
Loan commitments and financial guarantees | |
Opening balance | 230 |
Net transfers between stages | (19) |
Business activity in the year | 8 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4) |
Limit management and final repayments | (19) |
Ending balance | 196 |
Lifetime expected credit losses | Stage 2 | Impairment allowance | Debt securities and other | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 3 | Gross exposure | Retail mortgages | |
Loan commitments and financial guarantees | |
Opening balance | 5 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (4) |
Limit management and final repayments | 0 |
Ending balance | 1 |
Lifetime expected credit losses | Stage 3 | Gross exposure | Retail credit cards | |
Loan commitments and financial guarantees | |
Opening balance | 7 |
Net transfers between stages | 2 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1) |
Limit management and final repayments | 0 |
Ending balance | 8 |
Lifetime expected credit losses | Stage 3 | Gross exposure | Retail other | |
Loan commitments and financial guarantees | |
Opening balance | 64 |
Net transfers between stages | 26 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (47) |
Limit management and final repayments | 0 |
Ending balance | 43 |
Lifetime expected credit losses | Stage 3 | Gross exposure | Corporate loans | |
Loan commitments and financial guarantees | |
Opening balance | 812 |
Net transfers between stages | 144 |
Business activity in the year | 1 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 208 |
Limit management and final repayments | (223) |
Ending balance | 942 |
Lifetime expected credit losses | Stage 3 | Gross exposure | Debt securities and other | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 3 | Impairment allowance | Retail mortgages | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 3 | Impairment allowance | Retail credit cards | |
Loan commitments and financial guarantees | |
Opening balance | 1 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | (1) |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 3 | Impairment allowance | Retail other | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | 0 |
Lifetime expected credit losses | Stage 3 | Impairment allowance | Corporate loans | |
Loan commitments and financial guarantees | |
Opening balance | 22 |
Net transfers between stages | 1 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 20 |
Limit management and final repayments | (2) |
Ending balance | 41 |
Lifetime expected credit losses | Stage 3 | Impairment allowance | Debt securities and other | |
Loan commitments and financial guarantees | |
Opening balance | 0 |
Net transfers between stages | 0 |
Business activity in the year | 0 |
Net drawdowns, repayments, net re-measurement and movement due to exposure and risk parameter changes | 0 |
Limit management and final repayments | 0 |
Ending balance | £ 0 |
Credit Risk - Management adjust
Credit Risk - Management adjustments to models for impairment (Details) - GBP (£) £ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
Loans and advances | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 4,298 | £ 4,352 |
Proportion of Management adjustments to total impairment allowance | (0.90%) | (50.00%) |
Loans and advances | Impairment allowance pre management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 4,338 | £ 4,374 |
Loans and advances | Modelled ECL | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 3,700 | 3,700 |
Loans and advances | Individually assessed impairments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 300 | 300 |
Loans and advances | Non-modelled ECL | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 300 | 400 |
Loans and advances | Management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | (40) | (22) |
Loans and advances | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | 97 |
Loans and advances | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | (40) | (119) |
Loans and advances | Stage 1 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 97 | |
Loans and advances | Lifetime expected credit losses | Stage 2 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Loans and advances | Lifetime expected credit losses | Stage 3 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Retail mortgages | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 359 | £ 393 |
Proportion of Management adjustments to total impairment allowance | (0.60%) | 0% |
Retail mortgages | Impairment allowance pre management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 361 | £ 393 |
Retail mortgages | Management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | (2) | 0 |
Retail mortgages | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | 0 |
Retail mortgages | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | (2) | 0 |
Retail mortgages | Stage 1 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Retail mortgages | Lifetime expected credit losses | Stage 2 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Retail mortgages | Lifetime expected credit losses | Stage 3 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Retail credit cards | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 2,525 | £ 2,363 |
Proportion of Management adjustments to total impairment allowance | (1.30%) | 230% |
Retail credit cards | Impairment allowance pre management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 2,559 | £ 2,309 |
Retail credit cards | Management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | (34) | 54 |
Retail credit cards | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | 0 |
Retail credit cards | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | (34) | 54 |
Retail credit cards | Stage 1 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Retail credit cards | Lifetime expected credit losses | Stage 2 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Retail credit cards | Lifetime expected credit losses | Stage 3 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Retail other | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 166 | £ 238 |
Proportion of Management adjustments to total impairment allowance | (19.90%) | 880% |
Retail other | Impairment allowance pre management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 199 | £ 217 |
Retail other | Management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | (33) | 21 |
Retail other | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | 2 |
Retail other | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | (33) | 19 |
Retail other | Stage 1 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Retail other | Lifetime expected credit losses | Stage 2 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 2 | |
Retail other | Lifetime expected credit losses | Stage 3 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Corporate loans | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 1,195 | £ 1,317 |
Proportion of Management adjustments to total impairment allowance | 2.40% | (740.00%) |
Corporate loans | Impairment allowance pre management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 1,166 | £ 1,414 |
Corporate loans | Management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 29 | (97) |
Corporate loans | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | 95 |
Corporate loans | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 29 | (192) |
Corporate loans | Stage 1 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 97 | |
Corporate loans | Lifetime expected credit losses | Stage 2 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | (2) | |
Corporate loans | Lifetime expected credit losses | Stage 3 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Debt securities and other | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 53 | £ 41 |
Proportion of Management adjustments to total impairment allowance | 0% | 0% |
Debt securities and other | Impairment allowance pre management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 53 | £ 41 |
Debt securities and other | Management adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | 0 |
Debt securities and other | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | 0 |
Debt securities and other | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 0 | 0 |
Debt securities and other | Stage 1 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Debt securities and other | Lifetime expected credit losses | Stage 2 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | |
Debt securities and other | Lifetime expected credit losses | Stage 3 | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 0 |
Credit Risk - Narrative (Detail
Credit Risk - Narrative (Details) £ in Millions | 6 Months Ended | |
Jun. 30, 2023 GBP (£) economic_scenario | Dec. 31, 2022 GBP (£) | |
Disclosure of financial assets [line items] | ||
Number of economic scenarios, percentage | 100% | |
Credit risk | ||
Disclosure of financial assets [line items] | ||
Number of economic scenarios | economic_scenario | 5 | |
Stress horizon period | 5 years | |
Loans and advances | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 4,298 | £ 4,352 |
Loans and advances | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | 97 |
Loans and advances | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | (40) | (119) |
Retail credit cards | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 2,525 | 2,363 |
Retail credit cards | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | 0 |
Retail credit cards | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | (34) | 54 |
Retail other | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 166 | 238 |
Retail other | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | 2 |
Retail other | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | (33) | 19 |
Corporate loans | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 1,195 | 1,317 |
Corporate loans | Economic uncertainty adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | 0 | 95 |
Corporate loans | Other adjustments | ||
Disclosure of financial assets [line items] | ||
Allowance account for credit losses of financial assets | £ 29 | £ (192) |
Credit Risk - Macroeconomic var
Credit Risk - Macroeconomic variables used in the calculation of ECL (Details) | Jun. 30, 2023 | Dec. 31, 2022 |
Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4,020% | 3,940% |
Baseline | GDP | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.30% | 3.30% |
Baseline | GDP | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.10% | 1.80% |
Baseline | GDP | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.90% | (0.80%) |
Baseline | GDP | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.70% | 0.50% |
Baseline | GDP | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 0.90% |
Baseline | GDP | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 1.20% |
Baseline | GDP | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.80% | 1.80% |
Baseline | GDP | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 1.50% |
Baseline | GDP | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 1.90% |
Baseline | GDP | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 1.50% |
Baseline | Unemployment | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 3.70% |
Baseline | Unemployment | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 3.70% |
Baseline | Unemployment | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 4.50% |
Baseline | Unemployment | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 4.30% |
Baseline | Unemployment | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 4.40% |
Baseline | Unemployment | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 4.70% |
Baseline | Unemployment | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 4.10% |
Baseline | Unemployment | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 4.70% |
Baseline | Unemployment | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 4.20% |
Baseline | Unemployment | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 4.70% |
Baseline | HPI | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (6.10%) | 8.40% |
Baseline | HPI | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.70%) | 11.20% |
Baseline | HPI | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.30%) | (4.70%) |
Baseline | HPI | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 1.80% |
Baseline | HPI | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | (1.70%) |
Baseline | HPI | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 1.50% |
Baseline | HPI | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 2.20% |
Baseline | HPI | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 2.30% |
Baseline | HPI | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.70% | 2.20% |
Baseline | HPI | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 2.40% |
Baseline | Bank rate | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 1.80% |
Baseline | Bank rate | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 4.40% |
Baseline | Bank rate | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 4.10% |
Baseline | Bank rate | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 3.80% |
Baseline | Bank rate | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.40% |
Baseline | Federal funds rate | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5% | 2.10% |
Baseline | Federal funds rate | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.70% | 4.80% |
Baseline | Federal funds rate | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 3.60% |
Baseline | Federal funds rate | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 3.10% |
Baseline | Federal funds rate | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 3% |
Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 690% | 900% |
Downside 2 | GDP | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.50%) | 3.30% |
Downside 2 | GDP | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.50% | 1.80% |
Downside 2 | GDP | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (5.00%) | (3.40%) |
Downside 2 | GDP | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (4.80%) | (2.70%) |
Downside 2 | GDP | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.40%) | (3.80%) |
Downside 2 | GDP | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.30%) | (3.40%) |
Downside 2 | GDP | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 2% |
Downside 2 | GDP | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 2% |
Downside 2 | GDP | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 2.30% |
Downside 2 | GDP | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 2.60% |
Downside 2 | Unemployment | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 3.70% |
Downside 2 | Unemployment | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 3.70% |
Downside 2 | Unemployment | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.80% | 6% |
Downside 2 | Unemployment | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.70% | 6% |
Downside 2 | Unemployment | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.30% | 8.40% |
Downside 2 | Unemployment | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.60% | 8.50% |
Downside 2 | Unemployment | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.70% | 8% |
Downside 2 | Unemployment | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.50% | 8.10% |
Downside 2 | Unemployment | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.10% | 7.40% |
Downside 2 | Unemployment | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7% | 7.10% |
Downside 2 | HPI | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (10.20%) | 8.40% |
Downside 2 | HPI | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.80%) | 11.20% |
Downside 2 | HPI | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (20.50%) | (18.30%) |
Downside 2 | HPI | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (3.70%) | (3.10%) |
Downside 2 | HPI | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (17.70%) | (18.80%) |
Downside 2 | HPI | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (4.20%) | (4.00%) |
Downside 2 | HPI | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.60% | (7.70%) |
Downside 2 | HPI | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | (1.90%) |
Downside 2 | HPI | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.20% | 8.20% |
Downside 2 | HPI | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 4.80% |
Downside 2 | Bank rate | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 1.80% |
Downside 2 | Bank rate | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8% | 7.30% |
Downside 2 | Bank rate | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.30% | 7.90% |
Downside 2 | Bank rate | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.10% | 6.60% |
Downside 2 | Bank rate | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 5.50% |
Downside 2 | Federal funds rate | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.70% | 2.10% |
Downside 2 | Federal funds rate | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7% | 6.60% |
Downside 2 | Federal funds rate | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.50% | 6.90% |
Downside 2 | Federal funds rate | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.10% | 5.80% |
Downside 2 | Federal funds rate | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 4.60% |
Downside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1,520% | 1,760% |
Downside 1 | GDP | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.10%) | 3.30% |
Downside 1 | GDP | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 1.80% |
Downside 1 | GDP | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (2.10%) | (2.10%) |
Downside 1 | GDP | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (2.00%) | (1.10%) |
Downside 1 | GDP | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.60% | (1.50%) |
Downside 1 | GDP | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | (1.10%) |
Downside 1 | GDP | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | 1.90% |
Downside 1 | GDP | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 1.70% |
Downside 1 | GDP | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.90% | 2.10% |
Downside 1 | GDP | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 2.10% |
Downside 1 | Unemployment | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 3.70% |
Downside 1 | Unemployment | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 3.70% |
Downside 1 | Unemployment | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.10% | 5.20% |
Downside 1 | Unemployment | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.70% | 5.10% |
Downside 1 | Unemployment | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.20% | 6.40% |
Downside 1 | Unemployment | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.10% | 6.60% |
Downside 1 | Unemployment | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.90% | 6% |
Downside 1 | Unemployment | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.50% | 6.40% |
Downside 1 | Unemployment | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.60% | 5.80% |
Downside 1 | Unemployment | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.80% | 5.90% |
Downside 1 | HPI | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (8.10%) | 8.40% |
Downside 1 | HPI | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (1.20%) | 11.20% |
Downside 1 | HPI | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (11.30%) | (11.70%) |
Downside 1 | HPI | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.10%) | (0.70%) |
Downside 1 | HPI | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (8.20%) | (10.60%) |
Downside 1 | HPI | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.90%) | (1.30%) |
Downside 1 | HPI | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5% | (2.80%) |
Downside 1 | HPI | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 0.20% |
Downside 1 | HPI | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7% | 5.20% |
Downside 1 | HPI | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 3.60% |
Downside 1 | Bank rate | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 1.80% |
Downside 1 | Bank rate | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.10% | 5.90% |
Downside 1 | Bank rate | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.60% | 6.10% |
Downside 1 | Bank rate | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 5.30% |
Downside 1 | Bank rate | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 4.60% |
Downside 1 | Federal funds rate | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 2.10% |
Downside 1 | Federal funds rate | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.90% | 5.80% |
Downside 1 | Federal funds rate | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 5.40% |
Downside 1 | Federal funds rate | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 4.40% |
Downside 1 | Federal funds rate | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 3.90% |
Upside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1,300% | 1,090% |
Upside 2 | GDP | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.20% | 3.30% |
Upside 2 | GDP | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | 1.80% |
Upside 2 | GDP | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 2.80% |
Upside 2 | GDP | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 3.30% |
Upside 2 | GDP | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 3.70% |
Upside 2 | GDP | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 3.50% |
Upside 2 | GDP | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 2.90% |
Upside 2 | GDP | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 2.80% |
Upside 2 | GDP | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 2.40% |
Upside 2 | GDP | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 2.80% |
Upside 2 | Unemployment | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 3.70% |
Upside 2 | Unemployment | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 3.70% |
Upside 2 | Unemployment | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 3.50% |
Upside 2 | Unemployment | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.30% |
Upside 2 | Unemployment | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.40% |
Upside 2 | Unemployment | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 3.30% |
Upside 2 | Unemployment | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 3.40% |
Upside 2 | Unemployment | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 3.30% |
Upside 2 | Unemployment | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 3.40% |
Upside 2 | Unemployment | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 3.30% |
Upside 2 | HPI | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.40% | 8.40% |
Upside 2 | HPI | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 11.20% |
Upside 2 | HPI | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 10.60% | 8.70% |
Upside 2 | HPI | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.50% | 5.80% |
Upside 2 | HPI | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 7.50% |
Upside 2 | HPI | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 5.10% |
Upside 2 | HPI | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 4.40% |
Upside 2 | HPI | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 4.50% |
Upside 2 | HPI | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.80% | 4.20% |
Upside 2 | HPI | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 4.50% |
Upside 2 | Bank rate | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 1.80% |
Upside 2 | Bank rate | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 3.10% |
Upside 2 | Bank rate | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 2.60% |
Upside 2 | Bank rate | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 2.50% |
Upside 2 | Bank rate | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 2.50% |
Upside 2 | Federal funds rate | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 2.10% |
Upside 2 | Federal funds rate | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 3.60% |
Upside 2 | Federal funds rate | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | 2.90% |
Upside 2 | Federal funds rate | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 2.80% |
Upside 2 | Federal funds rate | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 2.80% |
Upside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2,470% | 2,310% |
Upside 1 | GDP | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 3.30% |
Upside 1 | GDP | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 1.80% |
Upside 1 | GDP | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 1% |
Upside 1 | GDP | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 1.90% |
Upside 1 | GDP | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.30% |
Upside 1 | GDP | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 2.30% |
Upside 1 | GDP | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.20% | 2.40% |
Upside 1 | GDP | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.20% |
Upside 1 | GDP | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 2.10% |
Upside 1 | GDP | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.40% | 2.20% |
Upside 1 | Unemployment | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 3.70% |
Upside 1 | Unemployment | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 3.70% |
Upside 1 | Unemployment | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 4% |
Upside 1 | Unemployment | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 3.80% |
Upside 1 | Unemployment | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 3.90% |
Upside 1 | Unemployment | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 4% |
Upside 1 | Unemployment | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 3.80% |
Upside 1 | Unemployment | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 4% |
Upside 1 | Unemployment | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 3.80% |
Upside 1 | Unemployment | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 4% |
Upside 1 | HPI | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (2.90%) | 8.40% |
Upside 1 | HPI | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.90% | 11.20% |
Upside 1 | HPI | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 1.80% |
Upside 1 | HPI | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 3.80% |
Upside 1 | HPI | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 2.90% |
Upside 1 | HPI | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.30% |
Upside 1 | HPI | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 3.30% |
Upside 1 | HPI | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 3.40% |
Upside 1 | HPI | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 3.20% |
Upside 1 | HPI | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 3.40% |
Upside 1 | Bank rate | 2023 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.60% | 1.80% |
Upside 1 | Bank rate | 2024 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 3.50% |
Upside 1 | Bank rate | 2025 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.10% | 3.30% |
Upside 1 | Bank rate | 2026 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 3% |
Upside 1 | Bank rate | 2027 | UK | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 2.80% |
Upside 1 | Federal funds rate | 2023 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.80% | 2.10% |
Upside 1 | Federal funds rate | 2024 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.40% | 3.90% |
Upside 1 | Federal funds rate | 2025 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.60% | 3.40% |
Upside 1 | Federal funds rate | 2026 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 3% |
Upside 1 | Federal funds rate | 2027 | USA | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 3% |
Credit Risk - Scenario probabil
Credit Risk - Scenario probability weighting (Details) | Jun. 30, 2023 | Dec. 31, 2022 |
Upside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1,300% | 1,090% |
Upside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2,470% | 2,310% |
Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4,020% | 3,940% |
Downside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1,520% | 1,760% |
Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 690% | 900% |
Credit Risk - Macroeconomic v_2
Credit Risk - Macroeconomic variables (specific bases and 5-year averages) (Details) | Jun. 30, 2023 | Dec. 31, 2022 |
Upside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1,300% | 1,090% |
Upside 2 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 15.10% | 13.90% |
Upside 2 | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.70% | 3% |
Upside 2 | GDP | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 15.90% | 14.10% |
Upside 2 | GDP | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.90% | 2.90% |
Upside 2 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.40% |
Upside 2 | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 3.50% |
Upside 2 | Unemployment | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.30% | 3.30% |
Upside 2 | Unemployment | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.40% |
Upside 2 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 25.80% | 37.80% |
Upside 2 | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.70% | 6.60% |
Upside 2 | HPI | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 23.60% | 35% |
Upside 2 | HPI | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.30% | 6.20% |
Upside 2 | Bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 0.50% |
Upside 2 | Bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 2.50% |
Upside 2 | Federal funds rate | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 0.10% |
Upside 2 | Federal funds rate | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 2.80% |
Upside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2,470% | 2,310% |
Upside 1 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.20% | 9.40% |
Upside 1 | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2% | 2.20% |
Upside 1 | GDP | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 11.90% | 9.60% |
Upside 1 | GDP | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.30% | 2.10% |
Upside 1 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 3.60% |
Upside 1 | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.90% | 3.80% |
Upside 1 | Unemployment | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.60% |
Upside 1 | Unemployment | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4% | 3.90% |
Upside 1 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 14.60% | 21% |
Upside 1 | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.80% | 3.90% |
Upside 1 | HPI | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 17.20% | 27.50% |
Upside 1 | HPI | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 5% |
Upside 1 | Bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3% | 0.50% |
Upside 1 | Bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.60% | 2.90% |
Upside 1 | Federal funds rate | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.50% | 0.10% |
Upside 1 | Federal funds rate | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.20% | 3.10% |
Baseline | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4,020% | 3,940% |
Baseline | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 1.40% |
Baseline | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.30% | 1.40% |
Baseline | GDP | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 1.30% |
Baseline | GDP | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1.60% | 1.30% |
Baseline | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 4.20% |
Baseline | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.20% | 4.20% |
Baseline | Unemployment | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 4.40% |
Baseline | Unemployment | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.40% | 4.40% |
Baseline | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 1.20% |
Baseline | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 1.20% |
Baseline | HPI | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 3.80% |
Baseline | HPI | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 2.10% | 3.80% |
Baseline | Bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 3.50% |
Baseline | Bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.10% | 3.50% |
Baseline | Federal funds rate | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.30% |
Baseline | Federal funds rate | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 3.50% | 3.30% |
Downside 1 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 1,520% | 1,760% |
Downside 1 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (2.70%) | (3.20%) |
Downside 1 | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.50% | 0.70% |
Downside 1 | GDP | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (2.30%) | (2.50%) |
Downside 1 | GDP | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 0.70% |
Downside 1 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.50% | 6.60% |
Downside 1 | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.60% | 5.40% |
Downside 1 | Unemployment | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.20% | 6.70% |
Downside 1 | Unemployment | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6% | 5.50% |
Downside 1 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (25.20%) | (17.90%) |
Downside 1 | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (3.40%) | (2.60%) |
Downside 1 | HPI | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (2.30%) | 3.70% |
Downside 1 | HPI | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0.80% | 2.50% |
Downside 1 | Bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.30% | 6.30% |
Downside 1 | Bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.20% | 4.70% |
Downside 1 | Federal funds rate | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.30% | 6% |
Downside 1 | Federal funds rate | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 4.50% | 4.30% |
Downside 2 | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 690% | 900% |
Downside 2 | GDP | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (6.90%) | (6.80%) |
Downside 2 | GDP | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.30%) | 0% |
Downside 2 | GDP | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (6.20%) | (6.30%) |
Downside 2 | GDP | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 0% | 0% |
Downside 2 | Unemployment | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8.50% | 8.50% |
Downside 2 | Unemployment | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7% | 6.70% |
Downside 2 | Unemployment | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 9.80% | 8.60% |
Downside 2 | Unemployment | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7.60% | 6.70% |
Downside 2 | HPI | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (41.50%) | (35.00%) |
Downside 2 | HPI | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (7.60%) | (6.40%) |
Downside 2 | HPI | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (10.10%) | 0.20% |
Downside 2 | HPI | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | (0.50%) | 1.20% |
Downside 2 | Bank rate | UK | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 8% | 8% |
Downside 2 | Bank rate | UK | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 6.40% | 5.80% |
Downside 2 | Federal funds rate | USA | Specific bases | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 7% | 7% |
Downside 2 | Federal funds rate | USA | 5-year averages | ||
Disclosure of nature and extent of risks arising from financial instruments [line items] | ||
Scenario probability weighting | 5.70% | 5.20% |
Segmental reporting - Analysis
Segmental reporting - Analysis of results by business (Details) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Disclosure of operating segments [line items] | |||
Total income | £ 9,804 | £ 9,990 | |
Operating expenses | (5,952) | (5,259) | |
Litigation and conduct | (34) | (1,833) | |
Operating expenses | (5,986) | (7,092) | |
Other net income | 2 | 0 | |
Profit/(loss) before impairment | 3,820 | 2,898 | |
Credit impairment charge | (688) | (293) | |
Profit before tax | 3,132 | 2,605 | |
Total assets | 1,246,636 | £ 1,203,537 | |
Total liabilities | 1,188,288 | 1,144,584 | |
Operating segments | Corporate and Investment Bank | |||
Disclosure of operating segments [line items] | |||
Total income | 7,362 | 8,086 | |
Operating expenses | (4,324) | (3,912) | |
Litigation and conduct | 2 | (1,632) | |
Operating expenses | (4,322) | (5,544) | |
Other net income | 2 | 0 | |
Profit/(loss) before impairment | 3,042 | 2,542 | |
Credit impairment charge | (20) | (31) | |
Profit before tax | 3,022 | 2,511 | |
Total assets | 1,147,200 | 1,111,200 | |
Total liabilities | 1,105,700 | 1,058,200 | |
Operating segments | Consumer, Cards and Payments | |||
Disclosure of operating segments [line items] | |||
Total income | 2,599 | 1,992 | |
Operating expenses | (1,544) | (1,285) | |
Litigation and conduct | (32) | (200) | |
Operating expenses | (1,576) | (1,485) | |
Other net income | 0 | 0 | |
Profit/(loss) before impairment | 1,023 | 507 | |
Credit impairment charge | (659) | (278) | |
Profit before tax | 364 | 229 | |
Total assets | 88,000 | 79,900 | |
Total liabilities | 82,400 | 85,000 | |
Head Office | |||
Disclosure of operating segments [line items] | |||
Total income | (157) | (88) | |
Operating expenses | (84) | (62) | |
Litigation and conduct | (4) | (1) | |
Operating expenses | (88) | (63) | |
Other net income | 0 | 0 | |
Profit/(loss) before impairment | (245) | (151) | |
Credit impairment charge | (9) | 16 | |
Profit before tax | (254) | £ (135) | |
Total assets | 11,400 | 12,400 | |
Total liabilities | £ 200 | £ 1,400 |
Segmental reporting - Split of
Segmental reporting - Split of income by geographic region (Details) - GBP (£) £ in Millions | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Disclosure of operating segments [line items] | ||
Total income | £ 9,804 | £ 9,990 |
United Kingdom | ||
Disclosure of operating segments [line items] | ||
Total income | 3,555 | 4,674 |
Europe | ||
Disclosure of operating segments [line items] | ||
Total income | 1,255 | 1,310 |
Americas | ||
Disclosure of operating segments [line items] | ||
Total income | 4,234 | 3,276 |
Africa and Middle East | ||
Disclosure of operating segments [line items] | ||
Total income | 42 | 31 |
Asia | ||
Disclosure of operating segments [line items] | ||
Total income | £ 718 | £ 699 |
Net fee and commission income_2
Net fee and commission income (Details) - GBP (£) £ in Millions | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | £ 4,453 | £ 3,939 |
Other non-contract fee income | 74 | 69 |
Fee and commission income | 4,527 | 4,008 |
Fee and commission expense | (1,721) | (1,169) |
Net fee and commission income | 2,806 | 2,839 |
Transactional | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 1,825 | 1,445 |
Advisory | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 457 | 512 |
Brokerage and execution | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 1,042 | 762 |
Underwriting and syndication | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 1,036 | 1,101 |
Other | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 93 | 119 |
Operating segments | Corporate and Investment Bank | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 2,689 | 2,521 |
Other non-contract fee income | 71 | 67 |
Fee and commission income | 2,760 | 2,588 |
Fee and commission expense | (747) | (461) |
Net fee and commission income | 2,013 | 2,127 |
Operating segments | Corporate and Investment Bank | Transactional | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 242 | 216 |
Operating segments | Corporate and Investment Bank | Advisory | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 363 | 440 |
Operating segments | Corporate and Investment Bank | Brokerage and execution | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 999 | 734 |
Operating segments | Corporate and Investment Bank | Underwriting and syndication | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 1,036 | 1,101 |
Operating segments | Corporate and Investment Bank | Other | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 49 | 30 |
Operating segments | Consumer, Cards and Payments | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 1,756 | 1,407 |
Other non-contract fee income | 3 | 2 |
Fee and commission income | 1,759 | 1,409 |
Fee and commission expense | (973) | (707) |
Net fee and commission income | 786 | 702 |
Operating segments | Consumer, Cards and Payments | Transactional | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 1,583 | 1,229 |
Operating segments | Consumer, Cards and Payments | Advisory | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 94 | 72 |
Operating segments | Consumer, Cards and Payments | Brokerage and execution | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 43 | 28 |
Operating segments | Consumer, Cards and Payments | Underwriting and syndication | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 0 | 0 |
Operating segments | Consumer, Cards and Payments | Other | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 36 | 78 |
Head Office | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 8 | 11 |
Other non-contract fee income | 0 | 0 |
Fee and commission income | 8 | 11 |
Fee and commission expense | (1) | (1) |
Net fee and commission income | 7 | 10 |
Head Office | Transactional | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 0 | 0 |
Head Office | Advisory | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 0 | 0 |
Head Office | Brokerage and execution | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 0 | 0 |
Head Office | Underwriting and syndication | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | 0 | 0 |
Head Office | Other | ||
Disclosure of disaggregation of revenue from contracts with customers [line items] | ||
Total revenue from contracts with customers | £ 8 | £ 11 |
Dividends on ordinary shares (D
Dividends on ordinary shares (Details) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2023 | Dec. 31, 2022 | Jun. 30, 2022 | |
Dividends [Abstract] | |||
Ordinary shares | £ 700 | £ 0 | £ 200 |
Preference shares | 19 | £ 16 | 15 |
Total | 719 | £ 215 | |
Interim dividend | £ 648 |
Fair value of financial instr_3
Fair value of financial instruments - Assets and liabilities held at fair value disaggregated by valuation technique (fair value hierarchy) and balance sheet classification (Details) - GBP (£) £ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
Disclosure of detailed information about financial instruments [line items] | ||
Trading portfolio assets | £ 165,095 | £ 133,771 |
Financial assets at fair value through the income statement | 233,105 | 211,128 |
Derivative financial instruments | 266,128 | 302,976 |
Financial assets at fair value through other comprehensive income | 47,032 | 45,084 |
Trading portfolio liabilities | (70,269) | (72,460) |
Financial liabilities designated at fair value | (311,595) | (272,055) |
Derivative financial instruments | (254,794) | (289,206) |
At fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Trading portfolio assets | 165,095 | 133,771 |
Financial assets at fair value through the income statement | 233,105 | 211,128 |
Derivative financial instruments | 266,128 | 302,976 |
Financial assets at fair value through other comprehensive income | 47,032 | 45,084 |
Investment property | 2 | 5 |
Total assets | 711,362 | 692,964 |
Trading portfolio liabilities | (70,269) | (72,460) |
Financial liabilities designated at fair value | (311,595) | (272,055) |
Derivative financial instruments | (254,794) | (289,206) |
Total liabilities | (636,658) | (633,721) |
Quoted market prices (Level 1) | At fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Trading portfolio assets | 86,232 | 62,469 |
Financial assets at fair value through the income statement | 6,067 | 5,647 |
Derivative financial instruments | 3,484 | 10,054 |
Financial assets at fair value through other comprehensive income | 18,683 | 15,029 |
Investment property | 0 | 0 |
Total assets | 114,466 | 93,199 |
Trading portfolio liabilities | (36,740) | (43,679) |
Financial liabilities designated at fair value | (115) | (133) |
Derivative financial instruments | (4,064) | (10,823) |
Total liabilities | (40,919) | (54,635) |
Observable inputs (Level 2) | At fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Trading portfolio assets | 72,064 | 64,822 |
Financial assets at fair value through the income statement | 220,867 | 199,370 |
Derivative financial instruments | 258,112 | 287,749 |
Financial assets at fair value through other comprehensive income | 28,299 | 30,051 |
Investment property | 0 | 0 |
Total assets | 579,342 | 581,992 |
Trading portfolio liabilities | (33,477) | (28,725) |
Financial liabilities designated at fair value | (310,388) | (270,880) |
Derivative financial instruments | (245,461) | (272,020) |
Total liabilities | (589,326) | (571,625) |
Significant unobservable inputs (Level 3) | ||
Disclosure of detailed information about financial instruments [line items] | ||
Total assets | 17,554 | 17,773 |
Total liabilities | (6,413) | (7,461) |
Significant unobservable inputs (Level 3) | At fair value | ||
Disclosure of detailed information about financial instruments [line items] | ||
Trading portfolio assets | 6,799 | 6,480 |
Financial assets at fair value through the income statement | 6,171 | 6,111 |
Derivative financial instruments | 4,532 | 5,173 |
Financial assets at fair value through other comprehensive income | 50 | 4 |
Investment property | 2 | 5 |
Total assets | 17,554 | 17,773 |
Trading portfolio liabilities | (52) | (56) |
Financial liabilities designated at fair value | (1,092) | (1,042) |
Derivative financial instruments | (5,269) | (6,363) |
Total liabilities | £ (6,413) | £ (7,461) |
Fair value of financial instr_4
Fair value of financial instruments - Level 3 assets and liabilities held at fair value disaggregated by product type (Details) - Significant unobservable inputs (Level 3) - GBP (£) £ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
Disclosure of detailed information about financial instruments [line items] | ||
Assets | £ 17,554 | £ 17,773 |
Liabilities | (6,413) | (7,461) |
Corporate debt | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 1,710 | 1,677 |
Liabilities | (35) | (49) |
Reverse repurchase and repurchase agreements | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 44 | 37 |
Liabilities | (643) | (434) |
Non-asset backed loans | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 7,946 | 8,105 |
Liabilities | 0 | 0 |
Private equity investments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 138 | 140 |
Liabilities | 0 | 0 |
Other | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 3,184 | 2,641 |
Liabilities | (466) | (615) |
Interest rate derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 2,520 | 2,361 |
Liabilities | (2,043) | (2,858) |
Foreign exchange derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 182 | 1,513 |
Liabilities | (176) | (1,474) |
Credit derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 342 | 290 |
Liabilities | (694) | (603) |
Equity derivatives | ||
Disclosure of detailed information about financial instruments [line items] | ||
Assets | 1,488 | 1,009 |
Liabilities | £ (2,356) | £ (1,428) |
Fair value of financial instr_5
Fair value of financial instruments - Analysis of movements in Level 3 assets and liabilities (Details) - GBP (£) £ in Millions | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Net assets (liabilities) [abstract] | |||
Derivative financial assets | £ 266,128 | £ 302,976 | |
Derivative financial instruments | 254,794 | £ 289,206 | |
Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 17,773 | ||
Ending balance, financial assets | 17,554 | ||
Financial liabilities | |||
Beginning balance, financial liabilities | (7,461) | ||
Ending balance, financial liabilities | (6,413) | ||
Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Net assets (liabilities) [abstract] | |||
Beginning balance, assets (liabilities), net | 10,312 | £ 5,925 | |
Purchases, fair value measurement, assets (liabilities), net | 3,882 | 9,507 | |
Sales, fair value measurement, assets (liabilities), net | (2,822) | (7,170) | |
Issues, fair value measurement, assets (liabilities), net | (226) | (13) | |
Settlements, fair value measurement, assets (liabilities), net | (1,088) | (525) | |
Total gains (losses) recognised in OCI, assets (liabilities), net | 0 | (2) | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities), net | 1,325 | 574 | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities), net | 104 | 87 | |
Ending balance, assets (liabilities), net | 11,141 | 9,433 | |
Derivative financial assets | 4,532 | 3,873 | |
Derivative financial instruments | 5,269 | 4,379 | |
Recurring fair value measurement | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Net assets (liabilities) [abstract] | |||
Total gains (losses) in the period recognised in the income statement, assets (liabilities), net | (295) | 866 | |
Recurring fair value measurement | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Net assets (liabilities) [abstract] | |||
Total gains (losses) in the period recognised in the income statement, assets (liabilities), net | (51) | 184 | |
Recurring fair value measurement | Investment property | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 5 | 7 | |
Purchases, fair value measurement, assets | 0 | 0 | |
Sales, fair value measurement, assets | 0 | (1) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 0 | 0 | |
Total gains (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | |
Ending balance, financial assets | 2 | 5 | |
Recurring fair value measurement | Investment property | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Recurring fair value measurement | Investment property | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (3) | (1) | |
Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | |||
Net assets (liabilities) [abstract] | |||
Beginning balance, assets (liabilities), net | (1,190) | (2,049) | |
Purchases, fair value measurement, assets (liabilities), net | (281) | (94) | |
Sales, fair value measurement, assets (liabilities), net | 5 | 5 | |
Issues, fair value measurement, assets (liabilities), net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities), net | (47) | 217 | |
Total gains (losses) recognised in OCI, assets (liabilities), net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities), net | 505 | 217 | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities), net | 459 | 358 | |
Ending balance, assets (liabilities), net | (737) | (506) | |
Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Net assets (liabilities) [abstract] | |||
Total gains (losses) in the period recognised in the income statement, assets (liabilities), net | (188) | 849 | |
Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Net assets (liabilities) [abstract] | |||
Total gains (losses) in the period recognised in the income statement, assets (liabilities), net | 0 | (9) | |
Trading portfolio liabilities | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial liabilities | |||
Beginning balance, financial liabilities | (56) | (27) | |
Purchases, fair value measurement, liabilities | (16) | (35) | |
Sales, fair value measurement, liabilities | 4 | 3 | |
Issues, fair value measurement, liabilities | 0 | 0 | |
Settlements, fair value measurement, liabilities | 0 | 0 | |
Total gains (losses) recognised in OCI, liabilities | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, liabilities | 8 | 0 | |
Transfers out of Level 3 of fair value hierarchy, liabilities | 9 | 6 | |
Ending balance, financial liabilities | (52) | (82) | |
Trading portfolio liabilities | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial liabilities at fair value through profit or loss, category trading | |||
Financial liabilities | |||
Total gains (losses) in the period recognised in the income statement, liabilities | 15 | (29) | |
Trading portfolio liabilities | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial liabilities at fair value through profit or loss, category other income | |||
Financial liabilities | |||
Total gains (losses) in the period recognised in the income statement, liabilities | 0 | 0 | |
Financial liabilities designated at fair value | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial liabilities | |||
Beginning balance, financial liabilities | (1,042) | (404) | |
Purchases, fair value measurement, liabilities | 0 | (5) | |
Sales, fair value measurement, liabilities | 0 | 0 | |
Issues, fair value measurement, liabilities | (226) | (13) | |
Settlements, fair value measurement, liabilities | 0 | 47 | |
Total gains (losses) recognised in OCI, liabilities | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, liabilities | 290 | 81 | |
Transfers out of Level 3 of fair value hierarchy, liabilities | 463 | 37 | |
Ending balance, financial liabilities | (1,092) | (439) | |
Financial liabilities designated at fair value | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial liabilities at fair value through profit or loss, category trading | |||
Financial liabilities | |||
Total gains (losses) in the period recognised in the income statement, liabilities | 4 | (22) | |
Financial liabilities designated at fair value | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial liabilities at fair value through profit or loss, category other income | |||
Financial liabilities | |||
Total gains (losses) in the period recognised in the income statement, liabilities | (1) | 2 | |
Interest rate derivatives | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 2,361 | ||
Ending balance, financial assets | 2,520 | ||
Financial liabilities | |||
Beginning balance, financial liabilities | (2,858) | ||
Ending balance, financial liabilities | (2,043) | ||
Interest rate derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | |||
Net assets (liabilities) [abstract] | |||
Beginning balance, assets (liabilities), net | (497) | (260) | |
Purchases, fair value measurement, assets (liabilities), net | 0 | 25 | |
Sales, fair value measurement, assets (liabilities), net | 0 | 0 | |
Issues, fair value measurement, assets (liabilities), net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities), net | 19 | (4) | |
Total gains (losses) recognised in OCI, assets (liabilities), net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities), net | 544 | 271 | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities), net | 446 | 6 | |
Ending balance, assets (liabilities), net | 477 | (276) | |
Interest rate derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Net assets (liabilities) [abstract] | |||
Total gains (losses) in the period recognised in the income statement, assets (liabilities), net | (35) | (305) | |
Interest rate derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Net assets (liabilities) [abstract] | |||
Total gains (losses) in the period recognised in the income statement, assets (liabilities), net | 0 | (9) | |
Foreign exchange derivatives | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 1,513 | ||
Ending balance, financial assets | 182 | ||
Financial liabilities | |||
Beginning balance, financial liabilities | (1,474) | ||
Ending balance, financial liabilities | (176) | ||
Foreign exchange derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | |||
Net assets (liabilities) [abstract] | |||
Beginning balance, assets (liabilities), net | 39 | 2 | |
Purchases, fair value measurement, assets (liabilities), net | 0 | 0 | |
Sales, fair value measurement, assets (liabilities), net | 0 | 0 | |
Issues, fair value measurement, assets (liabilities), net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities), net | 0 | (9) | |
Total gains (losses) recognised in OCI, assets (liabilities), net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities), net | 13 | (65) | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities), net | (15) | 25 | |
Ending balance, assets (liabilities), net | 6 | 226 | |
Foreign exchange derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Net assets (liabilities) [abstract] | |||
Total gains (losses) in the period recognised in the income statement, assets (liabilities), net | (31) | 273 | |
Foreign exchange derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Net assets (liabilities) [abstract] | |||
Total gains (losses) in the period recognised in the income statement, assets (liabilities), net | 0 | 0 | |
Credit derivatives | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 290 | ||
Ending balance, financial assets | 342 | ||
Financial liabilities | |||
Beginning balance, financial liabilities | (603) | ||
Ending balance, financial liabilities | (694) | ||
Credit derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | |||
Net assets (liabilities) [abstract] | |||
Beginning balance, assets (liabilities), net | (313) | (386) | |
Purchases, fair value measurement, assets (liabilities), net | (191) | (36) | |
Sales, fair value measurement, assets (liabilities), net | 5 | 5 | |
Issues, fair value measurement, assets (liabilities), net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities), net | 66 | 60 | |
Total gains (losses) recognised in OCI, assets (liabilities), net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities), net | 52 | 20 | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities), net | 16 | 55 | |
Ending balance, assets (liabilities), net | (352) | (381) | |
Credit derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Net assets (liabilities) [abstract] | |||
Total gains (losses) in the period recognised in the income statement, assets (liabilities), net | 13 | (99) | |
Credit derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Net assets (liabilities) [abstract] | |||
Total gains (losses) in the period recognised in the income statement, assets (liabilities), net | 0 | 0 | |
Equity derivatives | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 1,009 | ||
Ending balance, financial assets | 1,488 | ||
Financial liabilities | |||
Beginning balance, financial liabilities | (1,428) | ||
Ending balance, financial liabilities | (2,356) | ||
Equity derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | |||
Net assets (liabilities) [abstract] | |||
Beginning balance, assets (liabilities), net | (419) | (1,405) | |
Purchases, fair value measurement, assets (liabilities), net | (90) | (83) | |
Sales, fair value measurement, assets (liabilities), net | 0 | 0 | |
Issues, fair value measurement, assets (liabilities), net | 0 | 0 | |
Settlements, fair value measurement, assets (liabilities), net | (132) | 170 | |
Total gains (losses) recognised in OCI, assets (liabilities), net | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets (liabilities), net | (104) | (9) | |
Transfers out of Level 3 of fair value hierarchy, assets (liabilities), net | 12 | 272 | |
Ending balance, assets (liabilities), net | (868) | (75) | |
Equity derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category trading income | |||
Net assets (liabilities) [abstract] | |||
Total gains (losses) in the period recognised in the income statement, assets (liabilities), net | (135) | 980 | |
Equity derivatives | Recurring fair value measurement | Net derivative financial instruments | Significant unobservable inputs (Level 3) | Net assets (liabilities) at fair value through profit or loss, category other income | |||
Net assets (liabilities) [abstract] | |||
Total gains (losses) in the period recognised in the income statement, assets (liabilities), net | 0 | 0 | |
Corporate debt | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 1,677 | ||
Ending balance, financial assets | 1,710 | ||
Financial liabilities | |||
Beginning balance, financial liabilities | (49) | ||
Ending balance, financial liabilities | (35) | ||
Non-asset backed loans | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 8,105 | ||
Ending balance, financial assets | 7,946 | ||
Financial liabilities | |||
Beginning balance, financial liabilities | 0 | ||
Ending balance, financial liabilities | 0 | ||
Private equity investments | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 140 | ||
Ending balance, financial assets | 138 | ||
Financial liabilities | |||
Beginning balance, financial liabilities | 0 | ||
Ending balance, financial liabilities | 0 | ||
Reverse repurchase and repurchase agreements | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 37 | ||
Ending balance, financial assets | 44 | ||
Financial liabilities | |||
Beginning balance, financial liabilities | (434) | ||
Ending balance, financial liabilities | (643) | ||
Other | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 2,641 | ||
Ending balance, financial assets | 3,184 | ||
Financial liabilities | |||
Beginning balance, financial liabilities | (615) | ||
Ending balance, financial liabilities | (466) | ||
Trading portfolio assets | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 6,480 | 2,281 | |
Purchases, fair value measurement, assets | 2,285 | 2,957 | |
Sales, fair value measurement, assets | (1,876) | (781) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (402) | (319) | |
Total gains (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 1,022 | 284 | |
Transfers out of Level 3 of fair value hierarchy, assets | (676) | (291) | |
Ending balance, financial assets | 6,799 | 4,256 | |
Trading portfolio assets | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (34) | 125 | |
Trading portfolio assets | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Corporate debt | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 595 | 389 | |
Purchases, fair value measurement, assets | 338 | 90 | |
Sales, fair value measurement, assets | (118) | (144) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (53) | (17) | |
Total gains (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 36 | 43 | |
Transfers out of Level 3 of fair value hierarchy, assets | (29) | (11) | |
Ending balance, financial assets | 774 | 404 | |
Trading portfolio assets | Corporate debt | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 5 | 54 | |
Trading portfolio assets | Corporate debt | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 4,837 | 758 | |
Purchases, fair value measurement, assets | 919 | 2,448 | |
Sales, fair value measurement, assets | (1,152) | (459) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (311) | 0 | |
Total gains (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 556 | 50 | |
Transfers out of Level 3 of fair value hierarchy, assets | (334) | (113) | |
Ending balance, financial assets | 4,519 | 2,695 | |
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 4 | 11 | |
Trading portfolio assets | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Trading portfolio assets | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 1,048 | 1,134 | |
Purchases, fair value measurement, assets | 1,028 | 419 | |
Sales, fair value measurement, assets | (606) | (178) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (38) | (302) | |
Total gains (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 430 | 191 | |
Transfers out of Level 3 of fair value hierarchy, assets | (313) | (167) | |
Ending balance, financial assets | 1,506 | 1,157 | |
Trading portfolio assets | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (43) | 60 | |
Trading portfolio assets | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Financial assets at fair value through the income statement | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 6,111 | 6,079 | |
Purchases, fair value measurement, assets | 1,847 | 6,684 | |
Sales, fair value measurement, assets | (955) | (6,396) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (638) | (470) | |
Total gains (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 96 | 154 | |
Transfers out of Level 3 of fair value hierarchy, assets | (151) | (23) | |
Ending balance, financial assets | 6,171 | 6,163 | |
Financial assets at fair value through the income statement | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (92) | (57) | |
Financial assets at fair value through the income statement | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (47) | 192 | |
Financial assets at fair value through the income statement | Corporate debt | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 1,079 | 816 | |
Purchases, fair value measurement, assets | 0 | 45 | |
Sales, fair value measurement, assets | (120) | 0 | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 0 | (148) | |
Total gains (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | |
Ending balance, financial assets | 936 | 768 | |
Financial assets at fair value through the income statement | Corporate debt | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (20) | 55 | |
Financial assets at fair value through the income statement | Corporate debt | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (3) | 0 | |
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 3,268 | 2,985 | |
Purchases, fair value measurement, assets | 1,053 | 1,848 | |
Sales, fair value measurement, assets | (305) | (757) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (483) | (315) | |
Total gains (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 28 | 52 | |
Transfers out of Level 3 of fair value hierarchy, assets | (106) | 0 | |
Ending balance, financial assets | 3,380 | 3,737 | |
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (33) | (76) | |
Financial assets at fair value through the income statement | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (42) | 0 | |
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 140 | 148 | |
Purchases, fair value measurement, assets | 0 | 19 | |
Sales, fair value measurement, assets | 0 | (60) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (5) | 0 | |
Total gains (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 3 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | (4) | |
Ending balance, financial assets | 138 | 124 | |
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (5) | 7 | |
Financial assets at fair value through the income statement | Private equity investments | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 8 | 11 | |
Financial assets at fair value through the income statement | Reverse repurchase and repurchase agreements | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 38 | 13 | |
Purchases, fair value measurement, assets | 0 | 66 | |
Sales, fair value measurement, assets | 0 | 0 | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 0 | (12) | |
Total gains (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 46 | 95 | |
Transfers out of Level 3 of fair value hierarchy, assets | (29) | 0 | |
Ending balance, financial assets | 44 | 178 | |
Financial assets at fair value through the income statement | Reverse repurchase and repurchase agreements | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (11) | 16 | |
Financial assets at fair value through the income statement | Reverse repurchase and repurchase agreements | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 1,586 | 2,117 | |
Purchases, fair value measurement, assets | 794 | 4,706 | |
Sales, fair value measurement, assets | (530) | (5,579) | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (150) | 5 | |
Total gains (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 22 | 4 | |
Transfers out of Level 3 of fair value hierarchy, assets | (16) | (19) | |
Ending balance, financial assets | 1,673 | 1,356 | |
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (23) | (59) | |
Financial assets at fair value through the income statement | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | (10) | 181 | |
Financial assets at fair value through other comprehensive income | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 4 | 38 | |
Purchases, fair value measurement, assets | 47 | 0 | |
Sales, fair value measurement, assets | 0 | 0 | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (1) | 0 | |
Total gains (losses) recognised in OCI, assets | 0 | (2) | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | |
Ending balance, financial assets | 50 | 36 | |
Financial assets at fair value through other comprehensive income | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Financial assets at fair value through other comprehensive income | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Financial assets at fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 0 | 0 | |
Purchases, fair value measurement, assets | 47 | 0 | |
Sales, fair value measurement, assets | 0 | 0 | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | 0 | 0 | |
Total gains (losses) recognised in OCI, assets | 0 | 0 | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | |
Ending balance, financial assets | 47 | 0 | |
Financial assets at fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Financial assets at fair value through other comprehensive income | Non-asset backed loans | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Financial assets at fair value through other comprehensive income | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | |||
Financial assets | |||
Beginning balance, financial assets | 4 | 38 | |
Purchases, fair value measurement, assets | 0 | 0 | |
Sales, fair value measurement, assets | 0 | 0 | |
Issues, fair value measurement, assets | 0 | 0 | |
Settlements, fair value measurement, assets | (1) | 0 | |
Total gains (losses) recognised in OCI, assets | 0 | (2) | |
Transfers into Level 3 of fair value hierarchy, assets | 0 | 0 | |
Transfers out of Level 3 of fair value hierarchy, assets | 0 | 0 | |
Ending balance, financial assets | 3 | 36 | |
Financial assets at fair value through other comprehensive income | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category trading | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | 0 | 0 | |
Financial assets at fair value through other comprehensive income | Other | Recurring fair value measurement | Significant unobservable inputs (Level 3) | Financial assets at fair value through profit or loss, category other income | |||
Financial assets | |||
Total gains and (losses) in the period recognised in the income statement, assets | £ 0 | £ 0 |
Fair value of financial instr_6
Fair value of financial instruments - Unrealised gains and losses recognised in the period on Level 3 assets and liabilities held at period end (Details) - GBP (£) £ in Millions | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Disclosure of detailed information about financial instruments [line items] | ||
Trading income | £ 3,853 | £ 5,026 |
Other income | 39 | 31 |
Other compre-hensive income | (2,620) | 280 |
Significant unobservable inputs (Level 3) | ||
Disclosure of detailed information about financial instruments [line items] | ||
Trading income | (291) | 950 |
Other income | (54) | 7 |
Other compre-hensive income | 0 | (2) |
Total | (345) | 955 |
Significant unobservable inputs (Level 3) | Investment properties | ||
Disclosure of detailed information about financial instruments [line items] | ||
Trading income | 0 | 0 |
Other income | (3) | (1) |
Other compre-hensive income | 0 | 0 |
Total | (3) | (1) |
Significant unobservable inputs (Level 3) | Net derivative financial instruments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Trading income | (186) | 862 |
Other income | 0 | (1) |
Other compre-hensive income | 0 | 0 |
Total | (186) | 861 |
Trading portfolio liabilities | Significant unobservable inputs (Level 3) | ||
Disclosure of detailed information about financial instruments [line items] | ||
Trading income | 15 | (35) |
Other income | 0 | 0 |
Other compre-hensive income | 0 | 0 |
Total | 15 | (35) |
Financial liabilities designated at fair value | Significant unobservable inputs (Level 3) | ||
Disclosure of detailed information about financial instruments [line items] | ||
Trading income | 2 | (14) |
Other income | (1) | 0 |
Other compre-hensive income | 0 | 0 |
Total | 1 | (14) |
Trading portfolio assets | Significant unobservable inputs (Level 3) | ||
Disclosure of detailed information about financial instruments [line items] | ||
Trading income | (35) | 121 |
Other income | 0 | 0 |
Other compre-hensive income | 0 | 0 |
Total | (35) | 121 |
Financial assets at fair value through the income statement | Significant unobservable inputs (Level 3) | ||
Disclosure of detailed information about financial instruments [line items] | ||
Trading income | (87) | 16 |
Other income | (50) | 9 |
Other compre-hensive income | 0 | 0 |
Total | (137) | 25 |
Financial assets at fair value through other comprehensive income | Significant unobservable inputs (Level 3) | ||
Disclosure of detailed information about financial instruments [line items] | ||
Trading income | 0 | 0 |
Other income | 0 | 0 |
Other compre-hensive income | 0 | (2) |
Total | £ 0 | £ (2) |
Fair value of financial instr_7
Fair value of financial instruments - Sensitivity analysis of valuations using unobservable inputs (Details) - Recurring fair value measurement - Significant unobservable inputs (Level 3) - GBP (£) £ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | £ 784 | £ 727 |
Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 1 | 0 |
Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (1,219) | (967) |
Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (1) | 0 |
Corporate debt | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 23 | 45 |
Corporate debt | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Corporate debt | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (22) | (27) |
Corporate debt | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Non-asset backed loans | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 295 | 244 |
Non-asset backed loans | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 1 | 0 |
Non-asset backed loans | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (535) | (450) |
Non-asset backed loans | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (1) | 0 |
Private equity investments | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 7 | 10 |
Private equity investments | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Private equity investments | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (7) | (10) |
Private equity investments | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Other | Favourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 112 | 53 |
Other | Favourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Other | Unfavourable changes | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (109) | (64) |
Other | Unfavourable changes | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Interest rate derivatives | Favourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 123 | 119 |
Interest rate derivatives | Favourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Interest rate derivatives | Unfavourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (186) | (155) |
Interest rate derivatives | Unfavourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Foreign exchange derivatives | Favourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 11 | 16 |
Foreign exchange derivatives | Favourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Foreign exchange derivatives | Unfavourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (17) | (22) |
Foreign exchange derivatives | Unfavourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Credit derivatives | Favourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 27 | 79 |
Credit derivatives | Favourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Credit derivatives | Unfavourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (79) | (71) |
Credit derivatives | Unfavourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Equity derivatives | Favourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 186 | 161 |
Equity derivatives | Favourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | 0 | 0 |
Equity derivatives | Unfavourable changes | Derivatives | Income statement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | (264) | (168) |
Equity derivatives | Unfavourable changes | Derivatives | Equity | ||
Disclosure of detailed information about financial instruments [line items] | ||
Sensitivity analysis valuation due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions | £ 0 | £ 0 |
Fair value of financial instr_8
Fair value of financial instrument - Narrative (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2023 | Dec. 31, 2022 | |
Brokered certificates of deposit | ||
Disclosure of detailed information about financial instruments [line items] | ||
Deposits at amortised cost | £ 4,648 | £ 5,197 |
Exit price adjustments derived from market bid-offer spreads | ||
Disclosure of detailed information about financial instruments [line items] | ||
Increase (decrease) in derivative fair value adjustments | (23) | |
Fair value adjustments | (543) | (566) |
Uncollateralised derivative funding | ||
Disclosure of detailed information about financial instruments [line items] | ||
Increase (decrease) in derivative fair value adjustments | 13 | |
Fair value adjustments | (24) | (11) |
Derivative credit valuation adjustments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Increase (decrease) in derivative fair value adjustments | (78) | |
Fair value adjustments | (241) | (319) |
Derivative debit valuation adjustments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Increase (decrease) in derivative fair value adjustments | (12) | |
Fair value adjustments | 196 | 208 |
Significant unobservable inputs (Level 3) | Financial instruments at fair value, category | Recurring fair value measurement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 183 | 106 |
Additions, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 107 | 49 |
Amortisation and releases, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 30 | 65 |
Significant unobservable inputs (Level 3) | Financial instruments at amortised cost, category | Recurring fair value measurement | ||
Disclosure of detailed information about financial instruments [line items] | ||
Aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 24 | 25 |
Additions, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 0 | 0 |
Amortisation and releases, aggregate difference between fair value at initial recognition and transaction price yet to be recognised in profit or loss | 1 | 3 |
Significant unobservable inputs (Level 3) | Favourable changes | ||
Disclosure of detailed information about financial instruments [line items] | ||
Increase in fair value measurement due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions, assets (liabilities) | 785 | 727 |
Decrease in fair value measurement due to change in one or more unobservable inputs to reflect reasonably possible alternative assumptions, assets (liabilities) | £ 1,220 | £ 967 |
Fair value of financial instr_9
Fair value of financial instruments - Fair value adjustments (Details) - GBP (£) £ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
Exit price adjustments derived from market bid-offer spreads | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | £ (543) | £ (566) |
Uncollateralised derivative funding | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | (24) | (11) |
Derivative credit valuation adjustments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | (241) | (319) |
Derivative debit valuation adjustments | ||
Disclosure of detailed information about financial instruments [line items] | ||
Fair value adjustments | £ 196 | £ 208 |
Fair value of financial inst_10
Fair value of financial instruments - Comparison of carrying amounts and fair values for assets and liabilities not held at fair value (Details) - GBP (£) £ in Millions | Jun. 30, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Financial assets | ||||
Debt securities at amortised cost | [1] | £ 35,245 | £ 27,303 | |
Reverse repurchase agreements and other similar secured lending | 1,293 | 725 | ||
Financial liabilities | ||||
Repurchase agreements and other similar secured borrowing | (25,156) | (11,965) | ||
Debt securities in issue | (58,377) | (60,012) | ||
Subordinated liabilities | (36,325) | (38,253) | £ (32,185) | |
Fair value | ||||
Financial assets | ||||
Debt securities at amortised cost | 33,869 | 27,006 | ||
Loans and advances at amortised cost to customers | 148,490 | 154,721 | ||
Reverse repurchase agreements and other similar secured lending | 1,293 | 725 | ||
Financial liabilities | ||||
Deposits at amortised cost | (307,811) | (291,552) | ||
Repurchase agreements and other similar secured borrowing | (25,153) | (11,966) | ||
Debt securities in issue | (58,266) | (59,895) | ||
Subordinated liabilities | (35,403) | (38,686) | ||
Gross exposure | ||||
Financial assets | ||||
Debt securities at amortised cost | 35,245 | 27,303 | ||
Loans and advances at amortised cost to customers | 147,992 | 155,204 | ||
Reverse repurchase agreements and other similar secured lending | 1,293 | 725 | ||
Financial liabilities | ||||
Deposits at amortised cost | (307,820) | (291,579) | ||
Repurchase agreements and other similar secured borrowing | (25,156) | (11,965) | ||
Debt securities in issue | (58,377) | (60,012) | ||
Subordinated liabilities | £ (36,325) | £ (38,253) | ||
[1]For the fair value of debt securities at amortised cost see page 37. |
Subordinated liabilities - Subo
Subordinated liabilities - Subordinated liabilities (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2023 | Dec. 31, 2022 | |
Disclosure of detailed information about borrowings [line items] | ||
Opening balance | £ 38,253 | £ 32,185 |
Issuances | 3,502 | 15,381 |
Redemptions | (3,661) | (8,367) |
Other | (1,769) | (946) |
Closing balance | 36,325 | 38,253 |
Total subordinated liabilities | 36,828 | 38,774 |
At fair value | ||
Disclosure of detailed information about borrowings [line items] | ||
Opening balance | 521 | |
Closing balance | £ 503 | £ 521 |
Subordinated liabilities - Narr
Subordinated liabilities - Narrative (Details) - GBP (£) £ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2023 | Dec. 31, 2022 | |
Disclosure of detailed information about borrowings [line items] | ||
Issuances | £ 3,502 | £ 15,381 |
Redemption of subordinated debt | 3,661 | £ 8,367 |
Barclays Bank PLC loans issued intra-group Barclays PLC | Barclays Bank PLC | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | 3,365 | |
Redemption of subordinated debt | 3,644 | |
USD Notes | Floating interest rate | ||
Disclosure of detailed information about borrowings [line items] | ||
Issuances | 137 | |
Redemption of subordinated debt | £ 17 |
Provisions (Details)
Provisions (Details) - GBP (£) £ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
Disclosure of other provisions [line items] | ||
Provisions | £ 732 | £ 858 |
Customer redress | ||
Disclosure of other provisions [line items] | ||
Provisions | 35 | 46 |
Legal, competition and regulatory matters | ||
Disclosure of other provisions [line items] | ||
Provisions | 59 | 113 |
Redundancy and restructuring | ||
Disclosure of other provisions [line items] | ||
Provisions | 17 | 45 |
Undrawn contractually committed facilities and guarantees | ||
Disclosure of other provisions [line items] | ||
Provisions | 467 | 532 |
Sundry provisions | ||
Disclosure of other provisions [line items] | ||
Provisions | £ 154 | £ 122 |
Retirement benefits (Details)
Retirement benefits (Details) - GBP (£) £ in Millions | 12 Months Ended | ||||
Dec. 31, 2019 | Jun. 30, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Sep. 30, 2021 | |
Disclosure of fair value of plan assets [line items] | |||||
Surplus in plan | £ 4,000 | £ 4,600 | |||
Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | Pension defined benefit plans | United Kingdom | |||||
Disclosure of fair value of plan assets [line items] | |||||
Surplus in plan | £ 4,100 | £ 4,700 | |||
Employer contributions | £ 286 | ||||
Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | Pension defined benefit plans | United Kingdom | Deficit contributions valuation recovery plan 2022 | |||||
Disclosure of fair value of plan assets [line items] | |||||
Surplus in plan | £ 2,000 | ||||
Defined benefit plans other than multi-employer plans, state plans and plans that share risks between entities under common control | Pension defined benefit plans | United Kingdom | Deficit contributions valuation recovery plan 2019 | |||||
Disclosure of fair value of plan assets [line items] | |||||
Surplus in plan | £ 600 |
Other reserves - Other reserves
Other reserves - Other reserves (Details) - GBP (£) £ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
Disclosure of reserves within equity [line items] | ||
Other reserves | £ (3,388) | £ (1,464) |
Currency translation reserve | ||
Disclosure of reserves within equity [line items] | ||
Other reserves | 3,667 | 4,992 |
Fair value through other comprehensive income reserve | ||
Disclosure of reserves within equity [line items] | ||
Other reserves | (1,284) | (1,342) |
Cash flow hedging reserve | ||
Disclosure of reserves within equity [line items] | ||
Other reserves | (5,940) | (5,557) |
Own credit reserve | ||
Disclosure of reserves within equity [line items] | ||
Other reserves | (27) | 467 |
Other reserves | ||
Disclosure of reserves within equity [line items] | ||
Other reserves | £ 196 | £ (24) |
Other reserves - Narrative (Det
Other reserves - Narrative (Details) - GBP (£) £ in Millions | 6 Months Ended | |
Jun. 30, 2023 | Dec. 31, 2022 | |
Disclosure of reserves within equity [line items] | ||
Other reserves | £ (3,388) | £ (1,464) |
Currency translation reserve | ||
Disclosure of reserves within equity [line items] | ||
Other reserves | 3,667 | 4,992 |
Increase (decrease) in equity | (1,325) | |
Fair value through other comprehensive income reserve | ||
Disclosure of reserves within equity [line items] | ||
Other reserves | (1,284) | (1,342) |
Increase (decrease) in equity | 58 | |
Changes in fair value | 96 | |
Net gains transferred to net profits | 19 | |
Tax | 19 | |
Cash flow hedging reserve | ||
Disclosure of reserves within equity [line items] | ||
Other reserves | (5,940) | (5,557) |
Increase (decrease) in equity | (383) | |
Changes in fair value | (1,262) | |
Net gains transferred to net profits | (724) | |
Tax | (155) | |
Own credit reserve | ||
Disclosure of reserves within equity [line items] | ||
Other reserves | (27) | 467 |
Increase (decrease) in equity | (494) | |
Tax | (188) | |
Loss on change in value of foreign currency basis spreads, before tax | 682 | |
Other reserves | ||
Disclosure of reserves within equity [line items] | ||
Other reserves | 196 | £ (24) |
Merger reserve | ||
Disclosure of reserves within equity [line items] | ||
Increase (decrease) in equity | £ 124 |
Contingent liabilities and co_3
Contingent liabilities and commitments (Details) - GBP (£) £ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
Contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | £ 27,149 | £ 25,800 |
Commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | 325,579 | 334,977 |
Guarantees and letters of credit pledged as collateral security | Contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | 19,108 | 17,700 |
Performance guarantees, acceptances and endorsements | Contingent liabilities and financial guarantees | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | 8,041 | 8,100 |
Documentary credits and other short-term trade related transactions | Commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | 1,356 | 1,748 |
Standby facilities, credit lines and other commitments | Commitments | ||
Disclosure of contingent liabilities [line items] | ||
Notional amount | £ 324,223 | £ 333,229 |
Legal, competition and regula_2
Legal, competition and regulatory matters (Details) £ in Thousands, $ in Millions | 1 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||
Mar. 31, 2023 GBP (£) | Jan. 31, 2023 lawsuit | Apr. 30, 2021 USD ($) | Jun. 30, 2023 GBP (£) lawsuit plaintiff | Jun. 30, 2023 USD ($) lawsuit plaintiff | Jun. 30, 2022 GBP (£) | Dec. 31, 2021 GBP (£) | Dec. 31, 2018 GBP (£) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 lawsuit | Dec. 31, 2016 lawsuit | Dec. 31, 2013 GBP (£) | Dec. 31, 2008 USD ($) agreement | |
Disclosure of contingent liabilities [line items] | |||||||||||||
Losses on litigation settlements | £ | £ 34,000 | £ 1,833,000 | |||||||||||
Sterling LIBOR case in SDNY | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Number of lawsuits with damages sought | 2 | ||||||||||||
Non-US forex civil actions | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Number of lawsuits with damages sought | 2 | 2 | |||||||||||
US residential and commercial mortgage-related activity and litigation | RMBS repurchase requests | Originated and sold to third parties by Acquired Subsidiary | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Number of lawsuits with damages sought | 2 | 2 | |||||||||||
Number of lawsuits dismissed | 1 | 1 | |||||||||||
Civil actions in respect of VRDO | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Number of lawsuits with damages sought | 2 | 2 | |||||||||||
Civil actions in respect of VRDO - SNDY | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Number of lawsuits with damages sought | 3 | 3 | |||||||||||
Civil actions in respect of the US anti-terrorism act - EDNY | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Number of lawsuits with damages sought | 6 | 6 | |||||||||||
Number of plaintiffs | plaintiff | 4,000 | 4,000 | |||||||||||
Number of lawsuits dismissed | 3 | 3 | |||||||||||
Number of lawsuits dismissed and appealed | 1 | ||||||||||||
Number of lawsuits subject to appeal | 2 | 2 | |||||||||||
Number of lawsuits stayed | 2 | 2 | |||||||||||
Civil actions in respect of the US anti-terrorism act - SDNY | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Number of lawsuits with damages sought | 2 | 2 | |||||||||||
Derivative transactions civil action | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Loss contingency, damages sought, claimed amounts, value | £ | £ 329,000 | ||||||||||||
Over-issuance of securities | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Number of lawsuits with damages sought | 2 | 2 | |||||||||||
HMRC assessments concerning UK VAT | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Loss contingency, damages sought, claimed amounts, value | £ | £ 181,000 | ||||||||||||
HMRC assessments concerning UK VAT | Barclays UK PLC | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Loss contingency, damages sought, claimed amounts, value | £ | 128,000 | ||||||||||||
Barclays Bank PLC | FCA proceedings and other investigations | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Number of advisory service agreements | agreement | 2 | ||||||||||||
Loss contingency, financial penalty warning | £ | £ 50,000 | ||||||||||||
Barclays Bank PLC | USD LIBOR cases in MDL court | Lawsuits with damages sought | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Number of lawsuits with damages sought | 1 | 1 | |||||||||||
Loss contingency, damages sought, claimed amounts, value | $ | $ 100 | ||||||||||||
Barclays Bank PLC | Japanese Yen LIBOR civil actions | Exchange-based class claims | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Losses on litigation settlements | £ | £ 17,750 | ||||||||||||
Barclays Bank PLC | Non-US forex civil actions | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Number of lawsuits pending | 1 | ||||||||||||
Barclays Bank PLC | Consolidated FX action | Barclays Capital Inc | Securities and Exchange Commission | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Losses on litigation settlements | $ | $ 384 | ||||||||||||
Barclays Bank PLC | BDC Finance LLC | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Litigation settlements approved, value | $ | $ 3.3 | $ 298 | |||||||||||
Barclays Bank PLC | HMRC assessments concerning UK VAT | |||||||||||||
Disclosure of contingent liabilities [line items] | |||||||||||||
Loss contingency, damages sought, claimed amounts, value | £ | £ 53,000 |
Barclays Bank PLC parent comp_2
Barclays Bank PLC parent company information (Details) € in Millions | 6 Months Ended | |||
Jun. 30, 2023 GBP (£) | Jun. 30, 2023 EUR (€) | May 31, 2023 GBP (£) | Dec. 31, 2022 GBP (£) | |
Disclosure of detailed information about business combination [line items] | ||||
Other reserves | £ (3,388,000,000) | £ (1,464,000,000) | ||
Barclays Bank Ireland PLC | ||||
Disclosure of detailed information about business combination [line items] | ||||
Additional investments in subsidiaries | 130,000,000 | € 150 | ||
Carrying value of investment | £ 2,500,000,000 | |||
Barclays Bank PLC | Barclays Asset Management Limited, Barclays Investment Solutions Limited and Barclays Bank UK PLC | ||||
Disclosure of detailed information about business combination [line items] | ||||
Consideration transferred, acquisition-date fair value | £ 3 | |||
Barclays Bank PLC | Barclays Asset Management Limited, Barclays Investment Solutions Limited and Barclays Bank UK PLC | Merger reserve | ||||
Disclosure of detailed information about business combination [line items] | ||||
Other reserves | £ 124,000,000 |